var title_f15_32_15872="BPH combination therapy";
var content_f15_32_15872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 586px\">",
"   <div class=\"ttl\">",
"    Combination therapy for benign prostatic hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 566px; height: 441px; background-image: url(data:image/gif;base64,R0lGODlhNgK5AfcAAP///+ETDI8BAQ8CAppWQ6E6Jz8tLS8CAh0oJE8AAAMKCBpDNqhMO9okGNEtJPULCT8QEO94dgMeFR8ODh8CAj8AAAAAAD8iIjNNRS8bGz09PX8nJwEJB+UkHiZvVwAcE0AFBS8NDf+ZM/8AAIiIiO7u7gCZZt3d3URERDMzMyIiImZmZru7uxEREZmZmVVVVXd3d6qqqszMzAAHBX9/f01YVJWbmf+yZf/lzABfQAB8U//Mmf/58r/l2f+fP/+/v/9/f/8/P+/v73/Msv+/f//Zsv/s2f+sWe/59f/SpQCPYA+fb1+/nz+yjP/y5f/FjP+lTP8fH/9fX//v7y+sgv8PD9/f3wA5Jv/f34/SvP+5cv+fn/+Pj0+5lR+lee8AAFlcXN/y7P/fv8/s4s/Pz5/Zxf9PT/8vL98AAP+vr//Pz5+VlX9vb6/fz2/FqQBzTP9vb28AAL8AAL+/v38AAJ+fn4BMM8AmGUBzTM8AAF9NTW9hYQCGWV8AAJ8AAGBfQK8AACCGWfAJBlBpRrAvIK+vr4+GhnBWOZBDLDB8Ux8REdAcExCPYG+FaZ8bGyJGOt+npy+FaQATDAcAAJ+ZhY+ynN9TU8/Cwn93d39TU7O6uK+kpCYsKRNnS69/b3B2dC8gIO85NswqIcQnHG2LgfccG9dfKF9ZWQBWOTpQSStLQF9HR087O4dPN+dVUI9kZNw1K58uLrdiVO8YFn9FRZ+MjL9MJg8HB9+1tW8MDN5sMP+VemORcd9YOJdFMae1sd+Li98bGwljRdcxGjORcZNkTqXLuadcS49tbV86OoePd99wZ9t+Q782KFd8Wo8ZGf9vX/+LN28SEreilAkfGP/Z1B2bcW9VVe9ZWa8rK8PXyy5yW/FqZ8+sosQ3LJuxqv9aVvc8OmudjV2EeHB2Wi2bcc9MI38WFroaEn2bgf82HP9pI9AWE9weFPksLL8vL/kNC/+bZ59KSk8pKc98KaVrWY+som82Nv98KfNzKJ+CgnmQiI86On9wcNtRSuc1MCH5BAAAAAAALAAAAAA2ArkBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrtitEQ4nFkCPLRWHBAoqDlC03LKHCggohVldUtrACo+jKpS+eJq16dGqLq19TjG3adWvUtXHDtn2bdW/ZE2n/LkpCRQnOJAoWP64iucLR0DG2kLFxekcYKk5oxK49I3fv2beH/8f4HXz3i+XJj0e/nv159+bFvyf6wjmJFwXrC7yvUIgFEQACaAFoEnEWAwAtlCADCixQZCCCCjIoEX8FraDCRBQSZCGG+FV4YUQZDrThhB1q+CFEIQo0IoglinjiQykCsCKKLar4okMxzghjjTLeiCOPOjaUo49CAkmkUCq4IJALKRSU5JJNIiQEJ/8FKIIFnBAYUQwpoNCChc5RxKWXYEIEA34kwAAACZcJdEIKlqnJ0JlrqsnmQG/G2RCdaa7ZJgB5oiCnQnza+WeggxKKpqF4winonIv62aiekNYpqZuOJopQoZcCmumekd6JKaWKWiqqp6SW2uepiIJq6qGfLv/EKauxyhoqrKkiqSQATDq5a68DQQedlVdaUEhFL1jQgkbJLivRCi2ggEIKL5zHZAkkdNkQtNJSa20K2GrLELfTVjvQtdn+mRC53p4LbrrbRlvut+GqixC75kJZb7zd5svru+IqhC+98I4rb7v6Fizwwf6iG/DC/RL88LoMS2zvQQO7u6/BEWussFD6AUAnQSGPjNAnVQZowSdidvllcxaN+XKYD8lQGc0ApLBrDM4yZLMFOOssEM8O/Rz0zj0rZHRBQgNAdENLE9T00wtFPdDUSSt9M9NIQ7211F17DTTXQ2eNkNUCYV3011eH7TPbabut9dhgl7023W3bTdRyyAH/wIIFDfINc0KKpCygIhM9mOCCDSauwoGLS/hQxjauUAIKON9bsYuWY87vvJxfnrlBlPfY+eikb1656ByDvrrnrSNsOusLlW7h6Z/LfjvtELs+O+y1q/476hUKvzvwFHf8OvEaGq8C7kVl1ubfjUuvEBsgCFsZCGxYZJ1G35t5K0Fsekadra+ST5kK56vK6EDls4/+qurG335Cs9a//v0H5a+++ZWi3//k575O+QmA83vffvaXQAPaL4AKPCABC3gqCfLPIP6DHwMbWMEHdsUK0JmBBUQ4GiskJUYEQQGPEoLCgahwRwp5YZFiuEKEtFAgMmTIDQGQQx3WEIc/VE4Q/3u4kB0SkYVDDKIQaQjDhBzRhklsIkKeyBULoGMEzMBKCVIAnIpssYsO4mJGvqgRMmLEjGcUYxrBmDg1XgSNb3RjHNkYEThaxI5esYADRmAKHlCFBKN5wWMsAsjKCPIihbTAISuSyEUyMpCDpEgjIylJSBLSkpc0JCUnhMlHahKRncRQKEX5SbFYQBYjsIUYJMPKVhLGAp4YQQOe4Mpa2nIvFujGCAJwhFv68pdysUAYRjACETgBmMhMJlosAIAAjCAfRVCmNKf5FWaKgo9EoKY2t2kVZh5jBOaAAjfHSc6mMDOWwzBmOdfJzqEwcxojaIcIktDOetpTJ8zsATFFoP+Fe/rznzFhZjNHgA8fAPSgCEWJQEcxAl2IwAgJjahEPSJQBoygF/OcqEY3WhGB1mMEsBDBDThK0pIyRKCUGEEHAGTSlro0WALRBjGhIAIcvPSmJBXoGAQxgniIYAc4DepEBQqAO4xgFyLopVCXelCiWnQZAPIjU6calmytgEnz4QlRizECfxxBBKukqli5cpomtYB5NyFqSmHxBBHQcqxwvUoJSPOCJqVAU1odiDGIKYakxvWvVJlrDGDQJBXgdSdE7QFPqwGgYwL2sU9JgQpQMFnABYWoSDDqD24ggmhC9rNLkUELeAMUogLAFyOIwA5EkE3QuhYpJ0jTri5LEAL/jMAVOBCBOF/L26Ic5zhCMa0yQAqAxvb2uD8hwWhHcyCSwOBiOKwMdA9i2koQEwBayChyt6uT5TJ3JCeQ7kEEh1aBmFafI8BCEvjJ3fbepAWC/K1JKjiQkO0QpgMZg2aNIAKDuve/MjnTbzcZEvoK5En/aohpAVCAEQABAD54KIAn7BI4Qae5HLHeAg+CYGCZV3ujKYhtXYFd7VL4xCix8HdJYmAAlEyJ5i1II0bwDwAUgb0ozrFJBkxgkJyKemsyTt9OWhDrPgAATmCpjpf8kUHymCThHU1ygMxD8Sq4IGUg5hQAQFObMvnLGYmBBbgkLAz7ZME90CwAiPBTMLs5/2ZjVnFlzNyTBSOhwVywsUjfzOfECeTJtC1IK0bADQDwIKp9TrRDeCzfQBNkxqEQyFfDquhKH0TMIKZzXguSjhEcGQBtfaulRz0QTGtP04g1yBC0DIC+KpXUsGY0cB09kB4sYgQ/MDSiYc3rNXERq7QWyBgIMYI8A4Cznu31qMuKoPLWZMECscMI4CCQ1bZW2ZWe6wrqmrPD4vMg5BhBpAGQ291iW9GCJSwADBtsgfBiBPAYiHHPrWjJUpYyjfsJtAGw6hEMBNn0VrRoSavvg2Th1rkGwHr7GfBEy4AEK3C2TfbdA2JvQSD89W/D3yytE4w2SqU9CBKk/WCBRBiiG/8H81xJAEg4zfbMCBnECMIxkOzSM+VfFqxoWHDXdgtkxqUYyMJxDubJdmaL3s7JvgHAhOsKJMkiIPqXYWDI8L68zggZgjMTzuWaSp3JLC/BYHv87YO0wagXFwibgfr1tqdk6WMg+UBuPFK3nxhbMMg7DLKaaoT8YQRBGAjUpWp3ACfrwgZhQb4nnhBnjCDoA5l04SfcAnvDIHwuBDnjEdIEpwsk1JP/r2BfmAJNc2nAz06I1keghoG4OvTunasLLk97g8h5zDRZOgCyYNQ0DOTQIiA87JFLrZ/hnmllzn1CeiD3yHd2+P8dLKoBAOiZ6B4JfzcDQawN/fbGIAZ8Jwj/2V+iewDgYQTuIEi5u49c5RJ8ICWAlgVKn/qEdN7fBJk3+1/78RSM9uouBh0tEH4sUX5MwFOt92/Pt3+upW1/xm4F8SUnIHZnZREu0BmWQWAaRmSq13sEsV7XxoCPdRzb9lv0J34WMFs9VxERBygVSD5CNjgLUX5tgAgORhAZJ4KQZWrJxzRf8lwpqBEocHX2BWMAUH5jcAgjoH0EcXI6CFg8iHgFwTOjMV0S8XAG0WGalxDlZ34jcAYFYXNPCFiy1mMs4AKyNREbeAJgpIUEAWIhphDl4HkCMXRj2F7TwhEsMF0vdmUK0QQISBBJpnF3iFyn12iMZBwEAWTk5Ycd/4hrBdFlhbhdtzd9DpEZlXEhVLaBM7gQWWCDJTcQazeJf4V6tteDMtGFPaCEUlAQdEeKY+V+K1YQ1ZeKC4EE5xd4gqhksDhV3jVnibd49acQjECHkgZWveiL8TVrBZGHONGFAACI6VUQoJeMSyVgiEgQh8iMtrgQTKBmBPF61ihUiQSMyCeF3agQQ9BgoSgQwCd84+hSv3h8UoOKAcUQbSBtrVgQkhePNwVfpmgQtXiPC9EDuWgQbRWC/mhS2MiN5PNrKUCAKwGNABAIxkhuurWQL1WJpFMZZiVxJkGRXkBMWGAQ+qeRJMWRKLhtdpV0E9kQTQCOBAFwKGlSA0l9Y/+mbhCYjgrhBuxoENxXkyQVfx+HavZWWcJIfg2RBdJGbQWRg/2TifxTSC0AgEKZTIdXGQNoEAOnG9bXEAYJeAfhhAbxAtTxAi0iWCJzJFf5SxJIgaMTWzBglUrJEGFgkVVwEGKIPzWiAoJ0X23pSrJ3NS6ZVg5hAqxWEHZ4Gq/BAlv5kJSVlIH5S/63AkBIl0rnEDEJiU/ZXwhxgfxjM4/xN+M3ma5EhVYWcg3RBcRmbJHodc0ILufCTDZzIC5gAaVpmq0klwBYhsO4EEPQlAcxigQRZaNxAre5H1qJmbrZSoqHEFE4iwSJjzKni664Z80JUM5oENFpjjypED2QCCP/kJcGAXXZCVDbuEnHcVfHIVoSqRIUKRCIOQJbZhDQQQPnaU8qCX+K5CZ4M50M4QUIdxBtFZ/5KU37ORCd8QJACJIlYaBN0JoH0VcGeqDA5GQBSRAu4F2y+ZUO4QbN94baY6HjJGYPZ4l4kiYkkJvw+RBZUJ32SSwVSqKtZKLsmY0D8ZzP+BDhOQJREKNWMqM0KhnGZ484tIXK5xBhMJ9AqjJDuk2Xd2rcCS44ChMVagID+oYy+qTcFHEZejVGWpeaaXEFYThXogXwyKXslKBWChFdEKIfJixJ5VhqWk83GRE855FZxYnPARFD8HfWWaYYF2E+4GWXqJWSCUiSWaeA/4F3eveeRaQmSKccMehsFdoG5/ejZToa+MkDX2ViD6FuBXGblsWohZGV3mkRJ/A4+WEfRlihPcCkDMEDbMZaEfECwMEzYraophoXVgVsEWh5mEcRC5qFv4Kk1BURJrB1DrFeSZWmMqIbt9ke1BNevNqrbsFsL8ifMUB6KIoZqUl9KYAzbhgscDijXoB2DyEGhIpyOvQiq1EZ14qtaqFt3LaC/Dl7LVB7GUFffciBD9EEcMoQRvBVPpBsBvEm2nF5vGJa1kqvdJFuhYVXxSedEqEfqzplltWIAPuhgBoRPJBdboUQJXB4KtAgyYknpQqxcnGU+JYQ0odIy9Uhmxiuff8KEVlwfmAoEW3FT9DKsoLRlb4Bf7L2m2ApqxJRBBF2BO4KtIXxcF6qjXD4rW8XEUvqTAkoEUZAqJTmtIJxe4PTnfQIoIfpgRThqQByc14bGLcnr3+GdO35mN/ZEFQwsBJRq0Tws2uLF4JyHMp1m4MyVx0SXg5KEkLaBdmHEc56BMJ3n3sbsb5xm4BLEAvaoEnqpzqbETjQroL6uHVRuZ0hZomyoaPRoXPLEGVQjPiHEU7wqQgrpJ5bZcoijFTJnALxNzabJxnYELirGcVpYSjAog5BqtLFc8IolytqtEf7AKynESELINcGu7ErEKL6Z7iHHQ/hcWambh5nuwWhvQT/wb1VuREykHfM+aVtKhEmYLYasVrFIizTe6vA4ZfYYoQCYTPvcYEuUALDWjUWkL9Jwr8XdEdVuia/SLUKNRFLAIodobRmKr30yphL4hnzkS4nexDG2R2dgTNvAi0/lMEH9p+e4sEbIYupKhDziMAnAbtNoIRMyBFG8MDxiyIvIpp+g5uLhmACwaA4VJi0qMMuJiePkhEpbBAAWcAuAbtucJAUtaUzrBAKKzLLkpy12bC52YIelxwww22TOi7JkcUychlcjK8XccQOSb3LKLwJLBFDoLofIcNPnBAlm4koK1C1yxAXaEgH9sXAK7x53J9hjCq76x1pfBBsKqYQEavM/1uSHfHAdBrHaHHIh5zEE7GkDMV1GwFihQrJaTHJd0rJE2ECDAwSzNS6AIKwnEwWd+qoeQepaywRVMCKISFQtAq9KLKytztaE6Rsq3oxmUFHNoTLfqPLA2wXqDq26SsRXcDEjcyp1QYgjNsQpCqMFVi9vbZFvgs/xgG+w+u2BFHNyJoWrLx3RiysxVyAFDEEFrm6JMGuutW0l9YCu0oQNvw358ZFK2AvPMxDEqeruFzPELwVx0xno4cfJ3i6DVEG88nIJVGw/YXKjFmtuGzPN+zKOpbB0hLIKeQcKEBHEQ04D5ujAvU3Fh2nFoCfFuG4F6HSH1F5k3V5/CN7tLevl/8bEbF6TZhMEjzAWSOLMcKSbwB9U4qasC0wrx5hnOG6z8izLj89EEEtEQHduRoR1QtR0DmjaRV7woisrD+ZEj2LpgnxsA8Lzi81zcrhzSuRzypyGcvBzQ4h1pZF1lCdyRxB1Qoh0/tK09AJAyq8whWxBPq4EjeWVPCssg3ysI6JQCblz5IpzCih1hr9yxEB1w2S2Lv8EHYtEJNQ1yOR1cgsI2EyhDUdEU3AzCmxtf1lqHD10SwQ0mVq1F2xBhawBhlhCBZgCBoh27Q9EmK3ApoGt+vpw68sEW6wzi2BtqDqY8JMdYqNTPHq2I5dRMstlUohBBPQBxOgJRQhBLdAB7f/oN3b3d3fXWAHHL4gVrgjAcFDMJ/1yRJ4KxJmTTJnab+7aVmuHd0JEd/1Nd9KgT0jwD0XsQcJMAIJsAcYwQYVMAIV0D0gUcQDwdzQEbyjncgmsEc5rRKLq7cxI8/4bTLSRNlr8n4wy+GL6uFFAUJ5MAJ5YAFoQEwu/uIwHuMqzuIjgAYWkOIynuMxbuMtbuMm1NKFTIteesbJLBFLimcwsbn9VdjBgRoSLZmOWdJW8Tc4k0joDROs7dqLKLcK5swr7eUSMQVpIAUgEAcuHgcJruNqruB04OJ0kOZrruMHYObEFAcZ4BHH0ZBk9xhit3kUYQLCCRMOvYBHCOYR8dzC/wiaZTFwqCNmanwTiD6ql+0QmR1jEvEDQHAGxNQHB/AFLv4FB6AHE7EJFODpxPQFFLAJFKEHBwDjoc4RYqtpHfdxygsRVGDaLvG8PW3pF/GwKTstj24V3SuDlJoUvi5QwE4RlX6ED4EFXGAGVfDijjAALf7iaDAAu/0Q1g0IMA4I2S0RazAApv7p2L4RsU6LQNNyQeihFNEFeEkTPXsDUmXXxw4owiLlOEHlB6HvB0Gq2QEzxO6f+D1FS0cZLVHvSP2/EbHsXSjmUhAFLx4FUrAFl3CulUEGEIHgMr7gEUEGFm8BGF9GRYvuMbBzZFwRlAWu2dyJFbHeidmv0T3UC/+htITN7G3B6Fw5WuVFvHDj1Aq/LZXh08v+Erqd27N9EJiu6S9uBlyQtfZZESBk8T+u7OAVA49xAqhmdLh58hNxeT7CsSxPEQrdAJyJEfo9mwOPg1AAYmox7BxclQG/EIMDMxJionsyrtBGWIC08IYOE9aN3eA9Edzt3QSiBs8O42cABBeerFPN2SIhWY8hZgDI3NWy7olYHGXpqo44EbHaDMUWZiQ+haHfEDwAx2Ph7xm7bjST+nGvEHOfHFaeEBiIhtmRstqMnLA79Bnh3wB+ERpfAbTw8BEvBWnQ3pu/0o4PEnMlJ8s/Xis6dhYR5RdorFBy/Oob6M/i5CA90dv/D9vm5cRNwe9oj9b5LSxhwvMiPBIYGIchHB0QIQSTEPgugeIzPvUTAUI9TuNVwPQMDRAABA4kWNDCQQs0Ci5kaBChwoYRFyJMKNGixRIWXgiUYQHGRZAFURxEcaIFCwAuVCxU4UKgixQEKc60EDLikkEjgtiMuGImSoE+KQK9aEHE0aMWoDwRw4PnU6hRCcpoYYFEQZVSVVwFsJWgV6lhX9ZMSXYsVD0W9IgdSBHi0ylppICIM8JunAp29e7l29fugbp3Q/xgW9jw4agjX8BQYYEoYoIsaJ4g+IIrjI1F2TZJNKIK4hOOyxIM/diiUaQiUB+9scMIT7eQw5pUyXWg/wuEtkOCBSuwt+yLuM/eNhuSzAA5A8gcLh7yB5Azdvsc+KL3y4E+frXznc73wFrg4cWzpYpwxfiFWQFIRklCRYkSvyM2h8rEhN0ph0uPHrg/5OqkxHjiiNR80KIIJ/5DL7iDVDjBK/mIk2FBCoEzgI4R6DCAuZCw4MKMKvZyZAA0+EJjgDWgWmOA6vb6AsUKY5SxPxJgcElG9dgTaCQLUFBQrCFM6GAEwhgiQTSChDpoPJrMcqIIInxIbammJKJvRoJwo0g3mUzD8suL1qCgui8okIeLH7AQ68qB4pIiir2ikGKLS5qkaDmbyLATITzB9HNGFlAqIYYS/mSITZt6MP/BmxG2YEhL01Y4L0ZEATAiCS1SE+GIHXA41NCGeLvqBZdcaKFQMGMDVSA1KPBDLz8o2OuMIOAA4ociw7QgxYKei24vM7hQYz7IKl31WMhSiCkGC2JAViBjLxrDhFZGAGKhGFpgNtIGvQQuWoFwGLBALZJwoslnRQXgSAtauPFPcCmcYosz6Mhrrwo2CCJEv6oIQgogtvghP4KEmKCPCYQAQI0P+bXrDDhytbLYZysWT1kAmHX22XglMiGnnYRagT3/FlqhBfRUBYkHKKFIDUDVLJZZICEmUfhPLKQI8UU5+JLjlpt/SAMIOIKAU7sgggCCi0xAGCHfo+2SMw2Cf+T/cGasMYIP1YFigIExFTBrtuKOI6KisygKUvIgbyXL2lJMVdO07LcXZMMCNgxT2aItgtArinsS8CuBPSJS4wcugAjiV73QsCCPEfKwAI0qglXzqb2lyrzumUmoCqGNBYKhydCPpZuhJu4boaH9hAMghQlX8NGhg95aFebTOYf2IbassEAOC6y42iIs4HBYih983zN4m6b4YQsgIAhshDgu0P36ij8HvSD4lB10bI4LC3IWIhlqnawXDoK9odxTnvs17DE3zIC64thQb4vS8FtqIKo2qDA9UMc634lfAf/UghdsjWsFwZjGyFaYMpjAAY2imFiO9JjQUIQyNsGdD8Rg/0CQ1OxmYZkDi0bwojngjyFYAELUzJCG07BlRSXay4l4BUIcUggzCmyIpNaTAm/BqzCKIoC1ECPCsECqIe7BHE2OkgSpjGQh6bPA+vy0BwsUDiqHS5yrYEUBgKVhYFFZw656ZYa/AeFy8+FdVPS0vD7lUI7AScFMSqe79hEECSb4g04QkxbwQCVb22JICdyluYEQ4ShEcApPhFKQbFEmBZMCyeag4jvgxZEhQiOa0fYigAN4RwB8CYIZlpYmiwjhFnQAGgCmwIWoBcFRfsrjHG0ZkjpS5I6cq+VAloCHEaTNMMdJTgpBIjKSIakgMIgJVCiiAYEk4ShHaCRImHmkgv+E5ioo4JJm5ochDbXpeUAww7604y9sIMdnA4jA4rZDK1v9YFgDYUNeKpAJKeilCnBYIy1v+U/xKHCB1+ulQJpgyadcKEPWe8ralCmQkjmzIDiQkg/gx5DGWMAF7jmB6yrzAmVtMCRIZEshTPiibDCuL/C81TwBsId78aUCWnTlOMvpML74yxKTG4HjSnSGWd4OoEMl6poMYx92WAASUcFVJx0xJrtQQB9S2Y9/XjC7qPhOeARxAoFEUISLZBQhBCFBM8vKk7vlDSqclEIQvGiXWOmllKfsZ0GUt6etNoSTRYsaYPQShxC4FFQILWphMVKjr8FApAQ1TJAgQIF5WMT/edBrK057OgBA6AUQA7CExEJSVdFIZkJSYQUFWLEQHmRKBEQIieuE4znKrKCZIMEk8yKCBZvu75Oh3MsBXuE/iYpFDcngrV4IaFjk5pCK2yMI12Iw2gcO8Q0kGoAxAYDbxCVtO1GoFRAuML275CUKXAAulkp4IusSZAesqWZEXEsWHlkRJPSj3v0W9hzFqZQvtAJCBG7Rs738bIRR6eWKWmQdGCVXwfFrQQpUgAIYtAC6AEifC0qQy49Ely1juMUoBTABT2qHv2gSrCEE6KIDjNIuyPOTIjysiIYUQUpQuOiCSkimAbzDsnuZq8D6uQfB9YVwmmsjVN64J00uWMky/8tIDFCwkRSUTgUxOVILGjNhoRbGxMZVsb8AJrDyEuSudgIG44Aa5vDEhR/F9W1DjOAyD1ZoAq+Cq6yC+S8giNEiY25SXge7ZEDrLiMuiHChB5KRj4yEBNrUcFis8F+9JGepbLmSGnRmlypIQbATKbJNfHVZAI8gOcEgL2pvcJQdoGcLzyjuX5BRmIKKJ9aBpvV4UvCCjhwkdBk5T1VYgOhGSwUU4KUeKNbU6TZtIWpAnZhNPASi3hI7DqHM9KYBoMjVttcwxasCz3zWSiLXTmazrnW5w+O1O6agBT5BmWQyjKxeYqLVxsUEhX6QT0zz81OSlUvUgjmnfsz7L+fQy/+ZCVKEaSbIMH3TSy5iii+aApSw5qb4jMq6ApgsllkH+cjoguhPRy/Ptgt6ZSyDCoA5WCC9BPk0sIQlED7TBBf49owU1miEinoqLCx0ISRE7ueKB13ohxFKTFrAJa9dxcnvhvdhFDXriZ9Rn2oEQAYqkAGCPBunEPPsvgtScrnOsqtHAWtbkF2QNKCRf3WF1tDd/vbD8Bqkr2N6hS/McYtB/eyIhArP9RILWVGgFv2O05zQTLuKbJLm+8QCD7DNWplEZAotlCsMiQV3zGeeJ01mZleYPuV1tevKwRbLEiwQBsTUUn/eTs6Bg2Xtw0w+lmlY76aqeaV761PfbBS35n3///uFOBgFD1YmsBXN6PAdZgEWSMVhamCBGrDlGjGtgDRuJaO0/w0a0RABjVGu8jbBMuzAJ3/5eVKeg1ASALwGgK+BnfzC1OADfPhA9NlSAwnwQQL2j8p5G1fdL/E7u1CHdWiSxbM5Dto7eFFA82tACjmBGnmXgVA3dlsPjyC9qMA/JTABJdg/sdBADvTAqMgAFdMLAcA6qbggtaEIvtEt3HmYLTi8Zhs3B6xBMOEhgti4C/Q4DHwKEDSBEOQ/H5SADQTCDhTCkGADgRuBA1Crp1CiJFG/i+A23AEH2OMgrCE3G9xCifAcXYIkGLgMpjMdtki5NwBCNHwDCzhDNGxD/zd0QzVkwzQEP5uIuZkAuosYpIcCAKFQgY87lLmZpht4gk6pMW+CNQaEDS5cxPHQHl0rCBkIw4GCv7CwAQXQATTUAQ7IgTfsxE7MAQ7ARCDURBugNKhAJseIqCRBGePAHXrQFKTwgRsggh0QAxzQNnSBNUScCUbsxcNAIBzsGoRogcWixEq8RBPQAQUoxWPERE3MgS5AgnBLvFP8CYZwm5DIANzBOhwQgx14ghtwGVhkjdZIAtxRoTWZG19cR7HYoa0piPRZgXicmVmzxBxYxsKwRwUYByCkgjEAlfMRiPWRnSQ8gCZpQoYwAhxIgh24Aa96mbnBAZ0Li1pyAhw4R/92zMinYBfmEshmwpjCkAyEwKqB4BGSnMF8tABmTMlSHIMlMIEl6AFDCUgKUx8sawg7pAg8ZAgewIEi2AEtwJ1YnMUdKIJbLAqauAiJ/MZwRArc0bYF7D2NNCxHBB+P7J4UgA+2wEYjeY/46CavQ0d0RAIqAMIsIKqCwp2mHEcRuIFyxAFDxEiB6MmfJIIbkJJxlMUOgqKmm8rkAsZ3JIhcsiOx4Mop4goSyIwY0ptE/I8isw8TYIKhSkt1FAiLZEi3ZMvuG8QdwJ2GPDW2hALOtMW2CMTuK7s/80vkcketFEzSKUyESIFibImXmC2U5Jws6EdpnKOoO42kjAi63AH/u8RLpzRNpHDLHUgCuLQSmpAx1phIkFPNwhrMR2wugZrEizDJ5rq1gqDNlLDN5SmgHnjJJfhHuMujpXwCzzRKqLQaAOCBHcDLG1C4VGGOxkRKqYS3+ywq6rTK9XiMQcHOqCCBk7QM0VHM29SdMShLEyiD89SbyjSqgnA8pCAC+qyQXDTF4aFBcxMoBsrKrXGgsFiBqziBFLgKHXEP+IiQsKSqB8umXEIBAV2iPWQXd0GCLgBCNxi63vRNXqTIs3MCbPOBHWjP8JBLCRXLvNO8/qxOqTCVg8gMHQEA7awktri7k+w82rAJKBSIJgMAxhAINwDCJtjNApIieLRJQ9FC/4nAAdAkUubMT2eaG0KUSIpMPfuU0zvNvCb1zywLi0kiyCxpCUO6yYbQQ9NQgQRKzIEog5f0xwJ6pBwkxteRQixhU4vAAXGEAtRsUZt4Ei3wAaEsEKJkzzhlQQ3dUF3Mu/0MD+8JUT9NTZvIIAs4ARTwEUHtj0lCIIlARRZQxbIavscYAy+AyTbAnmtqDkbjpjX9kiIQxyOAzsizCR4QEHFMirlhymuFReRUTvpE0ib60VQ9NnHty/C4ztYciEBpLkLpQZCgVZKojAyDsGOyRo6wgEKRjAUiSyAcgqzJqI1yEI8aiBcAKdkMCcngEhZojEOCjVZtiIQtiIVtFwmcy//4ZA1DBABwMYKG1JQbSAIjANfL/EzNFE1whY0ITdJ0fJklPTc72aW6iTVBJci5u7AxtIiA7AhnwY1JhEwmMFOsEaslGYizWhfbjIjy4JKjs8AZHY+kLYil1VeefIIKvVBEAVXi3BSmkInflIjgHM7iZFnNmRvOtFMCkwqFZMqnBFI95Tvg0EHCjB+ZnR2CNFGSaNqFoEkbrdhG7UfU45z3WhdKla2LoI3fyAiu0BYsMVzdQFyBUNyGEFKk6MzfrNYn2FYfIAIESdCnkMhR1UzQ/dyhpEVTZZ+uRa1uFM67hEWh5BRpxUI8DSibhQ+qKEZeGqrxhEnz7NEZCVwqVdP/9GiQB7kK+bDRWAUOLXEQCOES44VZgnBTbH2Zjk2Nj81Y9oFQiATd0J0bbwTHbfXYt1Q4jBxZLQDNcRRNWhQD0TUQc1HEXURV2ciIzEA+7MFUUAkDBnXQtisqLckNhugIQw1ehMCgXOJbAfbfhQBgkMCBI/jcI9ha+XnfsRpbsSUIhcRM84VFKMCdh4TFI2iNQpyIuWEZIthWKCCCKllMSktZyGiMxVC0hghGcwUoJPBZALABlUwudYGoFDhJ91oJhijYjMFXm9hhADBRH7aSudFcI/VRahzXaZxgi/ja1ZWb7JVFLSjKo8RP+IUb1UIK1+W0cr2IkXXLkz0MKFWf/0n0wo4kw8IKEhPwAAW4x5UsKnXRkgRqLQQeCMjdQ4m44yjFW4Ng4T9dVbG4yIg05IYQlw5mX/El5IFIz7U0zqQYDwiURIaoSueNzqJqA2EIxWTER7hL3iyxgAlDEo1KFUhuVlWlYKdUUuBsmSkhgnOk4qwl1Sw2yjM+jIvLuIUAzHSdYaKyRFEM5Tr+vYfq4z9kktMdrIc13bZ12DF2pme+lC8WXU0RTUIkTRGuYNkouvbrJtYU5Es1LDOEQwuwB7Z94n8ilZQ4la4YlY1gFnJmErHo3z00iWU2IPuVChzoTNPsVhy40FOVYsiQu5hIgZvtz02uT8P6QQ78gCuAyf8uyIK/jeCi2lvfKNECltWoUI+FYJd9LqB+psgRVmTg4LyYCJvgi1thJioQ7EAMYIJiRUMvYII2AFoVls5D/Og97hK0ZNVpPlv0ED7i8xYPddd/wj/9478xyIIueEk0pAI3kMmd5mloZudeTb9Svkk/7okuBtMGCWDS2JKpyCVL5WLbaaiwHh0LUAGyvrxWlg30swApRJWkNsbCej4kHIgeGAIGRcOKNs+C4GuslhE//uoeSmsKmxAhxtlafZSPUOAv8aEgdmwEdU9y1WrIuOSK1RiGVmqJuwgkaAOabsObLoPdZGoRPOzwcGdTKYGSUWyG6MMgwozCRYjMPjRTBhP/224I3MZo3SHRknwX0HZpN0Yu3g0DqJbqfnwEIgxC1w4Pjd4PjmRsPuTqgTiZa6TUvEUIkaIKsKTXGBGZVexu2z3Vtcaa2e0epsNrGU5uzfvrsryCDyhC6Z5usSJJQ1Kf9I4Rw3wJuH4KZt1O7K7tsOaRk3iKAE+JAV9cs1bXkTQMt54JsHybkh4qTVhDdF456fTOiFDoLxlIH3EdFMjKkKgRAKAKlCBIFmhYm7DsiOg8kCBx/jjxepaN0PhviILcdqQJGSXpBiTmTOSAbbhorM6og12I+DDgBaGi9REOeI1siZjYC+RDXKWIA0+SbmmIF9hyglVTKZ8JHg8PWt3t/3stc5soARINTCEvqrUxEtpuCCJ/RiD8Wb8E2EPjzhVM4kAz7+1mxVJ2EAj/aYh6UdYB74EQb5awioNev4bOmgz/ExkX4JEuCH20gTBIHZgcAp1WTQL1cjCvtQYXCCaakR2P4Tryc4kocO4Bcba4VZOoIn4urN+eVEKCChxeyR7g9CXQ36lkARm9sKsQDhfIDD4fOhsvDROljAgrdI0IPklh9YJQcRbHcj4s0aUtDMQ9kjpyckn/J0APCkG3wF+d8wQtg5r2gmPVSLvtkUIRDhnIpSUfOiifkNIoASrywwdUdI7Y9h3BVWqPjIzKMIJUiSiNu2bxCRYQcblNLsN0qP9LNzs9zQKpbgKrnm6NBw5Xn/KB95MHawybfXOiWnZlUkXDQIIhkOouQPKNf3mosPYF/41ctRi3foHQAPcsLKx7P+KTR/ewqGE0ZAKXp3jOluajh3nfs/IMo/mP/xMSIIFBgYEcf+mMDIMc7fRP319YVnqvx5K8rl/zi/MVdPSC6HUgXIKznIjY/Xq3n5HQXpB5Z5uFqNKe/r1KT5IHb4g2WHdgBwAymIEkcyPBf3vDr5C4t+QWuFlT90oWZfvyu3UvBXoAcFQylUkyUIArUIDB54nM3/zOP3zRN4ytqd0FCe4gRkw0h/zMG3c+LHfJ+JwLHwiVl2pimGMTuMfQv4j/zOdE3R994D9o+IjYos6ovfeNG4EJK3VAw+wIgWAWNQcAJHADOwfC3zcy3Ld+zg9+7heL/pz9sNBOlubDo/VO5Tf6ZvY9G3edQ6JnkOh9NwTFYvbEN6x+NLz+7s9/m6DOIAcIAAIHEixo8KBBFCQEsrBQ8MVCADBeICzosCLGjBo3cuzoEeELCxZSyADg4iILFRZauOAoBMEVEzJlXvmgZCbOnDmVfIiJs6Y1Jm2QfAQgUiSNohaPJlXqVONRC02fUq1q9SrWrFoRluhaYitCEipOAHiBAkBDFgDEdlURMeNFsHLn0s340qeJKwiEKL078wq1mzOpDOnxMa5VxHWL/ype7Pgx5MgcWaRgsSIF5swwFoccSTatQBQiz25sLPk0arsw8+596lcv3x5uqOBc0iVLmNJZTac2yLs38ODCOcawECNF1KMxhnf8zfw53ZeSWlOVTn0gkjJMvOD0IpToQRsWbFwVTx66QPNXo051yh69Uabw65aIUSLFixj6Y5CwsHk+Qs4BOKBrM/BllRAGYjRGFl3kRJhhA9mgQA4KnPfUhBVeyFyGFmIloEcgAifiae/NRcJyA53gH4G+tfjih7t1JBttM9mWxT4K6GCCDh46NeGOPW4YHJA8+lgViboNmGSJdHn1ZFf2wTgQk1NaKZCJT2W5ERJtbCdTDhzsKP+TkEoVSeaRwJ1p5JBKVYnRm5HF+dicGhWXnEgpXlnnlX0GF4Y4FryR0xuC6nQoToUOmqgFv2gpn1JzGMpoJEwM0UYP4HUEhgVgXMWpp/OBmhikVY0K1p146mkln366mloNEghmAk94IYpoTbPWaoJ3Q7mpVBgNLpHrTLvq1EQXQ2TRQ24IgUGhAqE+9WyF0j5HbbTrYYWttVl1lQIMXcnQAll9tvoqupHFepMSEtTw1Lq0SqCKgzhBGGJHXX45kxcLyCpvDWP0MMQQTdR4KBVNuFHYGAA8G2S2Tj1sZLfBTdxjxYx9qiPFcpVgAUUArPgWq+mafIJoFqhFUH8jfaX/EQktWECaishZ0JJHsfLhblU68ywQjbXd1iycGg18sEy3NQyAz+8ehEQPZQzRRRNLHHqFmDNhrNTEaGaMWtcdU3Vu2FuDpdILMIhG8pTnmgycCim8TJAMFpQErkYn4fwQRcXNzVENFjjds+BPa8cdv98dFPjgBDFY72CFLV64Rz20MYQbTXRiQQ455cD5rYh+3jlOn5Oi6WGlfoQEKaCXboEHlpaRac6Uzzhw5puTPtPndYDlgswiye2n22+jFkMLfw9EQgoCkUBzRSmwPVALKaqscYwZPf6g5AI1LVB2+8rUK+oHnVtD1mRyYGvoOWE9Jo/ry3Qv9h+NUTBN6cfP/75MTTShLLMQ8r2nRW0ITKja1fSnAw40TisnIAEMSKC8thnPSiq5WcxE0oKVOY80YjnISSygAqMED3pGWdnN6peYys1GaKr4V7segbQbEQ0qV0FfkBgIr6wtMBUttNHQmtORMJShC1YbjBswwEMGhqEHWShYE27lBYVdqgfxalfAnFgwpOVkigvrgWFwGL8GOol4FfTT8wQCgxEur3lrMeFBNigylhCkeljiYGlU5yY9aiR83CGWTHZFv+bwsSjoCxMZP3JIHYLvcN1RXNEw0iU3IE4mS2BCGYi2yEQCAGpSO+ARf2KTYvXkUP4DYA0LsknHuOAFdjTXGfs0rpLAoP95JwFA3e72H4y8YAVzXI5bytI3C0ywT9+Y1EwKpYnnMO6GtivI9uzVPVU+cyD3iyJOmpCFpRmkmZXDXSSQKZNCVWoIsyufRrw5F8tc0DhmjOWVWkYSk1xEnsUsyAls9p9g5lMke0vXmsoEneIZZSNBAyJuvCeBnTmNiEa0lxvaoCQMcQxNbVLhVsQSlXm+E54e/ShFIXbR4BCUSX7sjr/YJYFHVNIEl8wkvqpSJIEiiS42I4EMMPMqgoK0pxjJoAmB50+OALUgQk2hRzo00o2sQCRsg4FIVFCSEBWSqkgpyuOGNcpAllKb3CTkVami1OzJxWYteEHcdurTtc5Fbwf/gUFLYrYRtxoErmtpQVHU45QVSPUgLyjJC0KWLkmhIieosMAcnqNXJFXVKs87ylnLtSe2UlYr0ssI8jZyWYxkFqMe+Rge3ypYgLrOBJ9bamp4+pgH2mxVFKwsbIsSwhGuZDQHOYEKXDuQ2ZLQtgbBrW7h0liDNNUCK2hI8KaHFnJ1pLhsS5kcNYIykeCxIb7tiHg6d9qnOLcg0A2tcMOqFMqIpCDWnZlcZEAC8L5ItbEFqRxPQEe6zVcj8a2vQMb1T8jUTSDFkaxAXNBXjvB1qgip5Ubids9ffkQ8VxgPdwd8YDdGZkW+rIh8g/teKm24wx7pJYODKRYDawTEGQaA/4glfBo6+m1FakHB8DgC2oyAGLPJw0jdAMyRxRZlxry8cGTUlpEce9h8RT4yRvrJIhQvpJ1ITbI+BRJMJ+8XIdO9XkJIlJKVtMTFK4qKjgdS3OPW1gLTO8lYbnuUBwYvugRRiXIn2lyRkDm5BkFzmMHyZQugLHgpCDOckWwRQRN6SgpGSHFR018A/PcgH8xIGiXCxoKUQAVVDq9UnLLoRhvk0Rkhr2lwC0eQRCQFQCZIpS/tYfcWutVYQd49a9mf1LCYmLfMJ1lggNcht4CWzVvBWVawEPnGeTG1LsGt/yyRXSfZuFxBzqgdPTy8ARsAwp5jsTfMaldz+yMXdEEGV/+CR7Gc4Jao2TIdb1mCzqiAvZ0WXkmqLWCRjFYy6G6JutntboIIGSGmrjZHOoOCr8j7gvVG8ra7rXCPRHqNb07OwoWz5z4LD8AoCHa0Ix5TjXOcv72WiC0RY25Xd5cgxS2vZCAiEFOrKDkZ7zhcYC7zxcizJCOnJ7cLfJAVnFoyzPsK3oIp5pfPPEBFPzrSt+Jj4kZ133QR+FeELhCAJ92GVb861jUyZuQ6FdHMzvpkwS72sdPtIpw2b8LHnrKjZBm9ciY73LF+bBcDYJ5Uj7tcVlBvtlQ62xzGO+CTfm+RXa8zHA28A/n8kIiQ4OBGRjzkIy95pdT4zThzAYUjOfn/zXMe8imjWUMAffnM46n0pj896lOv+tWzvvWufz3sYy/72dO+9ra/Pe5zr/vd8x737XEVCnouEJVLxPEukhHytZV85TO/+TVd/vPJukLoR3/60j8jC5jLkOvxXeqad371wy/+sVGf/Ncfv3u0UlL1s//85oen90EDgM9zhKf2L7+W2g/+91t//+nH/68AYAD63/9p3P0J4GHoHwF6Fv+hXwH2HwQ2oAMOYARKYLcdoPs9YAXmXwZqoAVy4AIyoAd+4AiWoAm2GgaG4Map4ApOoAhS4AbCoAu24AzSIAiyIMIpYAy+oAySIA/+oA3eYA0KUQf2oBD6IBAKWgruYAIi/2AT4mD9OWEQGuEJPiEUvh0SWuHCLeEQYmEWTmESEuEVWt0YxlwRhmEUnqEWKtzvVUUbUsUbOkUcyqFWzGFR2OEdZgUefsQedkQf+qEe1qEgYsUfckQhdh4iJqIiLiIjNqIjPiIkRqIkTiIlVqIlngyfyd8lbiInwlPLdJ1SrEieVcXJ+R1RXZdTtEy7UUW/mcQFDVxRtOJ5uV1HtGIJpIyydcS8zczctCJH7CIsDgQKTNovvuJXrB3KbQSo5SL9ecQyfobN5KIyRmO55BR1OSM1iozNGJ9GDGOAGWNReCNaRAXRIYQ43mLFpUukzVooKt5WzNNJLBhH1BKJOUX2lf9EzMgjhl3XtRGbR3wZ6MUJQIqZG+GHR/RjCwwbKjLVsCXkQOgaMTIkthWE3nUEBAHAfWxG95kiy2xGRq6FR+INUYXkZsjXLjEcSc6fL+EWRxYERE5dQ7bkQ7YAGzUEK9Lk1BUkN8LIOobMUfSVNTobOvKiKBblzICiUOHXRjBPVXxMPaYizbhZUUSad6naTwXkU1BlRUqE8HEECuwNVYYjzoiFp4klQYhiUQBXWTDeTmJYbp3lW36EWk5EVaglloXlUrpFRM6fVTqaXm5fVv6ltYUMDHSllXzikokZRYCYDFCEQqwcCRjlCazIZsRjSpAFrP2iSDzlRxTHBRnmL37/nHz1JaTBkXopBVWelzQSFc3cRwsAmz4ixGkuTznKZkRkX7ntJUfM5kBUXkegjZSNXlEA50AQp0cQZwpckIpxBHGqwIU5XEfgpoAVBG8qI7lM5zimY3ReJxu5JmyqI2mw5LLZVsxcW3wcxQpIJlqKImK6Y2jGJkYAD1mMi4YRWFS5E1TiE2iWpkHcR1t2Gs2kEVmmZc/hJUecwIXJl1pgp1z2XOgpxX00mXD22GYJRIRSaJP9x2VA6GXJgHJmXkYoqCue5X7+lhwxqIUa5IGeKBsJqPehEc3wnFioRaTJALCpwMesinoqHnuC6GE4nUZknzDKJI4RU1ZCDwvUZliM/5qB8qdARBeKKiMcNemnBWRyjCJCJGlClOhVrqUa/eeSFgSV8udjjmN+EkTaRCeefIaSDsQsigSAjalBvCmfQaluHiZpeCgENc99nMVXjuMtDg8JRCafSSbhnUBDtEROSSlZ5CNVlIBD1g2QbkROneRUBiiOHqmYDVuFsuZApABpXBzDZaqYtqnzkKpR3WlFsIV5aV9HqJx4buSHDVswweqL8hKtLgS5lYWp2irJ6BqWxmeLoqpssVE/dqoushGohoapwgdiliRytMCyfuKw4SIL7ChZoGW4canIpMwqVsWWmVlVpAyR4lNULAQyqqqaHcVCHBWYthy74lI2dkS6Ev9evHplVBBjlHZjvkpZud4VvQnjQsJM8IRMuL2r8xRsb2onUSlsdh7eR2BnvUYsG7mrU2BnUK5mJ24sx3asx34syIasyI4syZasyZ4syqasyq4sy7asy74szMaszM4szdaszd4szuaszu4sz/asz/4s0Aat0A4t0Rat0R4t0iat0i4t0zYtZBTH10kGVCGs01Ztn5wAu8HA3YirnaxEZECtGoGM1Y5tLKnEcqzbQiAHR4Lt03qtRIgt2cZtutTNxy3sUXyM3QCAzCxHUnqtSuCjsy3PSIhGCsQA4c4nLtLS4K6EDNTNUcAAVIEq48ot5V5JO5Wp2mLkZuqtcdQNjoL/LVRtxt+yzEhYW+mGhATJjAzIV/JE7tueBdu6LlQ1a+XWLmqUwBrFa+bibUnsLVT5Eth6bkOAaH9QxNS+7Qug2crdzPH2R/PErtg6r+1O74s0FUXs7ub6rrOxrWioxH4VL/Iir/LWHfNGb+lCL0VIL/WuL3PIAAqkyNrMH9d6L6Qah2fS067xlpiK7fFObf2ubgu0rvk2D3KFbfqWLvsmMHDgrrdGBPKIBLLR296a7ki4LYpxLekaL/+KrfvCW/iqb8pA7gArMAkbz4rcWAmn8NEdrwq3sAu/MAzHsAzPMA3XsA3fMA7nsA7vMA/3sA//MBAHsRAPMREXsRErXO8l/7ESLzETy94RI17aVWIUP3GRTfEkWjEVa9vNYnEWxxYXQ+IXdzFlxUkd+E7IhrEYr9WbiAeEBQdauimWMdycFMekSgZuWWpBpfHYVUl2bRdVnNxfyaV7FgXPNeWtPoWIhkZUsMCbousi41LeEgQa6zFIMUl2gUkbKwWMZWvyCnKwZkQhU0VZkuI1hkacrUhJlCma9twkU7JHJckl804mO+MgD5/wRJ3NoEBnKORNHeqKkCuWRJUMnNdXspHhEVxyipCOpamUNaObcJAqU+SFRbN/RW0ru3IskUgsvw5qhYWP7irLqcDANQRFxOPIMFqhpnNlGqliWtuFTSc4+9JllP+ECliqpRXnwK2Ia53cmpkPNN9rfrnj2r0Fkf0dNl8dYjCB6JSW5zC0jXwVy/homWbWPZ+QL7ujpRkqWuqabYXydE40XoVyKBfn3lR0RTMGeJ2EgQXfnUXyG2PJQWNdQi/07jR0TT90ltYySKMYzlyPoeptDGg0n83oG7nzN86fA4f0hY10cJJ0U5vcmvqzVI9jnmFZQcN0TFcdidSBQ5uWBZjxR2BGSWAtuI3FffhSRft0Ottc8gj1CSBYn0oEacCzWbOcSPccM/P0U6O0QODaXb0MCuySXzsqo1lzVmt1R3B1TfeOU5QAIAPWLeu1RRulzMRXOmdroUbrso7LzGD/5zEbNWgvD7OZNGnuXFRgpLeuDPDMzVB+a1mw8mEnHZMoNiaDtYf13Xzk0qDF9tFViWIztqAhTx1XWD0fH2/P3Jtw9Vef8XEXHRnbtsdec3N3FM1K93SHXc1a93W/VnZvd8dpd+eBt3cTiHhvXnmP93yct+SpN3oP1Ba39xa+N3xfoHzPt6uRiOp1LHvbN0nVnwj8N4AH+H5DmmLI6UOmGXQ0RH1iNX8XGn4HOISLQJxERSAjGrce6pkWKWc6RXFI8mmXRTpm7FSxakUMeIOjxoNHOIBPuFqsm6tK84HWskWWo29WxQVJ8rgNj6i2EtBFZV+a+IlLRoqruIQ/s5jJ//NSk9loqOZXHJULrB0LDGU+240KWJoxa9BZSLnyvNIvg2JR2CSV4FGZLtryABldlniQExpiEAGRS3ibu7mK+4ARlDgHTeddh3ZxLkS6wcAbYy6hrkCTj9CuCpmfn6U7UiY9/c2eoedBgHkwi5BaXMZXnN26sYy6Anma0wlBsDmRW8Cbe3qcz3mA1PkI3XkoI2i8wtgKdJk7Jkd6uuNHM95ZuLqhl8t6yrgymsYK4NV93OfcvMDf7KskZ3oOlsanG/nUIXmyg/YLKFuZusBlvMAb42dfw/oIlWkaUbu52jqPDvKi01mjm4ajO48b+bWlfx+xa7GxtzmLY6Qr5Vrz5P+UL/Ub3uhpPuGj3GAZjH3FoL7xdNbSt/ipoLINl3f7J+f0boWMqO6WHd1jXe0kpqc7XQy5ik/4UaDAVOGWCLEcZ6NA9o2EW6xb01HwtVqrv49Qrw9utwpPaAVWtWP2wRvE5cqrdkbVWF7pk/64xK+af7N7bOm2sxKrce+8F9df6r1XLcV8ZCi4GRJ90dtsxDu9Dsps1Eu9Gq5s1Vs9E7Js1mv9F6ps13t9FXK92LNV2Gfd2Zc9GLZs2qt9Gna321dyfcc9PMVJIRSCyLY93aP7RgjBBEzAgXys3u+90X0EG4AACLBBizB1RWgiRiwresSM0g8+4Q/9RljBLeRBHtz/ghU8Sr9qBeNXBYlfhSySI2qnIzC+jMt7YeWjS5WsQh+MwAj0wSqA67aFPlUoJSJf17hbm05aW0wGdMxTfusbNABIgewnv/LLvhwMwBfI/hcMgBws//JXgRpgBJh/4kpWsHHZjFoEpbIbdSEr2XMKs1ECc9m9DPB4f4b3/lYWZlV+KkcSf/HnsUAgP/UrfwXQgfIDBJ0KIwgWNFhFDQCFCxmysMAQwAkLMiTCAEDCAgkAK1IAeLECgIwXG0GSNIkCRcQWLmRYOAEAhguJJyoCcGGhBEMXKha6WLmxo04LQ4m6gKiQREqFDoemeFkiRYsVKHIulKFx4cejWx9u9foV/2xYsWPJljV7Fm1atWvZtnX7Fm7ctl3HrqFgkCCFNWsdLkVBlMVMAH1t8iQhFeuKkopNWmChEMaLEi1QrJAR0aVgwT15KtzpuTPapEehjhxNQgXWiCUXMhZLV25s2bNp17Z9G3du3WVhgxUyARDeEYAmCFFLuMVIAI4FE/4ccqqKEq4ZM3YMWTmJFS1IzNTsUmfo5897Ei26dfTR0S0eF/Z7VOvr3fPp17d/H39++r2/sgEhnCAQ2DjuoRIsiMEm5sBzjicUjHKoBBg6kiEFkBhDKaSVXJAMABRg8A68zRRqqarxQjsrvY00OiEFjVJQCkPUqmKoxbH40w/HHHXckf/HHt+68SgrbskDwBHyuMWKtAjDyIK/Aluwq8+YzCgiFSxQoUKTWBwKJAqboimzEMFjiDvQzDxLIqI08mko5by0wKkOzeuspZfk8xHPPPXck8/9xjrFvECJOqXPtmT08QXl7iyU0UYdfdRRICHN7cUeD7Nz0Uk13ZTTTmuT1NNQYwNV1FJNPXVTUlFdlTdWXX0VVjxVjZVWhWatFddcdUXr1l1X7dXXYIXdFdhhQy3W2GSVNRXZZSdt1tlopWVU0GqtvRbbbLXdlttuvf0W3HCxnZbccs09F9101V2X3XbdfRfeeOWdl9567b0X33z13Zfffv39F+CABR6Y4IINPhgp4YQVXpjhhh1+GOKIJZ6Y4ootvhjjjDXemOOOPf4Y5JBFHpnkkk12OCAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean adjusted change in International Prostate Symptom Score (IPSS) from baseline by visit and treatment group.",
"    <div class=\"footnotes\">",
"     * p&lt;0.001 for combination versus dutasteride.",
"     <br>",
"      &sect; p&lt;0.001 for combination versus tamsulosin.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15872=[""].join("\n");
var outline_f15_32_15872=null;
var title_f15_32_15873="AC joint and shoulder internal rotation";
var content_f15_32_15873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Internal rotation of shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with rotator cuff problems may also experience pain when their arm is adducted across the body, particularly if the shoulder is internally rotated, as in the photograph above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15873=[""].join("\n");
var outline_f15_32_15873=null;
var title_f15_32_15874="Traumatic perforation of TM";
var content_f15_32_15874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Otoscopic view of traumatic perforation of the tympanic membrane from a cotton-tipped applicator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 345px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFZAU4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooqxZWdzf3KW9jbzXM7/djhQux+gHNAFelxXqvhf4G+KtXmi/tEW+jwv3umy+P9xefwOK9e8Mfs8+FdOvo08Q3t3qZxyA3kRk/Rfm/Ws3VinY2WHqNXsfJmK2dM8La/qgB07RdRuVPRorZ2H54xX3X4c8D+FdH1MjRdI0y3MRHIiDMf+BHJJrrpJBCZI5Qqw7cqAMCvPxGZqi+XlL+ru9j4HtvhN4zldFl0aS1VmALXEioFB7kZzx7DPtXV237PPii5/wBTqugMPXzpx/7Sr6S1Z/PnJX7uat6Wwih3tkKB1rB5nJrSx6ryulGnzNu58t3vwB8UWn+s1DQz/uzS/wDxuqafBLxEzY/tDRgfeWX/AON19LazOZpwYj8p9apRWZVtxYnPWmsdWetzspZPh3C8739T54uPgf4kitpZY77R55EXKwxyyh5D6AtGFz9SBXN3fw08YWoJfQrpwOph2y/+gk19awxEtg9RV+xUJOuR1Na08bUe6RjWyigleLZ8MX+k6jpzEX9hdWxH/PaJk/mKo1+jTW8aQbpIkljI+66hh+Rrznxf8PPC+sl5LjQ7RHbq8CeU35rit446Ldmjy44CVR2gz4ror3rxB8EbFmdtH1Ge2bqI7hRIv0yMEfrXm+v/AA48SaMrSPYtdW6/8tbX94PxHUflXVGrCezIrZfiKKvKOndanG0U4qVYhgQRwQe1NrQ4gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKfDFJNKkUKNJK5CqiDJYnoAO9ADcVqeHPD2reJdRWx0LT7i+um/ghXOB6k9APc1638P/AIHXN1Ja3XjSR7CCVwEsUOJnPo5/gH689q+s/B3hPSfCWm/Y9Es4raI4LbF5P1PU/jXLVxUYOy1Zr7KSipS0ufOfg79m37PBHeeNr8eYeRYWbdfZpP8AD869l8M+FLHQLd4fD+mW9jGi5JiT5nH+0x5J+pro9YdlulklKMFJKKDkgVDpn2q/vWkjmCRKRuQdx6Vz05zqyvJnoUqapU+fT1ZHYW8Gx5NRUg5yD3zSW8K3lxMx3EAfIDWxq1oly0YUqCTyB3q7b20UG1UC7gOfWtHOMCZYr3eZXu/wOV1vw/PbWaXWlTMk6YMiseq/41VbxQ01kkc9ufOA2sfU11XiG4ktdLleIZfoMV5rE11JcYWINuOa86pRjWqc0z0svX1mnzVUny7Fm91FjFtjhC45yRV/Tr6GTS5I2X5j1NNbTbhow0qqqkdaW30tEiYh8AjBAqqlGnTOyUqMo2Xcy7kq/wDqxzUiIwXr2pxtRDJw24VYiQngDmsoRUnobymktCKGMlsjritDTLVpZ1zxmiK3cHdjitTSEZrpQBW7jynFXr+67FzVH+zQiIjgCudnuNxII4rovEAzKF68VheUuTlc0RprdnNhGuRNmW8CTMcjFU7m22Kyqpx3rdWEbugAqd7eMwOXA4rRzSVj0I4nkaPIPFPhDRdd3HULGMzdPPj+SQfiOv45ryPxP8J9Rsg02iSfboevlMNso/o36fSvoPVAq3LgD8KrRRMx3dKiGIqU3o9DrxGWYbFQ5pRs+6Pj24gmtpnhuInilQ4ZHUqwPuDUVfVvizwtpPiWApqdqpmAwlwnyyL+Pf6HivCvGnw61Tw8HuYAb3TRz50a/Mg/217fUcfSvRpYqFTR6M+WxuU1sKuf4o91+pw9FLikrpPLCiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorvfhR8NtS+IGspDCfsulxsBcXjDhf9lR/E38up91KSirsaTbsjC8GeEtX8Yaumn6JbGWQ48yRuI4l/vM3YfrX2P8HPhLoXgiyj1B0W91o8G8nXGw5xiNT90Z79TXQeDfCGieG9NOm6BGII4D5bg/ekf++zdya7bylkgEb/MuAD74rljiOeVraGs6ahFdzC1HTlubq6WdNs0kYeJlGSrKDyP0q3pWrw3FnbmbMMrfKyScEMBzUF4z2s+pyxSyzXKx+ZFFjhBjtVNootWt7RowwukyxDjBPbJrKtShLU6IJTXvvQJLeF9QuriNmkRiCv8As+taPh6OFTcPbKPLbAyO5qvetBY2DR7mRoepH8Wa0NCt/s+mxKQAW+Y/jWEZWaNK0r0vwJYrVPtbznnso9KssFTdJjnGCe9OAwSR1NKeQRWUqvu26nI25PUo6mvnweSP+WqnB964iC7TR72MzorAsEHPfNdJ4m1dNOtgiEGXpz2rjNYimuNM86VSuWDIfcc1yNTkmz2svpvktL4ZHda7C01tEUUKvcjtWPd+VBp6xocnPJrR8PXra34ajeQFJgux19xXMXSXG5oyMgGtYwU7NsnCQd3Tk7crIIxmTnkHpWnaorHHGRUel6Y9xdxowZQeua6OW303TkCykl8evNbSqRpxtE6cTiIqShG7fkZ7xlFUDHPatHSrZg4deMUQXUBs/tAh3YOFpbe/D5GwqvfaKwlWk0cE3OUWkh13apPdEtIAByarGC1il+Zsikvry38xvLbIP6VSM0UvIPNcsa027M0p058qvexKBbm4I6IelVL1ApZUPGKmtYPOnGBkUarB5J4Pau2nKLXmapqM1G5w2pQFr3kdalCIqbeM1buV82cKv3vWqNzFIvBzxVOm5bHvwnzpJsrXcGSCvNEMG0EMoII5B71YjDKg3jNPYqw46jmsJKUdzVzduU8h+IfwpttS82/8OKlrenLNbdI5T7f3T+n0rwi+tLiwu5bW8hkguIjteOQYKmvs/gSZbODzXN+P/A2l+MdPzKBbanGuIbtV59lb1Wu3C45xfJU27ngZjlMZ/vKCs+3Q+TKK1fEehX/h3VJdP1SExToeD1Vx2ZT3BrKr1001dHzLTi7PcKKKKYgooooAKKKKACiiigAooooAKKK6Hwb4an8RaiIxujs4yDPNj7oPQD3NJtJXZUIObUY7nT/Bv4Y3nj7VDNPvt9CtWBurkDlv9hPVj+lfV3grT7LTtHbS7KGOB9InJhVOC0bfz69aofBn7JpmgS6fAqIlv9yLpkH+Z963vENh/wATiC702T7PdfL5qjowHIx615tarKerVkelSoeyk4Pfv+hs+GBHLay3EwP2kzMsnruz3rfTKvsVR5YGSc96ydEVBf3argSDDyY6Zbv+lM0fVJdR17VYQm22s2ESnuzY5rNNppmFdc05PpubEqRxs07KN4XG7HOPSsiCR2bTb6aEpPKWidR2BzjP5frW72qtdRyOV2S+Wqg7jitasrIwpvozF1q0muLSRJNsapMJGfP3lByBW1YSB4FUZwoAz61zetyy6rqtrpVox8oqJZ5geij0+prf0nd9mJZlZCx2Y9K5E3dI6an8JJ7lx3CgE+uKJWKqSoy3Ye9VIy1z9qRshVfCmppXzvCOQ0YyRj2qeVNnPbWxwHiWFr7WHifdtUZx2zVnxQk7aTpPkYES5En5U2zaS51dlYkruO0Ed/c1teIoU/sWEZ+VRjI7GtopSi4nuOpyTpR7FPwLcK9tcRW5UsGy/P3TU15dw2t8cwKz4+7isT4W6Z9kgv7gTs7tMzFjzmt3WLV1uftO3JxkGspQVrR3M5uH1qSfUn0u4lutQ4TywBuxjpVLXI4UuZ5pZySeQM9Ks+Fbt7q6uiQPLHf39KztUiieeZXYZbIXnoa5alVRjZbhTg1Xa2sjTXYfD8AiP+s5zU5mhsbIAKDIy81z39pf8Su2s4vluYuCPU1kSaneQTMt2CcetcnvzdzeGDlUvfu36jrqZlmf5jknNTQXRC4HPpWW1z9qcFVO7JqVGdCqkZGOtbqCSseq6WlmdJpWoiGVS/3M81r64Ip4BNE4II6CuIE2Bwat6ffsFZCcrmsrSjK6OGrg/eVSO6IiMXRY9BU01sZ23KtMu8NONuOea1dHkzOg7V30qzWprUm4x50c9dW8kKkFCAfUVm79j9K73Xts0WCoDAc1xF5AyykjpmtaklVOjBV/ax95DGHmEEflUxQhM9qZGuzAx1qdfmHJrncXE6ZOxy3jbwlYeKdLa1vV2yqCYZ1HzRt/h6ivl3xR4fvvDerS2GpR7ZF5Vx92RezA+lfYsvDe1c/448F2njPRTaTYju4wWt7jHMbe/qp7iuvC4v2Xuy2PIzPL1iI+1h8X5nyHRWhrmk3mh6rcadqUJhuoG2up/Qj1B6g1n17Sd9UfKNW0YUUUUCCiiigAooooAKKKUUAaOgaRda7q1vp1gheeZseyjux9gK+jdH0638O+GYtJtolMStvklC/NI/qTT/hH4EPhPwzDqmpRAarf4dw3WGLqE9iep/LtXS6zZm3uQRGDBKd3HSvOr1lOXItke9l+GVOPtJbs2NH8M/a7CDV9NvZI5DHv8pCeW9DXTzW9/eWtvbyQrHqenhZwwb76Hgj8eRWJ8MrqcW2tWkA3PbxiSJT754/Q16DC63TQSxxjbc2338YPqFP5muiLjONmc2JquFS3YxvBkksmp6jLdjZPLt2xqcgKB1zVuNjZ+MmiEYSG7j35H8bgc/yrIt5zoGqI86lIJ3WMLjhB0PP1rq0gEt4JpirPExMJH90ivMrSlS80TXSUnJbNGhWRqG6008RGRpJXbG49wTkj8q1gaxPGMk0GiSzW4/eJyPyqfauoc1FLnSZmeG3judFvb2L5JC0kCkdUCnAqx4FeQaSY8mSGJiocnksDyKq6SosfBJMJ+ZiXc+hPJpPh9ujsJP3u6J5Wbb6MTSd4s7KkeaFR+Z1oTbE23Cu2Tn3qlZMJHL7t0kYMU3uRR4gleLS5TEcSHAHr1qGS4itoXZAVeVQzHHQ471NnsjlhByjfuYIkaPW7kiNRG+Nvsa3bmC31PTpbT7i43Ejsa49vN1PXLXynI2N82eA1dbdutlpErufLZid34VfJNK0TvxEVeCXxaGZ4Ekgijv7G1+dbeXBY9yaseKXupVS3tjt55+lczoviK10ZLkW9q8ryNvkYDqO1V9R8VXGpOPs0LRs3HzDFc08NX6HRTws5YlzS0Ol8NJb+H9NuEurnMjsXYZrkdbvVuJd0MpGOQAaz9Re4uAsMrnJIDGp1s1TceuBj6VEcNy/EerQw0ac3Uk7tjHMiypcZIkXoatS3kl4SLjqo5OKjwWXGMnHSm6UrX0+xBk9xWkYq50tRtzvoS2sTBhIMiMg5bHehLkGYrznpU+os9vE1vG3Ss6JSJAxPuaJ023oKC505Mt3LqsSsowCeg9ahSXy3zyAOtSspaMenaqFxvR8OcDHNJ07IuEb6GjFcDzN27qcYrqNLaJVDH8K4OWaJoFEYIdTXZ6Epnt1B4YCilTvq2ceOp8tO5d1X5xuX0rn5It0mCK6y4t1a02jGR3rm5I2WUgnnNbSrRWiOPCT92yIJ7PcmVGKzJAYW5Pet43CoCprndTlBmJHSsZVHM9HDuUnZj/MDAjtnFT206xEnsDzWNeXyWVnLcurOI8YjQZaRjwqqO7EkADuSK6Z/hhfWvhdNSs5C3ixwbi9gMv7q6JGfIB6LsGFR/b5uGOKo4WeIUnHoY4zGUsLKMKnX8F3PO/jN4LtvGWjfbdPRV1yzTMZHHnp1MZ9/T3+tfKrqyMyupVlOCCMEGvsnS5xcxmZN67WKSRyDY8Tg4ZWU8hgeCDWP4T+DWk+O/Hcnii6idfDKEEx/dXUJwfmKd/K45b+I5xxk16OXSqQTpT2W3+R42cYSnTtWpvf8fNHhGlfCjxbqngK58XWems+lwnIXnzZUGd0iJj5kXufrjODjg6/RX4q/EfQvhd4cjkulR7t08uw06HCmTaMDgfdQcZPboMnivz41zUn1jWb3UZobeCS7meZoreMRxoWOcKo6AV6h4RRooooAKKKKAFr1X4A+Bv8AhKPEbalex50vTSHbI4kl6qv4dT+HrXl9pby3VzFb26F5pXCIo7knAFfevw48KWHhjwLp2i2bobqOPzLiRf8AlrK3LH+g9gK5MXiFQj5s6MNT5pptaINZt/tWkPC/zZTGa5VJnu7OG1cHdbgZHcgV2uoPHBbsk5CrGpya423kRvElm0KbY5FZSD/EMV5aqX1R9JTatqbmi20umaxbahbSFLdsJdqBnenb8ia9PjC43LghuQfwridMZCfJ4Kn5SK6fQ5WazMMjZlgYoee3b9KyeM5ZanmZhSu+dIo+LPIa2SG4UtE0iMcL93nrmq17FNpuvJeCf/QjDt2luFP/ANetvVQHsbhGHDRlc1zuoLb6j4YAuid8QCSDPOR0pxrKrdMyoJtRXTZ/M1/Dl8moWQuFbDSMcqe3NJ4haKDQL37dcEAIW3AfMPTA71meHrR9Pt3lLgRPhoxntWdNp11Hrdtq+t3u/TlRmKPwsTcYGO+apKNJJoc6UfaOSlp0/wAkWWk/s/wp5NwGEksPmlgOv/16h8DR+T+9lk2pIvmY7H3rpdV8m903KFXLxkpjnINcbYSPay2VvEP3YBR8dl7VcpqZtRTq05J79TtxF9sufMlyIomyo9a5q6vrjW9aWwt1MVmSRJJjqoHSt7VZpbTTjcwAuQAGX1FZuhWTPcvd79sZPyIP8apWiuZmFNLllUfTb1ILeJbbxHb2ltH50cOVkb/nn6E1V8V2up6lrH2a2VhbAfMfU10F09nYXkzABb26UMyqck7e9Z9leXt9q0DxsBCqMrcfez3qoYiSk7FwlJv2qWy6jEij0WwaOe382QIAcLniuavrsXGpL5cDIAMquzGa9Ivbq3to1+0kc4ABGcms/UWs4dQtJpgkZRtnT724YArb+0JQexeGxUoPncbtnnSSpdzPiMghsNuGMEVNNYXUoLRlQO5JrudV0+wWcu0A3yZYkcZPr+lcXqVpcvdqllIQm0gkHPNcVbExryabsevh8X7ZJx0M21ZlZ1kPKnBI5pNGuf7M8S20rR7kZir+lV4Yb3TbmRpULI4JOe5qG4uG3LKybRkFawq0uVXjI9HlVVOL2aOl8Y+VDOl3ED5JPzYGetULaLepb16VLqWsSXNpbxCD5iRu44xVuKPH3R8vpWkNTlp81Kkoy3K6xgAg9qp6jASjZHuDWg2PN9OadcRB4Rg84pt20ZcanLJM5W3UCdSx4z0Nem+FootqBvTNeW3jeTOVAxtOa7jwLeyvcxRy8qe9craUrtlZrTlOhzo2vEN4qzbIDgKcHFc1PdtvJJFX/FiG1v5AueefrXO+XJKAxBGa6KdCFR3TObBUY+yUia4nZn+TpUTRqUO7qRmpIoCsgWXjPQ1DrYuv9GsdKVZNUvpRbWqsMgOQSXb/AGUUM59lNWqaT5YHTOrCjG7eiLnw10L/AISDxa2pXCbtK0STEWRxNeY6+4jU/wDfbDule3VleF9EtfDmgWelWO4w2ybd7fekYnLO3qzMSx9ya1a92jSVKCij4vF4mWJqurLr+RxXiv4daR4j1iO/uHuLfzMLfQ27bUvkA+VZO/oNwwSuVORjE/jXxVa+EbC2stPto7jVZ08ux0+P5FCrgbmx9yJeMnHoBkkCuurhfHnhKW8uzr2hRq2sJEIZoGIC3kSkkJk/dcFmKt05IbggrU7qLcVqZ02pSiqrfKfDXxgl1+fx/qUniu6N1qDMCsoG1DF/CEX+FQO316nJriq+jfjboUPijwmmv6ajG60/cJFZCr7AcOjKeQykHIPTBr5zqaNT2kbvc0xdD2FTlWz1XoJRRRWpzBRRSigD2D9nXwW3iHXLzVZk/wBHsE2xEjgzMOPyGT+Ir27UbnXfDTw3EUbTraH51yfnStH4E6HH4Z8HadZSqPPkXz7j18x+SPw4H4V0PjucpaSusYYDC5I7V5FXExqzcOh7FGEqUfZ91czNa1Ow1rw6LuzcefLHnYTjaT2rEiMWq6DbzK3kalYfLkfxAdqi0rTIjE0cgIi3feHbNUGdbDV/3Tl4QfLlx6djUexildG1Oq0zpvDur/bIm3r5dzEcOvr7101hqX2ef7QBliNrKD1FcHNYsbk6hpbBGiA3YPEg71JHqDk7TN5DseFI/WuOtg+fWJ6CUK6sz0yfWPMicmPKdQayJp7eYysFIVh8ytxmue0q+urjSpMyq0qOR0xwK1obm11ANLMm+7KBBEvAU1nTpqPusyWHVLVLQ3tFtUe3xE++NDwmentWB8SLmW9hGkeUUjlGUYN3qPSrm70G+nMis6SDIQ9jVSd/tmoR3V5fbI8nc+OI89BWlOm07tkLDNVfaPWPRnSaJB9g0lFLlvKjA5OeaxpSbO+lfdma6YbU9AOprV0mM2umedfSFhOxRUP8WOhrNvbYL4gsbx5PlVSmz+8DXRJXRFLWcup0ru+pJDFbMBC0eJBjOa0o/J0uxhjVcIvygVg+FJl0/T7xCSwSQsi9Tg9qRLq71aAtHGxZGLKDxWe7956HJLDtycdop/mQtufxDNdSNndEUUY6CtfQIvLl46beKpLpt6/WHbJnls1s20clo8MeQ27g+uK0bhB2Q684uHLF9PyKut20kmqadIsgWFXzID3x0rN8Q6XJceI7ad5ALRU37c4y46VuajaPdXNuR/q0OTzjmqPiYQq9vObd5p0ztIOAo7msqlVWaRlh5vmil2aGeIHaS2hnU/LjAPvXM22qRW825CCx4z6Vr3161zpmGO3b/CRjNcbaRxR203nnaFJOSa8yrNX1PYwdBezcZG2+o6Xdz7JpdrdSMYzWJqtzYIWW3AVB93HOarz3EVwVWDDIvAIFPtv7Osbea+1AMsduC6oRkk1rSqQj8TOtQ9j7yuRaHc3YBjvE2hmPlMwxkV08COFIYcKMZrzzxNd6zNc20+o2v2KGWPzbMg9VGOSPxFb3g/xUdRtWtr9fKnT5Q54D1rK8XeL0FKftYqcbHQi380FkODVW9nW1G24OM9CKmtphDMUc+4xRqKR3cRLAE9B7VUa3MtRR0n72xyuteVLGWi+9mug0LXrW3sosWuGUfe965G9l+zzCGYHC5y9PsJ3+42CrdD6Vz1aV9T1Z4eNakovVI7K71pb6LM0AJDcN7VZsLqzYR7wAD2rmprhUslj8v5s5JHpUMMhadQuai62ucf1SLi0tEdbrqRzRbocDaMirHwf0lr+SbxZeruWZDbaYCcgW+fmlHvIwH/AET1NcsbK58R6/beG7d5EhukMt9IpwYrUEB8Hszn5F78sw+7Xu1vDFbwRwW8aRQxqEREGFVQMAAdgBX0GW0dPav5HzmaYjkisNF36v/IkoopHZUVmdgqqMkk4AFeqeILVTVdSstIsZb3VLuCztIhl5p5Air+JrjNU8f/bHktvBlqmpyKSr6hKxSyiI4OHHMpHonHYstcjLpU15fJqWvXcmr6jGcxyTKFitz/0xiHyp9eWPdjXLWxlOlpu+x14bB1K77LuV9bng8S+KjqGhabLa6XOjR3812pjGoDbhWSEjcCBxvbaSOCrYUj5F+I3ht/CvjDUNLIPko++Bj/FE3K/4fUV9qQKxbpgYrxv9qDw19o0Ow8QQJ+9s3+zzkd42Pyn8G4/4FXJhsXz1fe0ud+Mwip0Eou/KfNNFLSV6p4oV1fwx0N9f8Z2NssZeOIm4kH+ynP8APA/GuUr6C/Zd0pI7fXNanXggWkZPbjc381rKvU9nTcjfDU/aVVE9l8Bai7alLbXS7fKUZz3FXPElydWjuoLUAwrld3qayvD1sJdYmuAf3ckZUe1bNtax2Nj5kg3KGPyZ5b3rw0oo9ytG8uYyPDbxTaDh3C3kcnlyof0NZWrQvY6mPPhzC7eXMPY9DVnQbR9QuNSjceW7ueM42nqtOmupLnU4oLyHJZRBLk/eI6Guumjjk7GLqbf8I5erDK7SaeyZBU5256E10mraHcXdhayyRi3WRQ6S5z1HFZvjDT7jT5ooS6zWssXlkEZMXsT64qvqOp6lBo1jpctxstxt+zSn+HHGCacoST901hVatYWzmudD1EQX+6S3m+QuBxntW7HDeJqMX2Qr5O4EY6/nVPUNWudFkSz8SWYv4ZAClxGvFbWhtpN4kn9hXRguNu4pIc8/jWNSc4rVXO2GKsmnrct6jf3k94kctkXULt8wfw/Wq8VvcESRPCvlkhlbHXBpp1GfT3iGoyh3YEPgcfWtiOYzW0TxqGhYZGO1c6rPqh35I8qWjJ5Q07x+bFiBCCijsag1i2je9SIuAwG+M+hrb0WYSyeRIoYqMg4qPX9PW5uElhISeMZB9fatlUUlY4Y1eSqovQxvCtwwn1O3nUPNGAxX0FaOg6lJqE0kdtEIEtx0I5as+3hlimuLqMhXuF8p2x6VH4auEtvEU1hISPMT5SD1NYuNpGtaEZxnPro/8zatrnUbtrqPcEMTgADgkUy+uJ4des1c7uO1OiiubPxIGwTbTKQzE9MdDWP4j1GKLVY54HDGGVVOOh7EVlOo7pWMqUFKfupWaO1bczAxuAADketcnqt/eSs0AkVouVbA71012ZGtTNbn59mQPXNee/a7oGSORSH8w4GP1pyo31uTl9LmblpoTa0jw6etxI4UKAGGfyrjLu6SQtHKx8v+L3rZ153l0+7jmJeMISeehHSuD0om7tF3SbCvzMTXHPDOTPpMNDlg0zqLG5hA8z5Y40HQ1m6r4h+3SraWAXETLJlhkMQc8+1YOthpAJGconTGcZo00xwwoltEfMbIZjWtPCxWrMqk7m5quoahrVyJNYmjm8pNsexdoVc56VCAsicDaF6YGKri3lkcHcR/Dj1rYW28uIKSMY7dzXXyLY50lHSCsWdK1WSJliuxujxw56itiVvl3oSUIzwaxoYC2UxyR0IrRggngjMYbAUcA96h0o30OinLXU5rWHYX2ZRujYDj2pjRvComt33wddo6in+I7gKhjnQrIvIFZUWqmzhfI3kkBRUzo1ErpaHpUp22NiW9LwjYcqvDe1Rvq0VjDLdTttihUuT14HtWU07SM09suQ3LIO9dT8K9BXxd4rS5niP9laM6yzhl4luescXuE4kb38v1NTRwjrVFEnHYqnhMPKo16ebPV/hd4fudK0WTUNXj2a3qhWe5U9YEA/dwf8AU8+rM5712lc94v8Y6J4Stkk1m8CTS58i1iBknnPokY5P16DuRXnfifXvEPiDTTM91/YOlSA7bS0l3Xci/9NZl4j/3Y8n/AG+1fQVcRRwkEpO3ZH5/SoVsVP3Vdt79DsfF3xD0nQLh7C2D6rrIH/HjaEEx+8rn5Yx9eSOgNeb6hf6n4puh/wAJVcI9oeV0q1JW1HtJnmY/72F/2RXNafax6dH5FnEkMIJO1RjJ7k+pPrW3p7pJKjOwHavIxOYzqaQ0R9VQyKlh481T3n+H3HYwyf6OqRqEjVQqqowAB0AqpJM8ch7qabFMEARTuHrVqHy3YbxXLCaSuHLydNBbaYkcrzWf4ts4Nd8OahpU2PLuoGiPsSOD+Bwa0rp1SMiPGRWK7M74Gc5ovdproJUlVTvsfEF3byWt1NbzrtlicxuPQg4NQ13/AMcNH/sj4g3pRcRXirdJ/wAC4b/x4NXAV9TCXPFSXU+QqwdObg+gV9e/CbTF0j4WaVG4IaeI3cvHPznIH5Y/Kvkmzga6u4LdM7pZFjGPUnFfbtkqW2mrpYXaEiCK3rhQMV5+ZTtGMe56WVU7zlPt+pB4XZopcnO2SUkewrT8REW0omlmCRKMBD3Nc/pUvkRu0hwkRP51W1K8v9TMc13asLcsFQ+3rXmU6cpSvI9OtsXPC0q3niidYmYRzLgtnv2q5JbKniO3t5VZ2Vtzdtw9jVC+T+yr6yvraIr5TL5iD+IGuw8SWMd4tveWjhHVPMB7/Su32iiuVHnyWpB4t0+S60sCzINozhnuOuztn6CucktUbRbrQb2ZVuI5FeC4P8fuK6C1v7gaGwjYRkxt5yOM8e1UtQ0y3vNItryVs3LoAZB0UDsPQ1pG7WpnsZ+nX24yaFr8ZZAA0UrDJ/Oq2u+FpNNRLrSw5Y/M3lHkr61qacz3k8U13EsjRHZE/TgDHNV4L280TU3FncK9vM+Jo5edgz29qlya22NE9DJ02/ge3a3vy+SdvnNk7RW9DK+iPbSQ3oubGboo7CqPiW0aIiRY0eEn/WKPlINVFjigubO50/N0IiGlg7Y74rCpBNcyOmFR7M9W0S6gc54EhXIHrUsccjtLOCSqj7prlbOX+1wLnR2zIhw6E4K+1dBZ6uI7ZoJVCTg4x61xczjLQzq0tXKnq2RX9t58GxX8tZBuDe9c99jaHUI5X3efGMlvYV1q2S3FruupNiFtyjPNZOoo6XzOFwqpx710OfPFI1w1WzcEa2uXUY0n7UsmSUwAOpz1rhIIt4RJ1KrI+4buvWui01kn01lu0IkLEgE8Cs6S0ZdUgec7I4jk5PGDRaKVzfBpUVKHqdrHOkOi+YJN4VDg+/pXHQ3vmqDLEFlJO7jpXQlUfSruWIhySOnQVlQNCFLllZyOgFOFr3ObDRUOZ2u7nM6ssd1b3iK/yBCOPXFcJ4R0iS6TV2vpxa6fp6bjMRxI56JXrrRAeYpiURy98V534utptJ0WWGJT9kLvK/8Atsfu/lVVPeWh6karnHkjocVc3H9oXab2BhjGFC+vrW/Y2xSBZEwF6VhaLAHSIleOprr7OCOOFUJJ5OR79qzXuoqeo/T41dGdgeD8tacFsD5cYyecnPYUtnAApEYGwnJq5BCsDgZJz0HpUuRSgWbeJI8cAsDiku0ZyCDxnpUqqWHOBnpUoXaoBG4ngAdzUxSb3FKyWpk6pp9rqkCQ3MZViwEcg9TXBeIvDt/od5L5itcWyniZR949+K9PupJ9KR7u+gEJgjMqbuQAOtTWNxLcWGlXc1i8093bSXcUY6YGCR+IYH8a9rB0qcqbdWdrHO8X7Jp30PEtQ1iDSLIXZMaDIjiEjYUueAG9B3PoAa7e18e3OkeFodE8EBbK3QM8+s38X766lY7nkjhP3csTgydBgBcDNc74ktNKv44Na0u18yykJk2MOYnPBYDt0xXLakxjkUO5Zdu7IPWuOo3RUvYdep1PCxx04yrO8Vsv8zcg8uSaa7mlmuNTkH7+4nkMksx92POPQDgdgK1rHV7iGEQu5MY+8G7VwIvpoZg5zxgiuksp/wC0YGZSFdBuI/vV41aDb5p6nt0oU4x5IxSSO0hmjuYztIB61WE4DnZn5TXOw3zj7wO327VpWl1G+MMGLcMBWUUaqmrXOx0e4Loct0rWW4CZriba7FtOCCdvcV0C6tBIgHfHFJVHF2Z5uIwz5rpaFy4uHJxnip7NQ5wR+NVrVDOQ2RW3Z2m0KSa9CEo8px1pRhGx4b+1No2NN0LV0Bykj2rnHZhuX/0Fvzr51r7I+P8Apwv/AIXaoAMvamO4U+gVhn9Ca+N69zAz5qVux8jj42rN9zqPhlYPqXj/AEG1jUsWukbGM8L8x/lX1vFvkXLnbKjZHvXzr+zXbwP8TYb64kKjTrZ7hVxkOSyxYPpxKT/wEV9O61aG2uXMeGhf51P+zXHmM17RJ9EehlOkJJ9f0OXltpZ7nUBCdpSMv7Gtq5hdfB9s0X71lCuxHOazLJI11e7AYgNGcAnqDVrRb14dO+wKw3LuwrdcZrz3VdzuqRuWb1odV0qMY/1keOOMMKm0zU/tX9m2lwjN9niKOF746E1laRGr6XJFuw0c53AHkZrT8JyJa+Kf3+0xT/uhmumnOO7PPrKxs6S8UxlyqgZICHsKfoFtaSS3ukSo0kEf74YPK5qTUbYWGuIsQxuYYHrmq8Uzad4phkm2gXha3fHQntWrdnoZNc0boyJYJNI1R7iLMtsGII7Y9qXVNMOqQyXsLhI1BK4/iHpXQ65ZF4XSORNzkpsA6ccfnVLTY420xLJG2PagiRD2aqT6mkYppHNWGp3M1vb6NcxB/wB4Ar47VBrVmumXKeUxhuTLjefu4q7ew3NjPEINsk8biQe4rc8aQC+0e3mVFJ++3HtSc7aF8rTRzlpdSWF0XkYwy53NJHwr59q0ftc8UkcsrebFJ82R1WsjSoI7mB4p2Y5Qsu6neHZ5POaCRc2JyGcn7uOlc1SOtztpabnfvJM+lxFn4BDLirKILy1cvy237vc1zdpqZluY4EINuowp9a1tPuGj1AR5696xjJxZjOi0m1vuUGlaEvBIp3YzGfQ+9HiaM3D6fPIHjMIHmY4De5q7qkDXTEBSJc4GPWptRQT2sUVxg3ESgED+IV0xejsPnTlCfrf8hthNKmpz22d9lPGPKIHX3qOa1060uGj8wtMDgio9Q1KfTtPAgMZnUbolx2/u1zM2pmVbjU7iM7ON2B0Nc06dVs0oUZTbley/M6XdNcTeWuNh4C9653xhp8s2kXdqw3uFLKO+a19F1BfMF0zgwgc1Rkv2lvZ2xn5uT7VMa7jozenCUZtJaI8s8ORnADqQRwwPrXVWiKl5HtG/IwV9qp6nZHT/ABFcx5+WTEqEdOa0YImW7t2QZI5zWkpp7HQlfU24kCDcqZb2qU8t8p5GOfWn9FPrjtTTtREMhwKhalEnzrGdq5J4xWjYsluMRoXudpGSMgVHHHiONMfvHPA711Ol6ZDYwme6IMoGWJ6AVvz06SvM87FYiMY2ZzzaCuv2cyaw7tDNE0OA2OCDn+dW4PEmnaFYLaaijRNYRrBCxX/XAKB8n5YqW7W9uk3onkxDO184CD1NYWt31qNPeCSAXDMoHmuuR9R6Vy/W5Xapv1OX2Crv3vuXQ88iupG877LboguLhvJgK9A7nC4/GuP+IOhPpuuXUFk5MtqF82MnOCRuP867uf55Y5WGxoW8xSvHI5FeK6j4kml8Q3c7yPIXlLSsTktW1L2snuetRm6UklsMN0JVzKfbA9asaZfyW8pCsdpGOtVNRj82eaWFMR4D8dMHvVfO1AQcD+dbypqSsz2ac0zqre+DSlCeMZrpNCuIGDBtq7eme9ed21yYwAwy3rW1Y3cbooBKtjvXFUoW2O2Ek0drqE/KzRuPLPytSR3m3+LPuPSo7xTDoSPjqQcVjRzN5bZIyx4rKdG6Li09D1rQ7lHtlO7sK6CC52DGRj0rx3SNYngcRFsYA4rs9P1dpVQMR0xmuL34OzPJxWAlfm6G/wCMbddT8K6zaHnzrOVAPfYcfrivhSvuuGdJISrHIYYPvXxR4r01NH8U6xpkUrTR2V5NbLIwwXCOVBI7ZxX0mTVOaMovyPkM3pOEov1PR/2arRrzxnq0cf3xpTsv1E0NfSVtdvfWi27EefBwV9R6V87/ALKk4g+Il8SRltMkUZ/66wn+lfR2sIthqiagq4hl4bHQGlj03V+R05VK9Lka7tepymqxvaX0cozg9CO49KrPMtrrEUwyIphwD3re8SW4eEXEZzARuBHr6VyGpSf6NBnBMZ+XHauNq253y97U1L9Gs9WgkUsLe5+YnPAIralsLiO4sL3zkNvMSI2A+64qr5MF74fimnkCKEOCfX2qlpF1Or2lm0hIhkEm1ugX1q4y6HBWhqeoLO2r6NDcKU+1xkK59CKwdU/4mGoWdtb/ADTrN5jOOwHeneGbpLfxDLboytZ3T5Ps2Km0u2eLxFqscSsMIVBfrj2rSJyxfLeJrOovDDcEhZYZNjn1rOjt0s9fvI5jmS5AJK+nY1d8O75rR1lGfJDqT/eI71W04edp93dMd05ywY9sdBVqVjRKzdv6uUtctTGnETiaIcHuRUk7s2gxxLhFxh2fv9K0Ly6OoeH7W/UASMNrY9RWdJIH0ZYJkx5p/KhzszeHvRV90zl7e0UXb2s8vlNKu6FulTaZbmw1F7KflJoySOx963dRsI2tbeR1y6EbGFSLbG7l3Ko+0xoQufShyTOhW+LoYOmNJYBbgLujDFCTyOta32hmnjmDfMWB49KhW3EWltbSZLDIJq3ZRq0cI4wMAn1rCVjbRLmZuICLpZMnJGatR2g855m+c4yKq2mCMSnDL0+lbHlsIEe3+fnmhM8itLlZz17axTTeeRz02nqfpWRZ6cPsWrWxQi2cF0Ld/YV1d/CGcbgAT2HY1nXTlkC9PLbDAdxW0aridFOq5RSR5/oc0enCZBcL5TRF/LfqD2qHT9U2275RiwBJJ9TXaahZ2kszTRW8QkI/u1Qa1hAIaJRjnAHWhuMlsepTrKWrW5xmvzzTw6XNcqQ6Axg9CR2rS04EzQtGCAo5zUPjQsslnwADuIHpxVnR3cQRZXIxkketckk0arl6I3FGGAz1p0y7lUYBwwNNJIIxjipJGIGV64qL2IZ1ej2oYpdXW1T1X0Aqh4g1gi+8uFtyDjHY07Q5DqqLazTBUiG5lU4Y1gSJGNVvZULGITFVz6DispTjUSutTzKNFOvL2m6LOqX2pXyILiRY7dMfJHxu+vtWPftuwEAIPyn0BrRupw8RC5GBWRdyhmWOI4x1NJHfCChGyVjB1OR4tP1MkZeOBmXH0r5z00effMTxuzuz3r6I1gltN1FX4kaJhkemK+ebJPKgWQE+YXbPtivVw9lBmD+I29OlMN8lvKC0EqlM+vpUTwNHExZlIBKgdxVW3utvlOCN0ThlHtTr2XzdSnkiYBW+bB9cVXLqehRqjlLGMleFHUd61/DWnf2xqK2yXaW7Y+UOfvH0FV9P0R7rTDfJdRgrJ5bRE/MPf6VsWui/ZhuikxcAZDDqPpUzlC1r6nbGpfY6LxNfLYQQ6a8ys4+ViD0I7VmxKG2MOVFYF5aSQXBadmklPJL85rS06banlg5zy2a45U1FaM66cn1NPcA4bO3nkn0rodHuS6rz0Nc3xJ0BIxg+1aekEQlcsM9vesKiR2L3o2O3tbmTYMdK+VfHr+Z458ROeralcn/yK1fVelgOilRn1r5S8dceN/EI/wCojcf+jWr1spSTlY+J4jtywt3Z337NUDzeN9RMRxJHpjuP+/0P+NfVtvDDqWmmK5PyycMP7p7V8tfsr3VvF8TZLS4ZhLf6fLbwYGQZAySYPoNsbfjivqN4nsbr95lY3OCPQ1pjkue55+Aqc1LkTs07oz7e2kttKu9PuFEssDFkHqO1ef62jRrKCgVGGR9a9H12J4XhvkZi0XEgH8SGuP8AFKRwyXMeBJHIA0fsP85rzrM9Wm+ZX7mbpcnn+EmjwzTRzYQdsGllulW6jmkKJOVERFYUCyraForhkwduM9+1Omtpo4Y7yXMqbwGI7GiFNJ3ZjWR3WhyIdGnk3r51rPu464rd8JTS6hdT6jeOyb8rHnoR3rA0IpHqX2W5VVt7uL73vitXw/NDBcQ2cu6SBGbBXt6Zre99DhasjZ8LXLQxXxmObZd4B/vEmpLUiDTYWGBFLIQwHpWHpxjSVi7uLRLksV7DJ710WqW7wSQtEubQNv3DoKpRS9StFL1H2QRLafTHACyAsntmsqWFoYYoJM7956+gq7q0yi8sXi+WRmDse2B/DVHWopLm8ur2dmSKN9qKp9uv60mm9zSjpLtf8x0f7/TCJX/1bZx6CniRmkM0Z2hRgEd6bo4tV06e8jZpFb5CCc5Ip9rbvPYCVOIye3apdjbmV22Q30ZUYboeuamgQJGmGDJjIwKsSwrLArA72AwR6VZ0gW6LJHJtzjjPrUu1hyq2h6FyH7PKis6nftwcVqWoaCJEQfKemayo4i+BGwSQ8itxN+ACucKMfWuWc+U8qv2QSRs6H5ULH1FYeoeUJXG0BycNitp7nyyBKhGe/as25vnFxtMEZU9yOauFSXQmgpJ6Iw2g3Fi33e2KYLUzRMqodw/ix1rZt4VuJCgXaw59jUixbUfGAO9auqkju+sNadTy/wAeW3kXemLICcoxpNHcxWeMZXPH1q38RpPM1KzgjBLJGz59BVCyniSNFYNjv7GsZSb1PVoybgmzcJ2hWPpzTpHAiBHXvVeRgIG2HIwCM1GJPMjO3nHWsrtm3LckjZ4rgvbylGIwSDjg0srrE+CcIRke5rPMhmO1TsIXBzRKnlRK00u4KMg+/apcS+VXuXvOVlPBFZV46CdjEwCKPmFV7i7CNksc98etZOoTLaI88s4SHbuLE9PXNbYbDe3qKF7GVRpItOr3FpdvFGXTaVZj0FeATWwi1C+sHfZIkm6Nj0IPWvfLlrpvBUOs2k0cHhrzkj+YESXRdwgZf9nLcfSvF/iLps2i+MZYZxsZJfLLH0PIP5GvZdCnQfs4yuzzFWjUd4s56GQwXJDBXH3TTpo3jG9s7d2AfWq1wohuHQuHKtwynginySGRPvn5OQtO3U6ITsXtKu3iulKlip6jPWu+t7tZ4gEYBgucHqK80s22XMfOBng11en3aqkm37wPGe9ceJp6po76FS8dSbWbuQPtfk9arWV2AfmO0ZzmpdYVZrdZlzubrWVEw3nIwAOlSopxOulVs7HZW1wXCMpwrCpt8kfzKwPPFc/p05LIvJxwRW6+xoQRkMf0FclSNtD06crrQ9P8FypNaLk/NjnPWvlf4hrt8f8AiZR21O6H/kVq948H6o1uxQvkE4HtXz/4zv4NV8Ya7qFpvNtd3888W8YbY8jMMjscEV25Mpc879LHx/E8HCUG+tzd+CuoDS/ir4YunOEF4kbH2f5T/wChV976vax3EO4jIYYOP51+bulXbWGqWd4hIa3mSUY9VYH+lfo9YX8dxaw3AbMM6LIPcMM1vmd4yjI+ewzad47o5+JcpJbXBJ2jbk9xXJ6laBIQk6kmBvK3Huh713t8irM3lpkZ+U+o9K5/U4kuAdwO1sq/t6V5/NdXPoMPO7v3PJNagNlLfW8QOI2Eg91rf8Qxx2/hi2azbdb3KLMT9e9V/E0CtFb3KhnIDQyEd8dKgt5jP4NawU7ntZsKD/zzbsPoaXM2b1Y6kyyN9lspndzGFyDnrXUabcJa6naKp/dFQ7e7GuEN3MbOCxQA26S7g2ORgdK6P7WssSGHrxuPpg1qm7HDONmdlbNHa3d1FcR5RzvYY4A7Vt6JIRDeWd5IGhkbdFk9FPQVykmpvfNPFAg2KoMrnqcVp6JJFcbUkc+Y4+QnuBRK61JlCM1ZmnrVk8SwSSEHadxcfdwOmKiYtqSqVwFHJU9xiq2otKli+nXEpdi25fpmodVvWjSJYkdZiuFCjk+1OMu70LgpKKv06j7eAW+mvEq7URyQPWtbSg01nJAuI2Iyop9zp9wuli5mC79qllHYVnwTbLqIwsSYsM1FSy1iCkqsGol21iw0sCjDn9TVjS7dZNSU7MKgwQe5pbwhL4TJj5gGwOgNWtJCySPdzNsJJCjOM1N2c9So+Ry7r8R8kJ+2vlc7fukU6d5VZN0hAAq7EVZwqZJUbiT61VMpEDzSxhskj6VzTszljNtpNFWC9l+0bGAkViAN1S6oWW9UIuSVrPgge51eJS2yJVzgdSa3kTzL52YZVAAPrV06airs0quNOaa7FewlR7kkgAquAajv5YyrgnauM1eS2RInTAHJIP1rg/iHrK6NpbpG4N3cgxRjPT1NYV6kZNRiFCKqzujib7UX1jxLe3K8W8f7qLHdR1NSx7AxSThPvVjWWY7WPywfMA5IrWjlDRKZAM7fzrWOise+mkrI0/OR4VUfKG6H2FVnlaCMrGTnuait5d0TIoyhORnqKdcyrDsS6U+Rjllp2Q1ULCzCRMugLMcH6VVkmEask6/uC2FJpEby4yqhwAcqT3FUb12a0UuSUyc5qXFFOqQXDxxyyB3AB6Vg63YXGupZW6WtxLocl/DHqFxGOI4dw3nPoBitOGGGVUN0SVJOG96k1TWbq28Nz6Zppa10t8+e/QyAjkU41+RrkWpzVr1I2TMr47eLdI1SfTfDHhp2XS9KxJIbMj7O2VUxqMHHykHjsa8x+IV5PfzRT3cjSyybWZm6khQP5Cp9SuLVJFs9KgEUAIGR1J9TWB4sm87WGRXJVFVevGcV6dNudRSZyKjGjDlWpmIBhB3q7bqCwjkUDd0OOajgtpJVBjB3Dmuh0+1SW0ZZgPNHfuK3nNI6Ka0MO2/dzgMgIDc1rW4EV185zuGVPYVUmg2yYzgKe/U1PKRJArRfw8Y75rGb5jspaFyFzJZSRsfmRice1UhIA/XBzjNS6bKJJirA7nUgiq7ArIePl9KhKzZvDc0rJyHPYnnNdFHMTErgDJ9e9czadec8jityzJkhC9cDnPQVzVFqerQehbS7e0tbmfAykTvgeyk14aTkk17J4rxa+FNQn5GUEQPuxA/lmvGq9LLafLCUu7Pk+KavNXhT7L83/wAAK+7vgprC658LfD1y7F5IoPs0h77oyU5/IH8a+Ea+qf2NtbW40zXdAnYkwSLdxKT/AAsNrYH1VfzrXHw5qV+x87QnySPeJAq8HJB+6QOlUL2wlVnYpmKQYOO3vW3cQiEnAO09M0kdy0UZEqqynqBXiqbi7JaHpxqtJOJ43OpK31q6hdpOwf7Q6GuWspRZ3CMQTvblT02nrXqXiC3t3F5OECyg5Uj9K8t1L5JC4GUR859Vpc1z2ovmV2Okt2iguYSxDrJvz6qe4/Ct3TpI3sncbEWJQOvL1mtPFfWztsPnpGQv+2v+NZVtJ5KwLKSd2SuKSbuYVIHcaFcta/ajIpw43MG7Ct/VoxHY2E1kwCB/vA8jNci2sLJbRxoFMkoAf6VtQJK2nfOzLDG3CHrWqfcwSsasbSX2pGRnXdBFtOe59RU0Ul1eCK+gRGMWQE7g1kaapOrArJgMhC/4VowXVxocqxx7CZGLMGPftTs9kaW93Q37XxNK7pDcQDZs+cNxVfUDG+qtJbEJE0e4qP73pVXWJ/PC3U8cUaOm07O5qCSTyLdCPnLnaprO1mTToxXvpWZsbmXS1Y/N5j53ela+mQr9m86bOxeIx7+tZGoBII7aOFnMbqMqf1rZ+1JEyRKFeJEAQdyar2jSaRy1k5QXL1bLkDGG0XyzvkJPPrVS+WZUiVsAM2SPep7e4O+O3WLDr8zEjAAqnrE5kulET5VF/WuZzctDmpRftLWJ7BAdULdCqVq8+YcdMc1zukq0Es9y8juzDbjsK3UkSKEszZwMk+tTWl7OOrJxEff0INUvo7ON2mcJEiF3Y9gK+ctV1uTxD4gn1G8P7gEpbx+iZ6/U11Hxk8VefcDQrGY73+a5Zew7LXBWKxpEN4wU5WsqEF8Uj0cNS9kr9WbsdynzCPKJ2+lPF4GDHONp6Vlhl3SF5MK3IzVdruMLLjgYzkVs2nsdsTqIbwKFONsR5DUmp3vmhVjw8bHkZ6VwVzrUyNtZyyf3c9KgPiM20bknkHt1rLkq/ZLseom+WVYcgjaAorJ1GTdDIsj7MkkjPFcVB4uWSPzPN25GDnt71DqWrtd2zKJCWYfKR0z2q4QqXtNWM2raly61orstkfJ6DHas6XULto7tbubzLdeEQ9N3tWHbWv2C6N3dz7zjIQdM1X1DVGuRsgIS3GQGPr611wopP3dSG+5BbhVuzMzYiiBkkJ7+i1zUspuryWdh99icelWby68z9xC7GI/6w5+8aXTkjRHaUgYHAPr2r04R5FdmD952LEE/lAqjfvOvPrWzpt8jsCy/vF+9jvXOfflaUgAE962rDUSLCC2a1hHlFm80fefJ71nUgrXOmJcljguHZ0IJY9v4aowLtlKj8a34ptPj0iaNYn+3M4aN1HG3vmsoiJ5p2TKqBuXH61jzXOqnqZzboLpZBkc9asSKzybv4TyDTZkMkfsOeatWUZlh4BDDp9KpvS50wjqT2ykKrn8K2NPBLHA+U8nPSsxYwpQZG0d/etaxYqQjY61y1Geph0Y/xXuxBodjZqxBuJTIR/sqP8WFeVV13xMv/tfiLyVYmO1iWIfXqf54/CuRr3MHDkoxTPz7Oa/t8bUktk7fdoFelfs8+JR4Z+KmkyyybLW8Y2UxJ4w/AP4NtrzWnRu0bq6MVdTlWBwQfWt5xU4uL6nln6eSxiQYbp61i6jbvbtGQcoTWb8KPFQ8YfD/AEjWAQ1xJEI7gZ6Sr8r/AKjP410eoWrXLxANhQea+elBxbjI7KFTle+hw+qQkO6FM+aCeelea+JLOW1++q4Jzx0xXsOtWzQEo5BHVTXHa/axXukSxHEcifNk98VlzJOzPo8PU54Jnm9od04jjbYw+eM9s+hqtqQ+5NHwMg7f7pzyKm1CE2lymwHbncGHamh0E6sw3RS/oam3U2lG6L9zeWc5imhjML4A46cVrjU5Z2Te+0beR6muPlDx3LwO2ELccdKu21wzsxYEgkAN6ULzOapCx3dm0bWCyklZo3+X/ard0Wey1NVTU3zITy/cD0FcJpN4kl6LOVyyRrwxPetbRr21aOeJ8rNz5b54zVXiR0sat7LFYX9zZee1xAMmEHnB9KS0laR7SyLAPy5z/D7Cql3D/ZCw38mJ5JBtYdfmPQimWo239pNcMC+d8hXsPStFG+w72Or1DUFurm0t4WKmHKSM3QitPS5IN0zOWd16HsOa4xZrefVi0jMIHf7o61v6bI6Ru6FRFO+yND1FRKmyHFOPKjopLt5JDMGKgjbxVKTdIp8obSxwSan0iP7TJKk52LCecHvVO/uVlksrS2DeaZDuOOCM1LSWiMKaipcsTb0p47ezkaVwyluQTXMeNPE8ekaPJeO22JBsjUnHmN2ArbmNu+qwaeuBIq7nPrjrXzV8ZfFqeIvHM9jayFdM0392qjgNJ3NcqoyrS12QqUY+05mt9f8AIzotT+0X8l3cgyXE7l2PvR/aABlLFi+7pWULxEUbAMAdqpXWpKpURnJycsa7I0eyO5Wvqa8uqMSVY8gZA9KqnUFCZaYbcetc9PdqT85PzDOaprMHVwi/M3QelbwwysU5pG7Leb5Sc4HVfesu7uW8xTnj+lUxcbW7/L61Akm85PIJ710Qo8pm6vYv7tyAonOentVo3MgUgyJFGvQE9qy5LyR8LAp3Y5I9KYLEyHdLMXY87P8AGr9mn8RlKq+hPc3yh12SNK+cgfw596hhU3c+25fYMbiifdxUkluR8sMKonT3NPsUhXUYo1ycRtu9atcqWhk5NlRlSG4cRkFB0NMx5kvPAPU1IY1jlmjbkA9aikUq4UE5xVo1hsS7S03l5zzjNb2lwRubePaSrORx1NYkMDGPep+9wCa6zTNsc0KDKNEA25f5VlUZumSXqLZ2vlxg4HyZPWqENu6MNxwNvFdc1lDewXJlzwPMQ4rA8k3DvMG+RQFrmcl0O6girbwl2KyKMdAD3rWttMeAEksVIxiq11tgv4AOeATXpS6at3o9vNHjJGTWfMr2Z3xirXPN2iw6g4H8TfSp4JEgt5LmU4jRSzk9gBmuml0F7mULHGwY8VyXxaibw/okFg2FnvDwB18tcZP4nA/OuuGGjO2oYnFrCUJVOqWnr0PJr65e8vJ7mXl5XLnn1NV6KK9Y/Nm7u7CiiigR9Gfsf+MxY65feFbyTEN+PtFrk9JVHzL+K8/8Br62r8y9E1O50XWLPU7CQx3VpKs0bDswOfyr9FPAfia18YeE9O1yxI8u6jBZM5MbjhkPuDkV5GYUuWSqLZmkH0JfEkYMPmAAuorzjxSjMscg5jdgp9q9T1iAy2rmNQWx39K8x1xwT9j8p/MdxtJHC89a8vla1PoMtmnC3Y4TVgBJPalTtc4BI6H0rEhUywyQA5Yfc9jmur8UCOXWECsVi+6x6fNiuXkxFcb4u3f1FVbQ9RCbFmszI7YnXhx703TrtI5AJfuAZIqK/f5/MVdueWA9arBg0e4f60DLD0HaoYSimjQt7tlkRk+UknLe1WbS5ZJJ0LZx8wPvWLBfQxGF7nPlbh5mB0Gea2vEelrpmqFbKZp7KSMSpKeoBHQ1cXGxyThY3k1NptLgty7Owbc3faausSkdulq+XfLsepJrl/DV80FzNB5O8zJg5/hqzo97s1BA74MchQZPArRTtsc020dvaSW9hCXkUS3Lrn1waveFdO/tbU981zMkcKmQKOgasfSbmGcXcahPNc4VyeB61v6bqi2sBh06Iu5/dyP2Oa0c3baxD5nHR6mppt8kZ1C3jLSebKTHJ6rU8KOrRu7ooTLbu4qvpkMsSlnCqoGwKO1TJDHeCSKMsY4xh2/Ws+VblK0SjZzywaBqWrzNuu7hpI4JG6qvPT8q+Sb6ymttTujcBmYuzOx/i5619Qapf/bLZrSFQlrDkKM14lr9p9u1y5t7dMuqlh71pQvsVGLV23qcbbsk5Kxv5YA+Uk9ao3iCSRcsAmMnByRWhFHaW1+o1UPHbKwztHOan1WXRnvx/ZCs0O3DM/c966L8r0RZhyqkYUn5lPSqMM5S5ZgAA3H0q9exHeqxkY6gVQwjOAQVUDB+tbQs0KSbJbuVHRdh4XnHrVRSc4HVuwq81sqwnDD5Ruz61Hax7GEjLwPun61SaS0Isy1DiCApDgzMAWPp7Vp21rFDZbrtStwWw2evtTLK1WK3lklX0Ye9arXNu/lPfKWCEOxA+8D2rnnU1silDqc5emWL5R82eVJ/hpugjGteZJ1ETtz2wDV/VHhudQk8vMcP8J9ah0ZPtOssoUBhbyggdDgGtIy916BKmV9qNfuVAKyKCB7mo5rNmucngEc+1X4FRGgkCZfylIJ6VLclGlhcA+Y/Bpe0s7IpRdiexsxcKmY8BMV0llYJHMr4xg9PUVn6bmNgjHlug/lW9PeJfIP3YthGNpx3I65rmq1XaxtTjd3LGsXUdrpkgUDMgwMd6xdOtjFBEjL8zje1V7mb7XdA7j9ni+7XX6LYxxWH229Yb3+4h9O1ZQ03PQpRscvHZteazHBGuXY/N7CvU7B0soY7UrkKoHPFN8H+HjaRS6nexAF8mMHsPWqElz5t5KQThXxWGKb+yehQUal4roejeGdPtJwJJdqgAsSeg9TXyH8YfE6eK/HmoXlqf9Ahb7Pajt5a8bvxOT+Nev8AxP8AGb+H/Bc9naylb7UQbdMHlU/jb8uPxr5qr08opz5HUn12PjM7qNV3SvewlFFFeweIFFFFABXv37KXxBGheIX8ManNt07U33W7MeI5/T2DAY+oFeA0+KR4pUkidkkQhlZTgqR0INRUpqpFxY07H6fOMqR6iuM8TWpSKQMvzBcg4rC+AXxGTx74RVbyRf7csAIrtM8v/dlHse/vmu81+ISWyk/eGa+bqwlCThI9DBVeSojx/VIIr9reKZfLjY73kHUEVw90qRxOoclkcqh9VzXo/iGxkj8ya1UkFcsAPu1wer6bNaW8V421rSVsA98+hqeWx9MpX1MqVuVjkA2vzkVl3Be0lZS33v1FaEqEoCpzz09qo3P79dkjbSCdhFFjVFWZjIQIolIHJxV+11ceX5FzI+OoJ/hrHLS25Ow7CAQG9c0lvcC2MyyRieOVdrKfXsfwo5OpE43N+SS5huY5knCLKMhl5qG61C30e6iluHaaJ2UvgZZ89gO5qnb3UElmqIT5wOCvaqeovdC4067tUWWfT7qK7SN+jmNshT9cV04KsqVVOX4o4cRSko3hqe62V1osGk2876beRrefLDiE7lOOprd0a3MMZ/s14J2KkiCVwsin/drgtU/aAuV0DSn0nQI7rWW3fbrR2Krb46bT3zzWtpfi/wACeNddmTR7yXSfFEtuZPtjxmMRMMbgC3BIr3ZVqVdNSivkeNKrUh8UbHV2kqwWnnajJNE6vzFjAPqK0NY1QNZBdF8tJJPlYA/wetX9NgnuvJtJ1ttS09Yxuvw6kvJ34Fch4iWwtr5dIiiu31l2LxWmlqJZmjPQsCQsYP8AecqvvXnTw1Bu8W79iliIyd5dCrMsVnZlL2CTJHyNtxuNeOandQQeJMQXaPqRZswQ/OY0HVnxwo+vPI4r6Bn8KX2o6X9t8f6oNO0WyiMj2NpMQfLUZJnuBg9BysYXHTc1eF6xdwPeXGo2llDp1rPH5VpYxRBBa2wOVUgfxt99z13Nj+Gsp0XRjzt69EbUcQ60uSK9WZOu6QLxHnZMs+DnHFcfb6fJF5rOmIVYgbuua7qDUfMdbZzlOqGqOt2EgKq4VUc8kHis1XbVpbnoQTi9TkBbeY2/OFQdPWqF3CoCsqg5OAM9q2dQga1PlhyrEfLn+IUywsPtUfm3B2qpwoHWtYtrU1aT2M+G2d4ncqS/TZj0p5QR8SfcXHHqa6e0sDNaM5Yrz1xWHqduyXDNINq54cc496XNzbERphbNLPHsb7uRgentT5FZMhuVXjH+FQRS4yIXLANkkjrVuOGWSUzsSUA+UAVPK7lz90qNHH5DM6kgMCRVrw5BCmpTSspSJbeT5s9CRgVdvLPZaskTZkbBZR3ojsZILIhSdrKDLx19qvoRF3MyNXMNtEUyEGxTj7w61IIi+owovG0ZYDkVqw6dcSSQlF2o/wC6Q46E1bm06LSZzaxSme5YfM3pmspSS23N7aWNPT9PSC0mnlRXfgoSelZGq3kKo8SODO55ANO1jUmjhW2iO+QYXCnJ3V2vw78H6ZBo1xq/ibBuZThI342//rqYw5dahUY8qucf4e00y7jMCEjOTkfer0jwVo8niPWgxiP2C2Ax6EisnWIkELLYxlFZjjivWvB11ZaB4Pht1AFyy7m9ya5a1fl+FHTipypUkqavJkfiieJLb7NGgUKMACuAuLeK2ikuLhhHGil2ZjgADkk1u6nqBubpj2z1rxj44+MBHAPDunyfvGAa7dTyF6hPx6n8PWlhac8RUUWRKv8A2bhuZ7/mzzLxxr7+ItfmugWFsn7u3U/woP6nrXPUUV9RGKglGOyPh6lSVWbnN3bCiiiqICiiigAooooA6f4deMb/AMDeKbTWdNYkxnbNCThZoz95D/ng4r768P69p/i/wta6zo0oltbhNy56oe6sOxB4Nfm9XqXwJ+KM/wAPtdMN6ZJfD94wF1EOTGenmqPUdx3H4VxYzDe2jeO6Lpz5Xc+s7+MqrzRDceVeP1rzTxrYNBodsVf935xby89DivVhc29w8V3Yyx3FjdIJYpozlXBHBBrhvE1hAb+VHy0Tbjz0U+teFbXU+qw0+ZHljEgcfL65qk4ySzbRt+7z3rS1WyuLRtzqDBKMofUViuQGww288iqtY7YsTcsnyzAMAPyNVHtSzgW7qWY/dJ4BqeVgQVRSR1XtVu1g0/U0hgNwbO6VDuI7kd6uMrBJmFJ5kNyEkhe3mT1GAfcetXILoM/+kn5Sc7x1q7carJe20UGpKs7xAos4GCqjoKh+wJHHbyQg3cN2+yLyhvmkb+6sY5J9gK2jFVHYylUUVeQRTjkxqBg/eA5P1ons7TWbmHTW0+W8u5jmKC0jJlfjnAUZx6noOpr07wX8EdZ1h0utfmk0PTXAPkLta7kHuOVj/HcfYV754R8IaH4Sszb6Dp8VuWA82Y5eWY+ryHLN+J47Yrpp5e27ydvTc8nE5nTS5aav+X/BPJPhP8KvFWlWKw6nr97oeiEs6aRZyq83zdd82CEOeyZPowNez6BoWmeH7M2uj2cdrEzF325LSMerOxyzsf7zEmtOuV+Jfi2LwZ4VuNRKLNeuRBZ25P8ArpmztB9hgsT2VTXpqMaaPDlKVSXmzzv42+KE1HV4vCltMFs7Ypcam/8AC78NFbn26SN7BB0Y15ZqOnS3E85/1u4/f7UzTJIJklk1W78x5C1xPK+A8srHLOfcn8uB2q2upJNbG3si0VrK4Y8feb1z2+lfP4jF+0qc1tOh9JhcH7GCT36nNypHaN5JIU5xu9KhvL0PGyE78ZGD0IqfW4IQzrC5eVTgH3rJFrIS6yK21Oc4rNWnqzv9nYlv5oLnRYbK6ti97GfkuB/zz/umrNikNrppiaJd7YKv6D/Gi8hkSwWdSCZjhBVdIXDhGbB6sM5q23bcSgTrdskflpEDEpO4nrRcwRxQebINxYZ8vGcUtpGAzuzZIOAv941PHC7TOZSOmeT0oVVR2Bp9DEsbINM0sUeFzlgatrHNEg8lMvnH0qz9ohSMxA5+nrVqIEqGU439CPWiWIb3RHs29yWwt0kljEcebhxyT0FW9RtkjsJJZgqNvC7agtZxDMSrBMDBbPes7VNWW7Jt1OYYslm/vGsPaVJOy2KVE1fAXh271jUL3QNN1qOO/wBhutOt79d0cqADdGsg+ZHTr0cFT0GCaztV0XWPDmpx2PiLT7m01G7mWONphmKTJ/gkGVb6A5HcCsuGe5tjbX1nM1vf20i3FtcDqjqcg+47EdwSK+vfAviHTPiV4Ijnv7K2lLDyNQsJ0EiRzAAlSG6qchlPcEGvWoUoV466SXXueViKlXAzutYP8PL/ACPD59E0XQL+S9EImuioVYeu1/XFdhpvh9bnTRd6sfMJO9YzwErd1b4SR2N+dR8HXKQyAY/s7UGaW2Psj8vEf++lHZayoNWm024j0zxXZS6NcyvtjNwwa3mPpHMPkY/7Jw3+yK5cRRr0XzWujrhmdOtFKL5X5lSz06Oe8EksYFrGeBjrU+sXNvJIIrXORgYFdZ5dkI/ICc9wK5bxnqOh+CNHn1vVcccQwgjdM/ZFH+cCuOMlUskrtnT9dgnz1L6bHA/E7xBB4O0IXDMralcgrbQHrnux/wBkf/Wr5duriW6uJbi5kaSaRi7uxyWJ6mtfxl4lvvFmv3Gq6m/7yQ4SMH5Yk7KvsKwq+jw1BUY26nzWPx08ZO8tlsgoooroOEKKKKACiiigAooooAKKKKAPW/gt8VJvCkqaPrUjy6FI+VJ5Nqx7j/ZPcfjX0vf/AGfULKG6gKXFrPht6HIKkdc+lfBteofCP4p3fg+dNP1MvdaC7fNH1aA/3k9vVf8AJ8/F4P2nvw3/ADPRwWN9i+Wex698Q7NbS8t7aNyYkXcnsD/9euDuCCMtgt3PrXq+qXNjqFt/a1u6XunXMeIpYzuGPT2I9K8uvreOC4eJSQoc5J7CvJs+p9LSknFNMoRzK0siyDkdBVW4lS3aOQtjLBR6kk8Aep9qt3kRO7kCQcqR/EK0PCWvT+FfEtnr1jawXVzADG8Uqgh42xuUNjKNxww6d8gkHSmoOSUnZBXnOMG4K7Ow8F/B7xH4kZbnUkbw/p78+ZOm65lX/ZiP3Pq/I/umvfvA/wAP/DngqI/2JYKLt12y3kx8yeUe7noO+0YX2rU8J+ItN8U6HBqujziW2l4IPDRuPvI47MO4/oRWxXu0qMKa91HyNfE1a7/eP5BRRRWpziEhQSSABySa+QPir40ufGfi977TpR/YtlutrD0dSfnmH++QMf7IX1Ner/tHeN/7M0hPC2mTbdQ1NCbplODDa9CPYyEFR7Bz1xXzcqOECB8Jj5QvavPxtXT2a+Z7OV4XmftpdNjQVrSKMm4gaeQ8q27GDUq6tdiEorBISdwXHSsox8cSYJHfmlCD7oYscda8lwR7yLbSsZCydeuafLezhlj3qobhj61XEhhjIjIHOee9PEsJZZpIN6qRlM/epOy6GrlZG21paSaYhF5GJ0OcFxWM5Cg/Pg92BzWxcav4OuNMuLZ9AlstR/hmEpIJrmVgTb+7lye4J7UaPdWM4u72La3ixYYffA/P3qBxLKDLPKWbpj2ppjG4ZkAXsetOlKwsokcOMZ47U0ktjRRJIAFVXTGScCrFxffZWUBsyf3R/CayHuOHWM9ehqaO1lnbcMnP3i1P2avdmqQ8NNcufmLMeozU/wAkNusKJukJyT/d+tRs23FtBy7H5mFdHpGkPFte5X92eoxksO1aRj1Jdhnh/QJtVEZmH7lT8x9BXo/h/WZvCPioavYozaQsSwalBGM7oF6TAd3jyT6ldw64qtaWE95c28VkvkW6Rjcg/nmvStH0eLTrX9zF5krrz3Jq41vZyUjgxvI6bpzW56ZBLHcQxzQSLJFIodHU5DKRkEHuKZe2ltf2ktrfW8NzbSrtkhmQOjj0KngivPvANzN4a1RfC9/ldPuQ0ujueiAfM9r/AMBGWT/Y3D+Dn0evbp1I1IqUdj5GcXCTizzu7+HT6Wxn8F35scc/2deFp7RvZed8X/ASVH9w18mftBab49HiF73xjpc1vp8Z8u1eAmW1RT0Accbj/tAE+lfe9R3EEVzBJBcxJLDIpV45FDKwPUEHqKlUacZc6WpTqzceVvQ/K+ivtz4i/s1eGPEJlu/DTtoGoNk+XEu+2c+6dV/4CQB6Gvlz4hfC3xX4ClY67prmyzhb63zJA3p838J9mAPtWpmcNRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHWeBvHGp+EZ3W2YT6dMf39nIfkf3H91vcfrXrep6toHiTTbbVdCuCZ5BsurJxiSEjoT6g+o4r54qxZXlxY3KT2krwzL0ZT/nI9q5cRhY1tVoztwmOnh3bePY9kMEj2+9WDRg4P8As1VYquOqA9OevvWDovjG3u08nUwLaY9JE/1bn3H8P8vpXpXw48CX/j6/MNqTBo1vIBdagOQvGfLi7M549lzk9gfMeFqKfJY+g/tCg6ftOb5dTf8A2fJPEa+NiugIX0hiBqry5EAUD5cH/ntyMAdQTu4wR9T1yc8vhr4X+Cs7UsNIsxhUX5pJpD2GeXkY/iep4rxPTfjhrR8Zvql7ED4cceUdMjCl4Y+0gbq0ncjO0jgcgGvVi44eKhKR89ONTGTlUhH+v8z6YrH8W+ILLwt4dvdY1Jj9ntk3bF+9IxOFRf8AaZiAPc1e0vULTVdOtr/Tp0uLO5jEsUqHIdSOCK+bvjJ4tsfGXjdfDzaqLLQtIZvMmHInugCG+oTlR/tF/QVpVqKnHmZjQoutNQR5drWpXut6zeaxrDiS9vZTJLtJIQdAi/7KjCj2FR+fHbqhgjMyk/NnsK1PD+jJcapdWsFyqlY3ZJZOkgHP61nanqkPlRQwQCExrhx/ePevDnUU3fqfU00oJRjsjPdg8jNEm1D0yaYrlNwLc5zx6VEZQWVlBKnnHt6UxSN5I4HqfSp5TpTuTtKDwhLR9/Y1FI0mAS+R2okd4cBlAIIIHqKrPuLPv6ZyB6VSiaIsOQ4/eMCcdT2pEkjSUEZYEdahQc+vHSpoI2baAvB9e1OyRrGI5WfIWMlVGfwqWGynlkBI37+Cc0+GHaXw4UHg8VZjzHhVYk46j1qdX8JdkiV7GCyZBdHcW6IKbNPcXTmO1XC/dAHan2lhNqFyDI7LgYYkZFdt4c8PSTbUsodzdDMw4zUtxh8TIe1zN0Xw/HYyRSXn7yQgFAOoNegaRoN7duJIICocbWnboB9K3NA8P2WlzxT6nIt3e9vRR9K655pr1WwVht14CqMVMqzlpE8+tiZR0gtO5UhtdP0i2itbQKZ2A3sPXvW7pEqKBgbmb8a5PWNU0Lw3p8uoa9qEVnbjODIcs59FXqT9K+dviR8eL/VIptM8HJLpemtlHuWP+kTD2I+4Ppz7ippYSriHpt3PJxdanCLg3dnrfx9+KmgaFps2j2Ugv/ESOssLW7jFjKpDJIW/vA/w9+QeCa9S+D/j60+Ingy21aDZHep+5vbcH/VTAc4/2T1HsfUGvzkdi7FnYsxOSSckmvRvgR8Rpvhz40iu5mdtGu8Q38S85TPEgH95Scj1GR3r38Nh44eHJE8aUnJ3Z+hlFRWlzDeWsNzaypNbzIskciHKupGQQe4IOalroJCs/wAQanp2jaJe6hrc8UGm28RaeSXlQvTBHfOcY75xWhXxx+2H4m8Sz+JINAvLOaw8ORAS2zZyt84HMhI4+XOAvUdT1GADxj4ja5pniLxjqOpaDo9vo+myv+5tYV2gKP4mAOAx6kLgD9TzNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGt4UXSH8SaaviV7lNGMyi7a2AMgjzzjP/wCvHTJr9BdX8V+D/hx8PrXUIZbS30JIQLCGzwftGRlVjA+8T1J9ySepr85Ksz311cWttbXFzPLb2wYQRO5KRBjlto6DJ5OOtAHq/ir4ov4/1xr/AFyT7M0eUtLUn9zboeynuxwNzHGfYAAQCURpG6gYPHByHHrmvJ6t2Oo3dic207oM529VP4HiuKvg1VfMnqephMydCKpyjdeW57x4S+IOt+FdH1LTNDmVbe/Qqiysc2ch+9NF2zgnK9CcH1DcvFEsUAiQAAcAkZ/P1rjbXxVkEXlsNx/5aRHH6H/Gt7T/ABDZyAeXcxhh2l+Q/rx+RNclajXUUnqkehQrYWUnKDs330NZ3uhF5ZdkCA7MHB596phFGNqHcB1Y5zVr7Q0xyUJCjOR6VFJtB3FcZGM5rlvbRo71HqiNoZPKDIRs+nQ1DnbFt27g/QmrL3G9dsaEDOKYUDggr07D+dO5rGLKpZmJVMjbwc805YlbAbO7vVkQMpVHIGKtGOMx5KEknGaHM3hHuVY4lMnyDOOM1chiQlvNlG7oEH9a0NOs4pZV81SqHjHrXRW3hmxvNShj0rKrtzLM/IVu9Lnh1ZblbY5mGzM8QVFwORg9SK6XRPCwu4AztsjwM5HNddZeHNNgmiVVa5u9v3l6GtU/2XpbtJ4mvbSytkHy+ZMqfoTSdRXtExnWjBXm7HPIljpti8FjbefKpwWxmtHQ7rWLwJb2GntDGf4wMY96x9c+MHgLQ1eLSI7jVJhkfuY9iH/gTY/QGvNfEPx98T3kUlvoMdvots/eEb5cf77dPwFbRwlSpry29Tza2cUYK0FdnvD3lpoBe/8AFWoW9hEvAM8mCf8AdXqT9K848eftD2yRvZ+CNPLt0N/eDj6pH/8AFflXzvqWoXmp3b3Wo3U91cOctJM5dj+JqpXdRy+ENZ6v8DxcVmNTESvsjT17XNT1+/a81m9nvLlv4pWzj2A6AewrMoorvStojz277hRRRQB9Y/sh/E4TQ/8ACDa3OPMjDSaXI7csvVofw5ZfbcOwFfUdflpp97c6df297YzPBd28iyxSocMjqcgj6EV9DfEj9o24174c2GlaGklnrV7AU1WdRtEWOCsR/wBvGc9gcdeQAd344/aW0/QfiJFpWmWaaloNqxhv7qNvnZ84Jh7EJg9eG5wQACfW9QsfCvxX8EKsvkarot6u+KWM4aNuzKeqOvoeeoI6ivzarvvhJ8T9a+G2s/aNOc3GmzMPtVhIxEco45H918DhvzyOKALvxl+EmsfDbUy0oa80KZ8W1+q8eySD+F/0OMjuB5pX3l4p+L/gPVPhJd61dmDU7K6T7OdJmwJXmIz5TL/DjruHAAyCeM/CEzK8rukaxqzEhFJIUegzk/nQAyiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKWkooAmguZ7c/uJpI+c/KxFaMfiHUkUg3HmA/wDPRQ38xWRRUuMZbouFScPhbR0lv4ruEZBNawSICN23crEd8HJAPvg/StS48Z2BAFvpN3GB/fvlc/pEK4eisnhqT3idMcwxMNpv8/zOtk8XqzA/YWyO5nz/AOy1aj8cwh1Mulu4HULchc/+OGuIoqfqdH+X8zT+1cX/AD/gv8j0v/hZVoluwh0KYXCqfKaS+DIrepURAkewYfWs2b4m64SxtEsrMtyfKiJ/9CJrhqKawtFfZM5ZhiZbzf5fkdNf+O/E18pWbWrwIRjbE/lj/wAdxXOzTSTyGSeR5JD1Z2JJ/E1HRW0YxjpFWOWU5Td5O4UUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15874=[""].join("\n");
var outline_f15_32_15874=null;
var title_f15_32_15875="Sodium morrhuate: Patient drug information";
var content_f15_32_15875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium morrhuate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=see_link\">",
"     see \"Sodium morrhuate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat varicose veins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702553",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to morrhuate sodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2739639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots or diseased arteries going to the legs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12084 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15875=[""].join("\n");
var outline_f15_32_15875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016549\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016548\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016553\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016554\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016556\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016551\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016552\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016557\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016558\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/21/43346?source=related_link\">",
"      Sodium morrhuate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15876="Lymphedema after breast cancer surgery";
var content_f15_32_15876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Tammy E Mondry, DPT, MSRS, CLT-LANA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15876/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/32/15876/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     LYMPHEDEMA OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema is swelling caused by a build-up of fluid, usually in the arms in patients who have been treated for breast cancer. Lymphedema is one of the most troubling complications that can develop after breast cancer surgery. Many patients find that lymphedema worsens the physical and emotional strain of dealing with breast cancer.",
"   </p>",
"   <p>",
"    The risk of developing lymphedema depends upon the type of surgery had, the time since surgery, and if radiation therapy was used. Generally, patients who undergo more extensive surgery, have many lymph nodes removed, or have radiation therapy to the axilla (arm pit) after surgery are more likely to develop lymphedema. Most patients who develop lymphedema do so within two years after their surgery, but it is important to note that it is a lifetime risk.",
"   </p>",
"   <p>",
"    More detailed information about lymphedema is available by subscription. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     \"Prevention and treatment of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHAT IS LYMPHEDEMA?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph is a clear fluid that contains mostly protein and white blood cells (the blood cells that fight infection). Lymph vessels drain lymph from the body's tissues and organs. The fluid is filtered through lymph nodes (also called glands) and eventually drains into the bloodstream (",
"    <a class=\"graphic graphic_figure graphicRef64350 \" href=\"UTD.htm?23/55/24439\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lymphedema can develop if surgery or radiation treatment affects the lymph nodes and vessels. Patients who have multiple lymph nodes removed (a full axillary node dissection) are more likely to develop lymphedema than those who have only sentinel lymph node biopsy. Patients who have both surgery and radiation treatment are at even higher risk.",
"   </p>",
"   <p>",
"    Lymph node biopsy and dissection are discussed in detail in a separate topic review. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"     \"Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LYMPHEDEMA SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial symptoms of lymphedema may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A heavy sensation or an aching discomfort in the arm",
"     </li>",
"     <li>",
"      Swelling of the affected arm or upper chest",
"     </li>",
"     <li>",
"      Fatigue of the arm",
"     </li>",
"     <li>",
"      Numbness or tingling of the arm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, these symptoms develop before swelling is noticeable. Let your doctor or nurse know as soon as possible if you develop any of these symptoms; recognizing and treating lymphedema in the early stages may prevent or slow its worsening over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVENTING WORSENING OF LYMPHEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lymphedema can do several things to prevent it from getting worse over time. Expert groups recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid trauma and injury to the affected arm. Blood draws, IV lines, injections, and acupuncture should be avoided in the affected arm, if at all possible. Avoid tight fitting clothing, blood pressure monitoring, or any activity that could interfere with lymph flow in the affected arm.",
"     </li>",
"     <li>",
"      Try to prevent infection. Practice careful skin and nail hygiene. Use skin moisturizers to prevent dry, cracked skin. Use an antibiotic cream or ointment on small skin cuts, such as paper cuts. Use protective gloves for household work and gardening. Use an electric razor rather than a razor blade to remove hair in the arm pit.",
"     </li>",
"     <li>",
"      Avoid heavy exercise and lifting heavy objects with the affected arm immediately after surgery. These activities may increase blood flow, which can worsen edema. Gentle stretching and range of motion exercises, provided by a healthcare professional, may be used immediately after surgery. Check with your doctor before resuming an exercise program after breast cancer treatment.",
"     </li>",
"     <li>",
"      Avoid exposure to extreme temperature changes to include hot tubs, steam baths, and saunas. Spending time in hot humid climates may worsen lymphedema.",
"     </li>",
"     <li>",
"      Some patients notice worsening of their lymphedema during air flight. Changes in the air pressure during flight can trigger swelling. If you have a confirmed diagnosis of lymphedema, you should wear some form of compression therapy while traveling by air. It is important that the compression garments be well fitted because if the garment is not properly fitted, it can reduce lymph flow. If you are at risk for developing lymphedema, you should understand the risk factors associated with air travel and should make a decision to wear compression based on your individual risk factors. Ask your doctor or physical therapist if you should be fitted for a sleeve to wear during air travel.",
"     </li>",
"     <li>",
"      Keep your weight under control. Obesity can worsen lymphedema and may limit the effectiveness of compression pumps or sleeves.",
"     </li>",
"     <li>",
"      Avoid resting your arm below your heart or sleeping on your arm for prolonged periods.",
"     </li>",
"     <li>",
"      Contact your doctor or nurse if the affected arm develops a rash, becomes red, blistered, painful or warm to the touch, or if you get a fever (temperature greater than 100.4&ordm;F or 38&ordm;C). These symptoms could signal a possible infection that could cause the beginning or worsening of lymphedema.",
"     </li>",
"     <li>",
"      If you develop lymphedema many years after surgery or have worsening lymphedema, contact your doctor or nurse immediately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LYMPHEDEMA TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no cure for lymphedema. The main goals of treatment are to control swelling, relieve symptoms, and prevent the swelling from worsening over time. Treatment should begin as soon as possible. A healthcare provider or program with expertise in treating lymphedema can be especially helpful.",
"   </p>",
"   <p>",
"    Because medicines are of little benefit and can sometimes be harmful, the most common approaches do not involve medicines. Instead, a therapy program that combines massage, skin care, exercise, and compression garments (compression bandages or a lymphedema sleeve) is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     IMPACT OF LYMPHEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;While lymphedema is not a life-threatening condition, it can have a major impact on your quality of life. A change in how your arm looks can be distressing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After breast cancer surgery, many patients are worried about how they look; having a swollen or misshapen arm can make this worse.",
"     </li>",
"     <li>",
"      If lymphedema affects the ability to use your arm, this can affect your quality of life, particularly if it is your dominant arm (eg, right arm if you are right-handed).",
"     </li>",
"     <li>",
"      Lymphedema can reduce tissue healing and occasionally causes chronic pain. For these reasons, prevention and early treatment of lymphedema are recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress in treating breast cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies.",
"   </p>",
"   <p>",
"    One example of a clinical trial that is investigating ways to reduce the incidence of lymphedema after breast cancer therapy is called CALGB 70305. This trial is currently enrolling women to determine if a combination of education, use of light arm weights with exercise, a light compression sleeve with vigorous activity, and regular breathing exercises can reduce the risk or severity of lymphedema after axillary lymph node dissection. Women are encouraged to enroll if possible. More information can be found online at",
"    <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/CALGB-70305\">",
"     www.cancer.gov/clinicaltrials/CALGB-70305",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H161\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3705030\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"     Patient information: Breast cancer (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=see_link\">",
"     Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?24/1/24594?source=see_link\">",
"     Patient information: Lymphedema after breast cancer treatment (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3705056\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"     Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link\">",
"     Clinical manifestations and diagnosis of lymphedema",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=see_link\">",
"     Prevention and treatment of lymphedema",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Cancer Institute",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"     www.nci.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      People Living With Cancer: The official patient information website of the American Society of Clinical Oncology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"     www.cancer.net/portal/site/patient",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Comprehensive Cancer Network",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nccn.com/\">",
"     www.nccn.com",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Cancer Society",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cancer.org/\">",
"     www.cancer.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Susan G. Komen Breast Cancer Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.komen.org/\">",
"     www.komen.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Lymphedema Network",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; (",
"    <a class=\"external\" href=\"file://www.lymphnet.org/\">",
"     www.lymphnet.org",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patient support",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://about.com/\">",
"       About.com",
"      </a>",
"      Breast Cancer Forum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"     file://breastcancer.about.com/forum",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15876/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15876/abstract/1\">",
"      Brennan MJ, Miller LT. Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. Cancer 1998; 83:2821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15876/abstract/2\">",
"      Lette J. A simple and innovative device to measure arm volume at home for patients with lymphedema after breast cancer. J Clin Oncol 2006; 24:5434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15876/abstract/3\">",
"      Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 2007; 245:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15876/abstract/4\">",
"      Bertelli G, Venturini M, Forno G, et al. An analysis of prognostic factors in response to conservative treatment of postmastectomy lymphedema. Surg Gynecol Obstet 1992; 175:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15876/abstract/5\">",
"      Rockson SG, Miller LT, Senie R, et al. American Cancer Society Lymphedema Workshop. Workgroup III: Diagnosis and management of lymphedema. Cancer 1998; 83:2882.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 882 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15876=[""].join("\n");
var outline_f15_32_15876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      LYMPHEDEMA OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHAT IS LYMPHEDEMA?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LYMPHEDEMA SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVENTING WORSENING OF LYMPHEDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LYMPHEDEMA TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      IMPACT OF LYMPHEDEMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H161\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3705030\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3705056\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patient support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/882\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/882|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/55/24439\" title=\"figure 1\">",
"      Lymph nodes body PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=related_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/1/24594?source=related_link\">",
"      Patient information: Lymphedema after breast cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=related_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15877="Brimonidine: Drug information";
var content_f15_32_15877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brimonidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/40/28292?source=see_link\">",
"    see \"Brimonidine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32228?source=see_link\">",
"    see \"Brimonidine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alphagan&reg; P",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alphagan&reg;;",
"     </li>",
"     <li>",
"      Apo-Brimonidine P&reg;;",
"     </li>",
"     <li>",
"      Apo-Brimonidine&reg;;",
"     </li>",
"     <li>",
"      PMS-Brimonidine Tartrate;",
"     </li>",
"     <li>",
"      ratio-Brimonidine;",
"     </li>",
"     <li>",
"      Sandoz-Brimonidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist, Ophthalmic",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Glaucoma, ocular hypertension: Ophthalmic: Instill 1 drop in affected eye(s) 3 times/day (approximately every 8 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32228?source=see_link\">",
"      see \"Brimonidine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years of age: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F142499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as tartrate [drops]: 0.15% (5 mL, 10 mL, 15 mL); 0.2% (5 mL, 10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alphagan&reg; P: 0.1% (5 mL, 10 mL, 15 mL); 0.15% (5 mL, 10 mL, 15 mL) [contains Purite&reg;]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove contact lenses prior to administration; wait 15 minutes before reinserting if using products containing benzalkonium chloride. Separate administration of other ophthalmic agents by 5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F142530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Brimonidine may be confused with bromocriptine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actual frequency of adverse reactions may be formulation dependent; percentages reported with Alphagan&reg; P:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (adults 1% to 4%; children 25% to 83%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Allergic conjunctivitis, conjunctival hyperemia, eye pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     1% to 10% (unless otherwise noted 1% to 4%):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5% to 9%), hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Alertness decreased (children), dizziness, fatigue, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (5% to 9%), dyspepsia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Burning sensation (5% to 9%), conjunctival folliculosis (5% to 9%), ocular allergic reaction (5% to 9%), visual disturbance (5% to 9%), blepharitis, blepharoconjunctivitis, blurred vision, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, dry eye, epiphora, eye discharge, eyelid disorder, eyelid edema, eyelid erythema, follicular conjunctivitis, foreign body sensation, irritation, keratitis, pain, photophobia, stinging, superficial punctate keratopathy, visual acuity worsened, visual field defect, vitreous detachment, vitreous floaters, watery eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, dyspnea, pharyngitis, rhinitis, sinus infection, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, flu-like syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anterior uveitis, bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (erythema, eyelid pruritus, vasodilation), tachycardia; apnea, bradycardia, hypothermia, and hypotonia have been reported in infants",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brimonidine tartrate or any component of the formulation; children &lt;2 years of age",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Patients receiving MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular insufficiency: Use with caution in patients with cerebral insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: Use with caution in patients with orthostatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Raynaud's phenomenon: Use with caution in patients with Raynaud's phenomenon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboangiitis obliterans: Use with caution in patients with thromboangiitis obliterans.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some formulations may contain benzalkonium chloride which may be adsorbed by soft contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Systemic absorption has been reported; children are at higher risk of systemic adverse events (Levy, 2004). Use contraindicated in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring efficacy: The IOP-lowering efficacy observed during the first month of therapy may not always reflect the long-term level of IOP reduction; routinely monitor IOP.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3013948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with",
"     <b>",
"      hypertensive",
"     </b>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng, gotu kola, licorice); may diminish antihypertensive effect. Avoid herbs with",
"     <b>",
"      hypotensive",
"     </b>",
"     properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd&rsquo;s purse); may enhance hypotensive effect.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F986416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F142483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alphagan P Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (10 mL): $194.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15% (10 mL): $213.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Brimonidine Tartrate Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15% (10 mL): $192.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (5 mL): $32.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Closely monitor patients who develop fatigue or drowsiness; IOP",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F142484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agglad Ofteno (DO, GT, HN, MX, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Alphagan (AT, AU, BE, BR, CH, CN, CZ, DE, DK, ES, FI, FR, GB, GR, HK, IE, IN, IT, MX, NL, NO, NZ, PL, PT, SE, SG, TR, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Alphagan-P (AR, BR, CO, CR, EC, HK, IL, KP, MY, PH, SG, TH, TW);",
"     </li>",
"     <li>",
"      Bridin-T (KP);",
"     </li>",
"     <li>",
"      Brimocon (CL);",
"     </li>",
"     <li>",
"      Brimopress (PY, UY);",
"     </li>",
"     <li>",
"      Enidin (AU, NZ);",
"     </li>",
"     <li>",
"      Iobrim (IN);",
"     </li>",
"     <li>",
"      Luxfen (BG);",
"     </li>",
"     <li>",
"      Nor-Tenz (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonism for alpha",
"     <sub>",
"      2",
"     </sub>",
"     -receptors; causes reduction of aqueous humor formation and increased uveoscleral outflow",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (74%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Byles DB, Frith P, and Salmon JF, &ldquo;Anterior Uveitis as a Side Effect of Topical Brimonidine,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 2000, 130(3):287-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/32/15877/abstract-text/11020406/pubmed\" id=\"11020406\" target=\"_blank\">",
"        11020406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy Y and Zadok D, &ldquo;Systemic Side Effects of Ophthalmic Drops,&rdquo;",
"      <i>",
"       Clin Pediatr",
"      </i>",
"      (Phila), 2004, 43(1):99-101.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9163 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15877=[""].join("\n");
var outline_f15_32_15877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142493\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142525\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142498\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142513\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142499\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142475\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142460\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142478\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142476\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142530\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142523\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142481\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142464\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298882\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142469\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013948\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142471\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F986416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142501\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142483\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142473\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142484\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142463\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142480\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9163\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9163|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/40/28292?source=related_link\">",
"      Brimonidine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32228?source=related_link\">",
"      Brimonidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15878="Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency";
var content_f15_32_15878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15878/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15878/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15878/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15878/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15878/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15878/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/32/15878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYP11B1 (or 11-beta-hydroxylase) deficiency is the second most common cause of congenital adrenal hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .) At an incidence of one in 100,000 live births, this disorder accounts for about 5 to 8 percent of cases of adrenal steroidogenic defects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In Israel, the incidence is as high as 1 in 5000 births among Jews of Moroccan ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/3\">",
"     3",
"    </a>",
"    ]. Like the more common CYP21A2 (21-hydroxylase) deficiency, CYP11B1 deficiency may be evident in neonates, children, or adults (late-onset).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of CYP11B1 results in decreased conversion of 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively (",
"    <a class=\"graphic graphic_figure graphicRef69032 \" href=\"UTD.htm?4/17/4382\">",
"     figure 1",
"    </a>",
"    ). The decrease in cortisol production causes an increase in corticotropin (ACTH) secretion. The resulting adrenal stimulation leads to excessive production of 11-deoxycortisol, 11-deoxycorticosterone, and adrenal androgens. The clinical manifestations of the disorder result from excess adrenal androgens and the mineralocorticoid actions of 11-deoxycorticosterone; 11-deoxycortisol has little biological activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYP11B1 deficiency is transmitted as an autosomal recessive disorder. It is caused by mutations of the CYP11B1 gene located on chromosome 8q21-q22. Most of the known mutations completely abolish the activity of the enzyme, but the clinical manifestations of the disorder vary substantially (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical presentation'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Mutations include missense mutations that result in loss of enzyme activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/4-7\">",
"     4-7",
"    </a>",
"    ], and frameshift [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/8\">",
"     8",
"    </a>",
"    ] and nonsense mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] that prevent synthesis of the enzyme. In two patients, the disorder occurred as a result of unequal recombination between the CYP11B1 and CYP11B2 genes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. One hybrid gene, consisting of the promoter and exons 1-6 of CYP11B2 and exons 7-9 of CYP11B1, coded for an enzyme with full 11-beta-hydroxylase and aldosterone synthase activities in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/11\">",
"     11",
"    </a>",
"    ], but was not expressed in the zona fasciculata due to replacement of the CYP11B1 promoter and regulatory elements by those of CYP11B2. The functional activity has not been assessed for all CYP11B1 mutations, but available data suggest that severe, classic presentations are associated with reduction in activity of 95 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late-onset CYP11B1 deficiency may be caused by mutations in the gene that do not completely abolish enzyme activity; seven such mutations have been characterized and shown to have 15 to 50 percent of normal function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of CYP11B1 deficiency in neonates are ambiguous genitalia in females (clitoral enlargement, labial fusion, formation of a urogenital sinus) and penile enlargement in males. The virilization of female neonates may be relatively mild or as severe as in CYP21A2 deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link\">",
"     \"Evaluation of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 25 patients, about one-half had relatively severe genital ambiguity or signs of hyperandrogenism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/15\">",
"     15",
"    </a>",
"    ]. The remainder presented in childhood with sexual precocity, early puberty in boys or acne in men, and hirsutism and menstrual irregularities in adolescent girls and young women. The milder late-onset form of CYP11B1 deficiency, in which hirsutism is the major manifestation of androgen excess, is analogous to late-onset CYP21A2 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The frequency of the late-onset form of the disorder is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertension occurs in approximately two-thirds of patients; it is most common early in life and uncommon in patients with late-onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. The hypertension is presumably due to excess secretion of 11-deoxycorticosterone; however, there is a poor correlation between the blood pressure and serum 11-deoxycorticosterone concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. Hypokalemia may be present and plasma renin activity is often low due to the excess mineralocorticoid activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension and hypokalemia are the primary clinical manifestations that distinguish CYP11B1 deficiency from CYP21A2 deficiency (in which mineralocorticoid production is reduced). However, some patients with CYP11B1 deficiency are normotensive, and a few have salt-wasting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/15,20-22\">",
"     15,20-22",
"    </a>",
"    ]. The reasons for this heterogeneity are not known.",
"   </p>",
"   <p>",
"    As in other forms of congenital adrenal hyperplasia, hyperplasia of adrenal rest tissue may present as retroperitoneal or testicular masses that regress with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CYP11B1 deficiency have a characteristic set of hormonal findings and some have hypokalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High serum concentrations of 11-deoxycortisol, 11-deoxycorticosterone, and the androgens dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA sulfate), androstenedione, and testosterone.",
"     </li>",
"     <li>",
"      Increased urinary excretion of the tetrahydro metabolites of 11-deoxycortisol and 11-deoxycorticosterone, which are normally present in trace quantities [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/25\">",
"       25",
"      </a>",
"      ]. Urinary 17-hydroxycorticosteroid excretion is high because 11-deoxycortisol reacts in the assay for these steroids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=see_link\">",
"       \"Measurement of urinary excretion of endogenous and exogenous glucocorticoids\"",
"      </a>",
"      .) Urinary excretion of 17-ketosteroids, most of which are androgen metabolites, is also increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In affected neonates, the diagnosis is established by high basal and ACTH-stimulated serum 11-deoxycortisol concentrations and increased urinary excretion of tetrahydro-11-deoxycortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/1,2,26-28\">",
"     1,2,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adolescents and young adults, basal serum 11-deoxycortisol values may be normal, and ACTH testing is often required to establish the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. An increase in serum 11-deoxycortisol greater than the 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile of control subjects has been suggested as a diagnostic criterion, but mutations have not been found in all individuals with abnormal responses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike patients who are heterozygous for CYP21A2 deficiency, carriers of CYP11B1 mutations have no detectable biochemical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little correlation between the clinical and laboratory findings and the specific gene mutation in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of CYP11B1 deficiency is directed toward providing glucocorticoid in sufficient doses to reduce ACTH secretion and therefore excess androgen and 11-deoxycorticosterone secretion. The goal is to ameliorate the hyperandrogenism and hypertension with as little glucocorticoid as possible, to minimize the risk of growth retardation, delayed sexual maturation, and other clinical manifestations of Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     Hydrocortisone",
"    </a>",
"    is used most frequently in children, the usual dose being 10 to 25 mg per m2 in divided doses. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , 0.5 mg at bedtime, also reduces ACTH secretion adequately. However, as in CYP21A2 deficiency, therapy with longer-acting glucocorticoids is considered to be more likely to inhibit growth and cause clinical manifestations of glucocorticoid excess than hydrocortisone.",
"   </p>",
"   <p>",
"    The response to therapy should be monitored both biochemically and clinically. Serum 11-deoxycortisol and DHEA sulfate concentrations and plasma renin activity should return to their normal ranges. Clinical monitoring consists of assessment of virilization and measurement of growth velocity and skeletal maturation in children, assessment of hair growth and menstrual regularity in adults, and measurement of the blood pressure in hypertensive patients in both age groups.",
"   </p>",
"   <p>",
"    The hypertension may persist even after adequate suppression of mineralocorticoid excess. Why this occurs is not known but antihypertensive therapy may be required.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    , and calcium channel blockers are most likely to be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in CYP21A2 deficiency, genital malformations in affected females may need to be corrected surgically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CYP11B1 deficiency can be diagnosed prenatally by measuring tetrahydro-11-deoxycortisol in amniotic fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/33\">",
"     33",
"    </a>",
"    ]. Prenatal diagnosis has also been achieved by amplification and direct sequencing of the CYP11B1 gene in DNA from chorionic villus biopsy samples.",
"   </p>",
"   <p>",
"    As in CYP21A2 deficiency, prenatal treatment can be effective in preventing ambiguous genital development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\"",
"    </a>",
"    .) This was illustrated in a report of a woman who had two daughters affected by CYP11B1 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/34\">",
"     34",
"    </a>",
"    ]. She was treated starting in the fifth week of her third pregnancy, blind to the gender and genetic status of the fetus, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    daily in three divided doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/34\">",
"     34",
"    </a>",
"    ]. Karyotyping by chorionic villus sampling revealed the fetus to be female at 10 weeks gestation and dexamethasone treatment was continued. The infant had normal female external genitalia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21167154\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CYP11B1 (or 11-beta-hydroxylase) deficiency is the second most common cause of congenital adrenal hyperplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"       \"Adrenal steroid biosynthesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deficiency of CYP11B1 results in decreased conversion of 11-deoxycortisol and 11-deoxycorticosterone to cortisol and corticosterone, respectively (",
"      <a class=\"graphic graphic_figure graphicRef69032 \" href=\"UTD.htm?4/17/4382\">",
"       figure 1",
"      </a>",
"      ). The decrease in cortisol production causes an increase in corticotropin (ACTH) secretion. The resulting adrenal stimulation leads to excessive production of 11-deoxycortisol, 11-deoxycorticosterone, and adrenal androgens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CYP11B1 deficiency is transmitted as an autosomal recessive disorder. It is caused by mutations of the CYP11B1 gene located on chromosome 8q21-q22. Most of the known mutations completely abolish the activity of the enzyme, but the clinical manifestations of the disorder vary substantially. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of CYP11B1 deficiency in neonates are ambiguous genitalia in females (clitoral enlargement, labial fusion, formation of a urogenital sinus) and penile enlargement in males. The virilization of female neonates may be relatively mild or as severe as in CYP21A2 deficiency. Hypertension occurs in approximately two-thirds of patients; it is most common early in life and uncommon in patients with late-onset disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established in neonates by high basal and ACTH-stimulated serum 11-deoxycortisol concentrations and increased urinary excretion of tetrahydro-11-deoxycortisol. Diagnostic criteria in adolescents and adults are uncertain, as basal serum 11-deoxycortisol values may be normal. With ACTH testing, an increase in serum 11-deoxycortisol greater than the 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile of control subjects has been suggested as a diagnostic criterion, but mutations have not been found in all individuals with abnormal responses. Hypokalemia may be present and plasma renin activity is often low due to the excess mineralocorticoid activity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy of CYP11B1 deficiency is directed toward providing glucocorticoid in sufficient doses to reduce ACTH secretion and therefore excess androgen and 11-deoxycorticosterone secretion. The goal is to ameliorate the hyperandrogenism and hypertension with as little glucocorticoid as possible, to minimize the risk of growth retardation, delayed sexual maturation, and other clinical manifestations of Cushing's syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CYP11B1 deficiency can be diagnosed prenatally by measuring tetrahydro-11-deoxycortisol in amniotic fluid [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15878/abstract/33\">",
"       33",
"      </a>",
"      ]. Prenatal diagnosis has also been achieved by amplification and direct sequencing of the CYP11B1 gene in DNA from chorionic villus biopsy samples. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/1\">",
"      White PC, New MI, Dupont B. Congenital adrenal hyperplasia. (1). N Engl J Med 1987; 316:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/2\">",
"      White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev 1994; 15:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/3\">",
"      R&ouml;sler A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. Am J Med Genet 1992; 42:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/4\">",
"      White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg-448----His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest 1991; 87:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/5\">",
"      Curnow KM, Slutsker L, Vitek J, et al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci U S A 1993; 90:4552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/6\">",
"      Krone N, Riepe FG, G&ouml;tze D, et al. Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. J Clin Endocrinol Metab 2005; 90:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/7\">",
"      Grigorescu Sido A, Weber MM, Grigorescu Sido P, et al. 21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005; 90:5769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/8\">",
"      Helmberg A, Ausserer B, Kofler R. Frame shift by insertion of 2 basepairs in codon 394 of CYP11B1 causes congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 1992; 75:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/9\">",
"      Naiki Y, Kawamoto T, Mitsuuchi Y, et al. A nonsense mutation (TGG [Trp116]--&gt;TAG [Stop]) in CYP11B1 causes steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 1993; 77:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/10\">",
"      Kuribayashi I, Massa G, van den Tooren-de Groot HK, et al. A novel nonsense mutation in the Cyp11B1 gene from a subject with the steroid 11beta-hydroxylase form of congenital adrenal hyperplasia. Endocr Res 2003; 29:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/11\">",
"      Portrat S, Mulatero P, Curnow KM, et al. Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:3197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/12\">",
"      Hampf M, Dao NT, Hoan NT, Bernhardt R. Unequal crossing-over between aldosterone synthase and 11beta-hydroxylase genes causes congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:4445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/13\">",
"      Parajes S, Loidi L, Reisch N, et al. Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/14\">",
"      Joehrer K, Geley S, Strasser-Wozak EM, et al. CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Hum Mol Genet 1997; 6:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/15\">",
"      Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983; 56:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/16\">",
"      Cathelineau G, Brerault JL, Fiet J, et al. Adrenocortical 11 beta-hydroxylation defect in adult women with postmenarchial onset of symptoms. J Clin Endocrinol Metab 1980; 51:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/17\">",
"      Lucky AW, Rosenfield RL, McGuire J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986; 62:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/18\">",
"      de Simone G, Tommaselli AP, Rossi R, et al. Partial deficiency of adrenal 11-hydroxylase. A possible cause of primary hypertension. Hypertension 1985; 7:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/19\">",
"      R&ouml;sler A, Leiberman E, Sack J, et al. Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Horm Res 1982; 16:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/20\">",
"      Holcombe JH, Keenan BS, Nichols BL, et al. Neonatal salt loss in the hypertensive form of congenital adrenal hyperplasia. Pediatrics 1980; 65:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/21\">",
"      Hochberg Z, Benderly A, Zadik Z. Salt loss in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Arch Dis Child 1984; 59:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/22\">",
"      Hochberg Z, Benderly A, Kahana L, Zadik Z. Requirement of mineralocorticoid in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 1986; 63:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/23\">",
"      Storr HL, Barwick TD, Snodgrass GA, et al. Hyperplasia of adrenal rest tissue causing a retroperitoneal mass in a child with 11 beta-hydroxylase deficiency. Horm Res 2003; 60:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/24\">",
"      Ghazi AA, Hadayegh F, Khakpour G, et al. Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia. J Endocrinol Invest 2003; 26:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/25\">",
"      GREEN OC, MIGEON CJ, WILKINS L. Urinary steroids in the hypertensive form of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1960; 20:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/26\">",
"      White PC, New MI, Dupont B. Congenital adrenal hyperplasia (2). N Engl J Med 1987; 316:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/27\">",
"      Lashansky G, Saenger P, Dimartino-Nardi J, et al. Normative data for the steroidogenic response of mineralocorticoids and their precursors to adrenocorticotropin in a healthy pediatric population. J Clin Endocrinol Metab 1992; 75:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/28\">",
"      Lashansky G, Saenger P, Fishman K, et al. Normative data for adrenal steroidogenesis in a healthy pediatric population: age- and sex-related changes after adrenocorticotropin stimulation. J Clin Endocrinol Metab 1991; 73:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/29\">",
"      DYRENFURTH I, SYBULSKI S, NOTCHEV V, et al. Urinary corticosteroid excretion patterns in patients with adrenocortical dysfunction. J Clin Endocrinol Metab 1958; 18:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/30\">",
"      GABRILOVE JL, SHARMA DC, DORFMAN RI. ADRENOCORTICAL 11-BETA-HYDROXYLASE DEFICIENCY AND VIRILISM FIRST MANIFEST IN THE ADULT WOMEN. N Engl J Med 1965; 272:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/31\">",
"      Pang S, Levine LS, Lorenzen F, et al. Hormonal studies in obligate heterozygotes and siblings of patients with 11 beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 1980; 50:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/32\">",
"      Zhu YS, Cordero JJ, Can S, et al. Mutations in CYP11B1 gene: phenotype-genotype correlations. Am J Med Genet A 2003; 122A:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/33\">",
"      R&ouml;sler A, Leiberman E, Rosenmann A, et al. Prenatal diagnosis of 11beta-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab 1979; 49:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15878/abstract/34\">",
"      Cerame BI, Newfield RS, Pascoe L, et al. Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. J Clin Endocrinol Metab 1999; 84:3129.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 126 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15878=[""].join("\n");
var outline_f15_32_15878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21167154\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21167154\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/126|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/17/4382\" title=\"figure 1\">",
"      11 beta hydroxylase deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41319?source=related_link\">",
"      Measurement of urinary excretion of endogenous and exogenous glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15879="Cutis marmorata";
var content_f15_32_15879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53396%7EDERM%2F50846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53396%7EDERM%2F50846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutis marmorata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutis marmorata is a normal reticulated mottling of the skin caused by vascular response to cold.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kenneth Greer,MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutis marmorata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A net-like, violaceous pattern is visible on the legs of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15879=[""].join("\n");
var outline_f15_32_15879=null;
var title_f15_32_15880="Detection of minimal residual disease in acute lymphoblastic leukemia";
var content_f15_32_15880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Detection of minimal residual disease in acute lymphoblastic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Wendy Stock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Zeev Estrov, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15880/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/32/15880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 80 percent of adults with acute lymphoblastic leukemia (ALL) achieve complete remission (CR) and up to one-half may experience prolonged disease-free survival and be \"cured\" of their disease. However, many will experience a recurrence and die of leukemia. Relapse is thought to result from residual leukemic cells that remain following the achievement of \"complete\" remission, but are below the limits of detection using conventional morphologic assessment. These subclinical levels of residual leukemia are termed minimal residual disease (MRD) and can be evaluated using more sensitive assays.",
"   </p>",
"   <p>",
"    This topic review will focus on the methods for MRD monitoring in ALL. The clinical significance of MRD detection in ALL and the use of MRD testing in acute myeloid leukemia and chronic myeloid leukemia are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=see_link\">",
"     \"Clinical use of minimal residual disease detection in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link&amp;anchor=H20#H20\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'MRD and relapse after allo-HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFICULTIES IN DEFINING COMPLETE REMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of induction therapy for ALL is achievement of an initial complete remission (CR), defined as the eradication of all leukemia cells (&lt;5 percent blasts) from the bone marrow and blood detectable by microscopic review and the restoration of normal hematopoiesis (&gt;25 percent cellularity and normal peripheral blood counts).",
"   </p>",
"   <p>",
"    While CR has historically been defined based upon morphologic criteria, it has been proposed that an assessment of MRD might define a more stringent \"complete MRD response\" that may be better able to predict prognosis. This approach is supported by several observations that illustrate the difficulty in ascertaining whether a patient with ALL in morphologic CR is likely to remain disease-free:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematogones &mdash; Morphologic evaluation may be unable to distinguish between ALL blast cells and lymphoid precursors (hematogones) or activated mature lymphocytes. This distinction is particularly difficult in samples of bone marrow recovering from chemotherapy or transplantation, where hematogones may account for 10 percent of the lymphoid cells.",
"     </li>",
"     <li>",
"      Sampling error &mdash; A single bone marrow specimen represents only a very small percentage of the total bone marrow cellular population and thereby presents a potential for sampling error. Documented cases exist in which a bone marrow aspiration was normal at one site and showed leukemia at another. While this may occasionally be true early in the course of the disease, it is less of a problem after chemotherapy has been given (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Source of cells'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Detection limits &mdash; The detection of ALL blasts by morphologic review or conventional cytogenetics is limited by operator error and the number of metaphases evaluated. In one study, the median lower limit of detection of leukemic blasts by conventional microscopic examination of bone marrow by two experienced cytologists was greater than 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/1\">",
"       1",
"      </a>",
"      ]. The sensitivity of cytogenetics for detecting residual disease is limited to about 5 percent when only 20 to 40 metaphase cells are examined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, a patient in clinical remission can harbor 10",
"    <sup>",
"     10",
"    </sup>",
"    leukemic cells, equivalent to a detection limit of about one malignant cell for every 20 to 100 normal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/2\">",
"     2",
"    </a>",
"    ]. On the other hand, more sensitive assays, such as polymerase chain reaction (PCR), may detect one leukemic cell diluted 10",
"    <sup>",
"     5",
"    </sup>",
"    times, or about 1 to 5",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    nucleated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=see_link&amp;anchor=H9#H9\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\", section on 'Polymerase chain reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The problem of defining CR is best exemplified by a study in which residual leukemic cells were monitored by PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk of relapse of ALL for children with &lt;15 or &gt;15",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    mononuclear cells after both induction therapy and consolidation therapy was 4 and 47 percent, respectively. These calculations indicate that routine microscopic and cytogenetic determination of complete remission (ie, one blast in 20 normal cells) allows for a residual blast count up to 300 times greater than the number capable of causing leukemic relapse (ie, &gt;15",
"    <span class=\"nowrap\">",
"     blasts/100,000",
"    </span>",
"    cells). This observation suggests that \"true\" complete remission must be determined by means at least as sensitive as PCR (",
"    <a class=\"graphic graphic_table graphicRef70804 \" href=\"UTD.htm?24/37/25179\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SOURCE OF CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRD analyses are typically performed on bone marrow specimens, but flow cytometry can also evaluated MRD in whole blood.",
"   </p>",
"   <p>",
"    Most studies of MRD have employed cells taken from a single bone marrow site. In one study, MRD levels in paired bone marrow samples obtained during the first year of treatment were comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/3\">",
"     3",
"    </a>",
"    ]. Differences, when present, reflected variations in the assay, especially when MRD was detected below its quantitative limit, rather than being due to differences in the distribution of leukemic cells.",
"   </p>",
"   <p>",
"    In some situations, the peripheral blood and bone marrow may yield similar information. As an example, using flow cytometric techniques, MRD was measured in pairs of bone marrow and peripheral blood samples collected from 226 children during treatment for newly diagnosed ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/4\">",
"     4",
"    </a>",
"    ]. MRD was detected in marrow and blood in 72 pairs and in marrow but not in blood in 67 pairs; it was undetectable in the remaining 579 pairs.",
"   </p>",
"   <p>",
"    Findings in marrow and blood were completely concordant in the 150 paired samples from patients with T-lineage ALL. In B-lineage ALL, only 37 of 104 positive marrow samples had a corresponding positive blood sample. The four-year cumulative incidence of relapse in B-lineage ALL was 80 percent for those who had peripheral blood MRD at the end of remission induction therapy but only 13 percent for those with MRD confined to the marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     METHODS FOR DETECTING MRD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of techniques have been studied for the detection of residual disease, including cytogenetics, cell culture systems, fluorescence in situ hybridization (FISH), Southern blotting, multicolor flow cytometry, and polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to apply these techniques for MRD detection, they must demonstrate three salient characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specificity &mdash; The ability to discriminate between malignant and normal cells",
"     </li>",
"     <li>",
"      Sensitivity &mdash; The ability to detect one malignant cell in a background of at least 1000 normal cells",
"     </li>",
"     <li>",
"      Reproducibility and applicability &mdash; The techniques must be standardized and reproducible, and results must be available in a timely manner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both PCR-based techniques and multicolor flow cytometry are able to fulfill the above criteria for detection of MRD for most patients (",
"    <a class=\"graphic graphic_table graphicRef70804 \" href=\"UTD.htm?24/37/25179\">",
"     table 1",
"    </a>",
"    ). The percentage of patients eligible for monitoring using each technique depends upon the phenotype and genotype of the leukemia.",
"   </p>",
"   <p>",
"    A multicenter study compared the ability of real time quantitative PCR and multicolor flow cytometry to predict bone marrow relapse using 726 surveillance samples from 228 children with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/8\">",
"     8",
"    </a>",
"    ]. Concordant results were obtained with these two techniques in 84 percent of day 29 samples using an MRD threshold of 0.1 percent. For patients with B-ALL, PCR and flow cytometry were equally able to predict bone marrow relapse. For patients with T-ALL, PCR was superior to flow cytometry in predicting bone marrow relapse. Neither method was able to predict isolated extramedullary relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POLYMERASE CHAIN REACTION (PCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) can amplify a DNA or cDNA sequence unique to the leukemic clone resulting in the detection of one malignant cell among 10(4) to 10(5) normal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/9\">",
"     9",
"    </a>",
"    ]. There are two types of targets used to detect MRD in ALL patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunoglobulin (Ig) or T-cell receptor (TCR) gene rearrangements",
"     </li>",
"     <li>",
"      Leukemia-specific chromosomal rearrangements",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of leukemia clones contain Ig or TCR gene rearrangements that can be used as targets. In comparison, leukemia-specific chromosomal rearrangements are found in a minority of cases.",
"   </p>",
"   <p>",
"    Quantitative measurement of MRD can be attained using real time quantitative PCR (RQ-PCR), dilution techniques, or the co-amplification of internal or external standards [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. RQ-PCR is generally preferred because it is less technically demanding (",
"    <a class=\"graphic graphic_figure graphicRef81663 \" href=\"UTD.htm?2/39/2686\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71655 \" href=\"UTD.htm?41/27/42431\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/54/13159?source=see_link&amp;anchor=H8006693#H8006693\">",
"     \"Polymerase chain reaction\", section on 'Quantitative PCR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Targets of PCR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ig and TCR gene rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Random deletions and insertions of nucleotides that occur during immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement result in the generation of unique junctional sequences that can serve as leukemic clone-specific markers. At the time of diagnosis, the precise nucleotide sequence of the junctional region of the Ig or TCR genes in the leukemic cells can be identified. Junctional region-specific oligonucleotides can then be designed to use as patient-specific probes (or primers) for MRD detection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chromosomal rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) can also be used to identify and quantify leukemia-specific breakpoint fusion regions resulting from chromosomal rearrangements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=see_link\">",
"     \"Chromosomal translocations, deletions, and inversions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oligonucleotide primers can be designed at opposite ends of the DNA breakpoint fusion region such that the PCR product contains the tumor-specific fusion sequences. Since PCR products should not exceed about 2 kilobases (kb) in routine MRD studies, DNA PCR amplification can only be used when breakpoints cluster in a small area (preferably &lt;2 kb). In ALL, DNA based PCR for MRD has been successfully performed for [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T-lineage ALL with TAL1 gene deletions (SIL-TAL1)",
"     </li>",
"     <li>",
"      t(11;14)(p13;q11) involving RHOM1-TCRD",
"     </li>",
"     <li>",
"      t(1;14)(p32;q11) involving TAL1-TCRD",
"     </li>",
"     <li>",
"      t(10;14)(q24;q11) involving HOX11-TCRD",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Advantages of PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of polymerase chain reaction (PCR) for MRD monitoring include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extraordinary sensitivity &mdash; While the sensitivity for each junctional region target varies, the sensitivity of PCR is typically 0.5 to 1.0 log higher than that obtained with flow cytometry [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Wide applicability &mdash; PCR testing is applicable to most cases of ALL given the high frequency of Ig and TCR gene rearrangements in ALL.",
"     </li>",
"     <li>",
"      Speed &mdash; In just a few hours, PCR can amplify a single DNA molecule a million-fold.",
"     </li>",
"     <li>",
"      Sample stability &mdash; The DNA samples tested with PCR are very stable during transport.",
"     </li>",
"     <li>",
"      Minimal tissue requirements",
"     </li>",
"     <li>",
"      Standardized method",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Limitations of PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disadvantages of polymerase chain reaction (PCR) for MRD monitoring encompass a variety of technical and biological issues including [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contamination of the reaction product, requiring strict quality control",
"     </li>",
"     <li>",
"      Poor reproducibility when small numbers of transcripts are present",
"     </li>",
"     <li>",
"      Evolution of the leukemic clone, subclone formation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of oligoclonal populations that can cause both false-negative and false-positive results [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Need for diagnostic sample &mdash; Since the junctional region rearrangements are unique to the leukemia clone, a sample from the time of diagnosis must be available to determine the appropriate primers.",
"     </li>",
"     <li>",
"      Restricted to experienced molecular hematology laboratories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oligoclonality of Ig and TCR gene rearrangements at diagnosis is a relatively frequent phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Primary and secondary rearrangements occurring during the course of the disease might result in the loss of specific junctional regions initially identified at diagnosis; therefore, it appears prudent to monitor ALL patients with two or more independent PCR targets in order to prevent false-negative results during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/7,21,22\">",
"     7,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     REVERSE TRANSCRIPTASE PCR (RT-PCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse transcriptase polymerase chain reaction (RT-PCR) can be used to identify leukemia-specific fusion mRNA created by DNA breakpoints that span areas larger than 2 kb, such as",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    resulting from t(9;22).",
"   </p>",
"   <p>",
"    In RT-PCR, messenger RNA (consisting of transcribed coding exons with the non-coding introns excised) is converted into complementary DNA (cDNA) by an RNA-dependent DNA polymerase, termed reverse transcriptase. The cDNA complex is then changed into double-stranded DNA, becoming the template for a subsequent PCR reaction. Results of RT-PCR are qualitative rather than quantitative (",
"    <a class=\"graphic graphic_figure graphicRef66809 \" href=\"UTD.htm?23/40/24206\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In ALL, RT-PCR has been used to detect the following transcripts:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      resulting from t(9;22) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       E2A/PBX1",
"      </span>",
"      in cases pre-B ALL with t(1;19)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       MLL/AF4",
"      </span>",
"      in t(4;11) leukemia",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       TEL/AML1",
"      </span>",
"      resulting from t(12;21) in precursor-B ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Advantages of RT-PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like PCR, RT-PCR is extraordinarily sensitive and rapid. Unlike Ig and TCR gene rearrangements, the leukemia-specific fusion mRNA is not specific to an individual and remains stable throughout the course of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Limitations of RT-PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common RT-PCR target used in ALL is",
"    <span class=\"nowrap\">",
"     BCR/ABL,",
"    </span>",
"    which can be found in approximately 25 and 5 percent of adult and pediatric cases, respectively. Other limitations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RNA degradation and inefficient conversion of mRNA to cDNA",
"     </li>",
"     <li>",
"      Method varies by center",
"     </li>",
"     <li>",
"      Risk of cross-contamination, requiring strict quality control",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MULTICOLOR FLOW CYTOMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multicolor flow cytometry uses a laser to determine specific immunophenotypic features of up to thousands of cells per second. MRD can be identified using flow cytometry based upon the aberrant expression of antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/2,29-33\">",
"     2,29-33",
"    </a>",
"    ]. The sensitivity varies with the number of simultaneous colors used (typically 6 to 9), but is in general 0.5 to 1.0 log lower than that of polymerase chain reaction (PCR).",
"   </p>",
"   <p>",
"    Two examples illustrate the power of multicolor flow cytometry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In B-cell lineage ALL, leukemic blasts may co-express T-cell antigens (eg, CD5 and CD7) or myeloid antigens (eg, CD13 and CD33), have asynchronous expression of antigens, or delete or overexpress a specific antigen (particularly CD10) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Using two four-color combinations of antibodies (CD19, CD45, CD20, CD10; and CD19, CD45, CD9, CD34), aberrant leukemic blasts could be identified in 81 of 82 pediatric B-lineage ALL cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In T-cell lineage ALL, leukemic blasts nearly always co-express terminal transferase, CD2, cytoplasmic CD3, CD5, and CD7 in addition to other T-cell antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/37\">",
"       37",
"      </a>",
"      ]. Cells with this immunophenotypic pattern are absent or rare in normal bone marrow or blood [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sequential MRD monitoring using multiparameter flow cytometry has been shown to be a valuable predictor of relapse in children with ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/38\">",
"     38",
"    </a>",
"    ]. As an example, in one study, the cumulative rate of relapse for those negative for MRD by flow cytometry was 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/39\">",
"     39",
"    </a>",
"    ], whereas it was 23, 43, and 72 percent for those with MRD of &lt;0.1, 0.1 to &lt;1.0, and &ge;1.0 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Advantages of flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages to flow cytometry for the detection of MRD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wide applicability &mdash; Immunophenotyping with flow cytometry can be applied to 80 to 95 percent of patients with ALL [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Speed &mdash; Same day reporting of results.",
"     </li>",
"     <li>",
"      Quantitative &mdash; Although not yet standardized, results from flow cytometry are quantitative rather than qualitative.",
"     </li>",
"     <li>",
"      Flow cytometry also provides additional information on the benign and malignant cells present in the sample, which may allow for drug targeting.",
"     </li>",
"     <li>",
"      Most published data use bone marrow as the sample source, but whole blood may be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Limitations of flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitations to the use of flow cytometry for MRD assessment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematogones &mdash; Low frequency normal hematopoietic progenitor cells (hematogones), similar to leukemic blasts, may express the same cytoplasmic or surface-bound marker profile, rendering distinction between normal and malignant cells difficult in this setting.",
"     </li>",
"     <li>",
"      Immunophenotypic shifts &mdash; There is also the potential for a change in immunophenotypic expression of the leukemic cells during disease progression, resulting in a false negative result [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low cellularity of bone marrow samples during and after induction therapy.",
"     </li>",
"     <li>",
"      Need for diagnostic sample &mdash; Although not strictly required for all cases, evaluation of the immunophenotype of the leukemic clone at the time of diagnosis is recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RESPONSE DEFINED",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to standardization of the techniques used to assess and quantify MRD, it is essential that clinicians and researchers use common terminology to report individual patient results and allow for the comparison of trial outcomes. As such, a panel of representatives of the major European study groups on childhood and adult ALL has proposed the following definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15880/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete MRD response &mdash; No MRD is detected with assessment that complies with a set of minimal technical requirements for the method used.",
"     </li>",
"     <li>",
"      MRD persistence &mdash; Presence of a continuously quantifiable MRD positivity measurable at at least two time points with at least one relevant treatment element in between.",
"     </li>",
"     <li>",
"      MRD reappearance &mdash; Conversion from MRD negativity to quantifiable MRD positivity, ideally with confirmation from a second sample prior to a change in treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term minimal residual disease (MRD) refers to residual leukemic cells that remain following the achievement of \"complete\" remission, but are below the limits of detection using conventional morphologic assessment. These subclinical levels of residual leukemia are thought to be responsible for relapse after initial disease response. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Difficulties in defining complete remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRD analyses are typically performed on bone marrow specimens, but flow cytometry can also evaluated MRD in whole white blood. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Source of cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both PCR-based techniques and multicolor flow cytometry demonstrate sufficient sensitivity, specificity, reproducibility and applicability for detection of MRD for most patients (",
"      <a class=\"graphic graphic_table graphicRef70804 \" href=\"UTD.htm?24/37/25179\">",
"       table 1",
"      </a>",
"      ). The percentage of patients eligible for monitoring using each technique depends upon the phenotype and genotype of the leukemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Methods for detecting MRD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymerase chain reaction (PCR) can measure residual leukemic cells by the identification of immunoglobulin or T-cell receptor gene rearrangements or by leukemia-specific chromosomal rearrangements. PCR can quantify MRD in most cases of ALL. The sensitivity is typically higher than that of flow cytometry and the samples tested are stable, allowing for transport. The disadvantages of PCR include the dependence upon a sample obtained at the time of diagnosis, potential false positives from sample contamination, and false negatives due to the evolution of the leukemic clone. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Polymerase chain reaction (PCR)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reverse transcriptase PCR (RT-PCR) can be used to identify leukemia-specific fusion mRNA, such as",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      resulting from t(9;22). RT-PCR is extraordinary sensitive and uses a leukemia-specific fusion mRNA target that is not specific to an individual and remains stable throughout the course of disease. However, RT-PCR is applicable to only a minority of patients with ALL and the mRNA target is more easily degraded during sample",
"      <span class=\"nowrap\">",
"       handling/transport",
"      </span>",
"      than the DNA used for PCR. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Reverse transcriptase PCR (RT-PCR)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multicolor flow cytometry can identify MRD based upon the aberrant expression of antigens seen on immunophenotype. The sensitivity is still high, but lower than that of PCR. This technique can be applied to the majority of patients with ALL and can be completed quickly. Although not yet standardized, results are quantitative and provide additional information on the benign and malignant cells present in the sample. As with PCR, there is the potential for false negative results due to a change in immunophenotypic expression. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Multicolor flow cytometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standardized definitions for \"complete MRD response,\" \"MRD persistence,\" and \"MRD reappearance\" have been proposed. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Response defined'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/1\">",
"      Cav&eacute; H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.",
"     </a>",
"    </li>",
"    <li>",
"     Van Bekkum DW. Reflection on the detection and treatment of leukemia. In: Minimal Residual Disease in Acute Leukemia, Lowenberg B, Hagenbeck A (Eds), Martinus Nijoff, Boston 1984. p.385.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/3\">",
"      van der Velden VH, Hoogeveen PG, Pieters R, van Dongen JJ. Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia. Br J Haematol 2006; 133:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/4\">",
"      Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002; 100:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/5\">",
"      Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/6\">",
"      Bacher U, Zander AR, Haferlach T, et al. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008; 42:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/7\">",
"      van Dongen JJ, Szczepaski T, de Bruijn MA, et al. Detection of minimal residual disease in acute leukemia patients. Cytokines Mol Ther 1996; 2:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/8\">",
"      Th&ouml;rn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol 2011; 152:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/9\">",
"      Br&uuml;ggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/10\">",
"      Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/11\">",
"      Cross NC. Quantitative PCR techniques and applications. Br J Haematol 1995; 89:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/12\">",
"      Morley AA, Latham S, Brisco MJ, et al. Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn 2009; 11:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/13\">",
"      Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993; 83:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/14\">",
"      Br&uuml;ggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/15\">",
"      Faderl S, Estrov Z. Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. Cytokines Cell Mol Ther 1998; 4:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/16\">",
"      Chen IM, Chakerian A, Devidas M, et al. Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. Br J Haematol 2006; 135:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/17\">",
"      Ford AM, Fasching K, Panzer-Gr&uuml;mayer ER, et al. Origins of \"late\" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. Blood 2001; 98:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/18\">",
"      Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003; 101:3635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/19\">",
"      Beishuizen A, H&auml;hlen K, Hagemeijer A, et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 1991; 5:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/20\">",
"      Steenbergen EJ, Verhagen OJ, van den Berg H, et al. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia. Leukemia 1997; 11:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/21\">",
"      van Dongen JJ, Breit TM, Adriaansen HJ, et al. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6 Suppl 1:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/22\">",
"      van Dongen JJ, Seriu T, Panzer-Gr&uuml;mayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/23\">",
"      Cazzaniga G, Lanciotti M, Rossi V, et al. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol 2002; 119:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/24\">",
"      Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/25\">",
"      Codrington R, O'Connor HE, Jalali GR, et al. Analysis of ETV6/AML1 abnormalities in acute lymphoblastic leukaemia: incidence, alternative spliced forms and minimal residual disease value. Br J Haematol 2000; 111:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/26\">",
"      de Haas V, Oosten L, Dee R, et al. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia. Br J Haematol 2000; 111:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/27\">",
"      Drunat S, Olivi M, Brunie G, et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 114:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/28\">",
"      Madzo J, Zuna J, Muz&iacute;kov&aacute; K, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 2003; 97:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/29\">",
"      Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/30\">",
"      Terstappen LW, Loken MR. Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. Cytometry 1988; 9:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/31\">",
"      Wells DA, Sale GE, Shulman HM, et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 1998; 110:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/32\">",
"      Dworzak MN, Fr&ouml;schl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/33\">",
"      Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009; 131:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/34\">",
"      Drach J, Drach D, Glassl H, et al. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/35\">",
"      Hurwitz CA, Gore SD, Stone KD, Civin CI. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. Leukemia 1992; 6:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/36\">",
"      Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia 1999; 13:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/37\">",
"      Krampera M, Vitale A, Vincenzi C, et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol 2003; 120:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/38\">",
"      Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/39\">",
"      Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/40\">",
"      Janossy G, Bollum FJ, Bradstock KF, Ashley J. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood 1980; 56:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15880/abstract/41\">",
"      Li A, Zhou J, Zuckerman D, et al. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood 2003; 102:4520.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4499 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15880=[""].join("\n");
var outline_f15_32_15880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFICULTIES IN DEFINING COMPLETE REMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SOURCE OF CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      METHODS FOR DETECTING MRD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POLYMERASE CHAIN REACTION (PCR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Targets of PCR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ig and TCR gene rearrangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chromosomal rearrangements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Advantages of PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Limitations of PCR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      REVERSE TRANSCRIPTASE PCR (RT-PCR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Advantages of RT-PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Limitations of RT-PCR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MULTICOLOR FLOW CYTOMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Advantages of flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Limitations of flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RESPONSE DEFINED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4499\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4499|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/39/2686\" title=\"figure 1\">",
"      Quantitative real time PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/27/42431\" title=\"figure 2\">",
"      Quantitative PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/40/24206\" title=\"figure 3\">",
"      Reverse transcriptase PCR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4499|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/37/25179\" title=\"table 1\">",
"      Detection MRD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18167?source=related_link\">",
"      Chromosomal translocations, deletions, and inversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31625?source=related_link\">",
"      Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/54/13159?source=related_link\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15881="Limb-girdle muscular dystrophy";
var content_f15_32_15881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Limb-girdle muscular dystrophy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15881/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15881/contributors\">",
"     Basil T Darras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15881/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15881/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15881/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15881/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/32/15881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function. Some of the genes responsible for these conditions have been identified. Muscle weakness is the primary symptom.",
"   </p>",
"   <p>",
"    The pathogenesis, genetics, and clinical characteristics of limb-girdle muscular dystrophy will be reviewed here. Other dystrophies are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=see_link\">",
"     \"Emery-Dreifuss muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=see_link\">",
"     \"Facioscapulohumeral muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limb-girdle muscular dystrophy (LGMD) is defined as a muscular dystrophy with predominantly proximal distribution of weakness which, early in the course of the disease, spares distal muscles as well as facial and extraocular muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/1\">",
"     1",
"    </a>",
"    ]. It includes a number of disorders with heterogeneous etiologies. LGMD is still used as a generic term to describe those patients with muscular dystrophy of girdle distribution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most cases of LGMD are inherited in an autosomal recessive fashion or are sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/2\">",
"     2",
"    </a>",
"    ], there are subtypes with an autosomal dominant pattern of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/3\">",
"     3",
"    </a>",
"    ]. In some families, the inheritance pattern cannot be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discovery of genetically distinct subtypes has redefined the classification of LGMD and has led to nomenclature designating the autosomal dominant forms as LGMD1A, 1B, 1C, etc, and the autosomal recessive forms as LGMD2A, 2B, 2C, etc (",
"    <a class=\"graphic graphic_table graphicRef78969 \" href=\"UTD.htm?21/34/22061\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Autosomal dominant subtypes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'Autosomal recessive subtypes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mutations within the same gene can result in different phenotypes that are sometimes not consistent with the strict definition of LGMD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54487187\">",
"    <span class=\"h2\">",
"     Calpainopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calpainopathy is caused by mutations in the calpain-3 gene (CAPN3) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/6\">",
"     6",
"    </a>",
"    ]. Calpain-3 interacts with cytoskeletal proteins such as titin and dysferlin, and plays a role in sarcomere remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. While the precise mechanism of calpainopathy is uncertain, loss of functional calpain-3 leads to abnormal muscle sarcomeres and eventual muscle fiber death. The phenotype of calpainopathy is variable, and ranges from pelvic and shoulder girdle muscle weakness (LGMD2A described below) to asymptomatic disease with elevated serum creatine kinase levels (hyperCKemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283166\">",
"    <span class=\"h2\">",
"     Caveolinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;With mutations in the caveolin 3 gene (CAV3), muscle disorders including asymptomatic creatine kinase elevation, myalgias and cramps, rippling muscle disease and distal myopathy appear to be more common than the classic LGMD presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283180\">",
"    <span class=\"h2\">",
"     Dysferlinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysferlin gene (DYSF) mutations cause two main types of muscular dystrophy (LGMD2B and Miyoshi distal myopathy) and other muscle disorders with variable phenotypes ranging from asymptomatic hyperCKemia to severe disability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/9\">",
"     9",
"    </a>",
"    ]. Mounting evidence suggests that these dysferlin myopathies (dysferlinopathies) are clinically more homogeneous than once thought. One retrospective report followed 29 patients with DYSF gene mutations (including 12 with LGMD2B and 14 with Miyoshi myopathy as diagnosed by initial symptoms) for a mean of 6.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/10\">",
"     10",
"    </a>",
"    ]. There were no differences between patients with LGMD2B and Miyoshi myopathy in the rate of disease progression or functional status. In addition, the pattern of muscle involvement on MRI was the same; the adductor magnus and gastrocnemius medialis were the first affected muscles in both groups.",
"    <br/>",
"    <br/>",
"    In experimental mice, deficiency of dysferlin disrupts the ability to reseal injured sarcolemma, resulting in muscle degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Accumulating evidence suggests that loss of dysferlin induces complement-mediated inflammation, which contributes to muscle injury in dysferlinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/9,13-18\">",
"     9,13-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4055140\">",
"    <span class=\"h2\">",
"     Dystroglycanopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in several genes, including Fukutin, FKRP, LARGE, POMGnT1, POMT1, and POMT2, have been identified as the cause of a variety of autosomal recessive muscular dystrophies known collectively as dystroglycanopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The underlying pathogenic mechanism for these mutations is reduced glycosylation of the extracellular alpha-dystroglycan receptor (ie, secondary dystroglycanopathies). Mutations in all these genes but LARGE are associated with autosomal recessive LGMD variants, now designated as muscular dystrophy-dystroglycanopathy (limb-girdle) types C1 through C5, with childhood or adult onset.",
"   </p>",
"   <p>",
"    In addition, a mutation in the core dystroglycan protein itself (ie, a primary dystroglycanopathy), caused by a missense mutation in the DAG1 gene, has been identified as a cause of LGMD associated with cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several of the gene mutations that cause secondary dystroglycanopathy are also associated with congenital muscular dystrophies, including Walker-Warburg syndrome, Fukuyama type of congenital muscular dystrophy, and muscle-eye-brain disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link&amp;anchor=H16#H16\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\", section on 'Congenital muscular dystrophies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4055162\">",
"    <span class=\"h2\">",
"     Laminopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the LMNA gene encoding lamin",
"    <span class=\"nowrap\">",
"     A/C",
"    </span>",
"    may result in the phenotypes of autosomal dominant Emery-Dreifuss muscular dystrophy and LGMD1B (cardiomyopathy with conduction system disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283195\">",
"    <span class=\"h2\">",
"     Sarcoglycanopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoglycanopathies (ie, LGMD2C, 2D, 2E, and 2F), are early-onset autosomal recessive LGMDs caused by mutations in alpha, beta, gamma, and delta sarcoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/23\">",
"     23",
"    </a>",
"    ]. These are members of the dystrophin-associated glycoprotein complex (",
"    <a class=\"graphic graphic_figure graphicRef66588 \" href=\"UTD.htm?3/48/3846\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of onset of LGMD varies from early childhood to adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. In most autosomal recessive cases, weakness occurs early and leads to significant disability during childhood. In other cases, particularly those inherited in an autosomal dominant fashion, the weakness may not be apparent until early or even late in adult life. The course is usually slowly progressive, with the exception of a few cases with rapid progression.",
"   </p>",
"   <p>",
"    Weakness may affect the shoulder girdle (scapulohumeral type), the pelvic girdle (pelvifemoral type), or both. Most childhood-onset cases have a pelvifemoral distribution of weakness. By comparison, adult-onset disease involves both shoulder and pelvic girdles with gradually increasing proximal limb weakness, thereby leading to restriction of mobility and eventually to wheelchair confinement.",
"   </p>",
"   <p>",
"    Even in mild cases, there is preferential weakness and atrophy of the biceps muscle. Neck flexor and extensor muscles may be concurrently involved. Facial weakness is usually mild and, in some cases, totally absent. Extraocular muscles are completely spared in the LGMDs. Distal muscle strength is usually preserved, even at the late stage of the disease.",
"   </p>",
"   <p>",
"    Intellect is usually normal, though intellectual disability is a feature of LGMD2K and has been reported in LGMD2N [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subtypes of LGMD have specific clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/23\">",
"     23",
"    </a>",
"    ]. They are discussed below according to pattern of inheritance (",
"    <a class=\"graphic graphic_table graphicRef78969 \" href=\"UTD.htm?21/34/22061\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Autosomal dominant subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of autosomal dominant LGMD (designated LGMD1) shows greater clinical heterogeneity, later age of onset, more gradual progression, and a creatine kinase elevation that may be minimal compared with autosomal recessive subtypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal quality of speech, dysarthria, and slow disease progression is typical in LGMD1A (myotilinopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac conduction defects, arrhythmias, cardiomyopathy, and mild elbow contractures are common manifestations of LGMD1B (laminopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/26\">",
"       26",
"      </a>",
"      ], thus overlapping with autosomal dominant Emery-Dreifuss muscular dystrophy. Sudden death may occur in LGMD1B. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=see_link\">",
"       \"Emery-Dreifuss muscular dystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LGMD1C is an autosomal dominant condition caused by mutations in the caveolin 3 (CAV3) gene on chromosome 3p25 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Caveolin acts as a scaffolding protein in the formation of caveolae, which are small invaginations of the cell membrane involved in T-tubule formation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Caveolin 3 localizes to the sarcolemma of skeletal and cardiac muscle and plays a role in signal transduction, sodium channel function, vesicular trafficking, and maintenance of plasma membrane integrity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with CAV3 mutations may develop symptoms in childhood or adult life. The phenotype is variable [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/3\">",
"       3",
"      </a>",
"      ]. Asymptomatic creatine kinase elevation, myalgias and cramps",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stiffness after exertion, rippling muscle disease, and distal myopathy involving the tibialis anterior or gastrocnemius muscles may be more common than the classic LGMD presentation (ie, proximal weakness, often with calf hypertrophy) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/3,28,32,33\">",
"       3,28,32,33",
"      </a>",
"      ]. Familial isolated hypertrophic cardiomyopathy has also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/34\">",
"       34",
"      </a>",
"      ]. Although inheritance is autosomal dominant, the lack of a family history does not exclude the diagnosis of LGMD1C. Mutations of CAV3 exhibit intrafamilial variability [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/4\">",
"       4",
"      </a>",
"      ]. Laboratory testing shows a 3- to 25-fold elevation of creatine kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/28\">",
"       28",
"      </a>",
"      ], and muscle biopsy demonstrates nonspecific myopathic findings with normal sarcoglycan, merosin, and dystrophin staining [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. However, staining for caveolin 3 may be reduced or absent in the sarcolemma, and electron microscopy shows diminished density or loss of caveolae in the muscle membranes. DNA testing for caveolin mutations is commercially available [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rippling muscle disease (RMD) is an allelic autosomal dominant genetic disorder with a phenotype that overlaps that of LGMD1C [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]. While some patients with RMD have mutations in the CAV3 gene, sporadic cases associated with myasthenia gravis have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. RMD disease typically starts in childhood or adolescence with myalgias, cramps, and stiffness induced by exercise, but rarely presents in adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/42\">",
"       42",
"      </a>",
"      ]. The most frequently affected muscles are the quadriceps and biceps brachii. Associated muscle hypertrophy, particularly of the calves, is common. Direct percussion of muscle produces continuous rolling, rippling waves of muscle contractions that spread across the muscle, sometimes with a distinctive rapid muscle contraction, and in some patients with a painful mounding up of the muscle. Percussion of muscle may also produce a contraction very similar to percussion myotonia. Muscle rippling is accompanied by needle electromyographic silence. In the absence of family history of RMD, an evaluation for myasthenia gravis may be necessary, particularly if genetic testing for CAV3 mutations is negative. In patients with severe stiffness and painful cramps, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/22/22887?source=see_link\">",
"       dantrolene",
"      </a>",
"      sodium or benzodiazepines may be helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/37,42\">",
"       37,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although there is controversy about the nomenclature and the linkage assignments of the subtypes designated as LGMD1D through LGMD1G, we are following the evolving",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim\">",
"       Online Mendelian Inheritance in Man",
"      </a>",
"      classification.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LGMD1E (previously designated LGMD1D) is characterized by adult-onset, slowly progressive muscle weakness with mild dystrophic changes, vacuoles and abnormal protein aggregation on muscle biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/43-46\">",
"       43-46",
"      </a>",
"      ]. The disorder is caused by mutations in the DNAJB6 gene at chromosome 7q36 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A disorder designated under the term myofibrillar myopathy-1 (MFM1), and previously designated as LGMD1E was described in a single family with cardiac conduction defects, dilated cardiomyopathy, heart failure, and early onset weakness [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/49\">",
"       49",
"      </a>",
"      ]. Although initially linked to chromosome 6q23, the condition was later discovered to be caused by a mutation in the gene for desmin located at 2q35 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LGMD1F and LGMD1G have similar presentations; however, juvenile onset with rapid progression occurs in LGMD1F [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. A subset of patients with juvenile onset show facial muscle weakness and scapular winging, but no ophthalmoplegia, developmental delay, or calf hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LGMD1H, described in a single Italian family, is characterized by variable age at onset and disease severity, with some patients developing adult onset slowly progressive proximal muscle weakness, while others present with earlier onset",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      less severe symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autosomal recessive subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with autosomal dominant disease, autosomal recessive LGMD (designated LGMD2) is usually associated with earlier age of onset, more rapid progression, and relatively high creatine kinase values.",
"   </p>",
"   <p>",
"    An affected child with autosomal recessive LGMD, particularly one with LGMD2I, may be indistinguishable on examination from a child with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD). However, unlike DMD, cognitive function is typically normal in children with autosomal recessive LGMD. An exception is LGMD2K, which is associated with mental retardation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LGMD2A (calpainopathy) is caused by a mutation in the gene (CAPN3) encoding the proteolytic enzyme calpain-3 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/54\">",
"       54",
"      </a>",
"      ]. It is the most common type of LGMD worldwide, though there is variation depending on the geographic region [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/6,55\">",
"       6,55",
"      </a>",
"      ]. The onset of LGMD2A occurs between 6 and 18 years of age in 71 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/56\">",
"       56",
"      </a>",
"      ]. There is significant involvement of the parascapular muscles, biceps, gluteus maximus, adductors, and hamstrings. Contractures are extensive and tend to develop early. Requirement for a wheelchair occurs between the ages of 21 and 40 years in 81 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early weakness and atrophy of the gastrocnemius with inability to walk on the toes and high serum creatine kinase concentration is supportive of dysferlinopathy (LGMD2B) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the sarcoglycanopathies (ie, LGMD2C, 2D, 2E, and 2F), the pattern of weakness is reminiscent of",
"      <span class=\"nowrap\">",
"       DMD/BMD,",
"      </span>",
"      including the calf hypertrophy, but cognitive function is preserved. Cardiomyopathy may occur. In a hamster model, gene therapy with the human delta sarcoglycan (SGCD) gene resulted in sustained restoration of gene expression in the heart and skeletal muscles, improvement in cardiac and muscle function, and a dramatic increase in lifespan [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An early foot drop may indicate telethoninopathy (LGMD2G) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LGMD2I, now designated muscular dystrophy-dystroglycanopathy (limb-girdle) type C5 (MDDGC5), is a frequent form of LGMD caused by mutations in the fukutin-related protein gene (FKRP). While phenotypically heterogeneous [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/62\">",
"       62",
"      </a>",
"      ], common clinical features of MDDGC5 include proximal muscle weakness and atrophy, calf muscle hypertrophy, increased incidence of cardiomyopathy, and elevated plasma levels of creatine kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. These features are similar to those of DMD and BMD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"       \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In a study that screened 102 patients with a suspected diagnosis of sporadic DMD or BMD who were negative for dystrophin gene deletions or duplications, the FKRP gene mutation that causes MDDGC5 was found in 13 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/64\">",
"       64",
"      </a>",
"      ]. This result suggests that a substantial number of patients with a phenotype of",
"      <span class=\"nowrap\">",
"       DMD/BMD",
"      </span>",
"      who are negative for dystrophin gene mutations may have a form of LGMD and should be tested for the FKRP gene mutation.",
"     </li>",
"     <li>",
"      LGMD2K, now designated muscular dystrophy-dystroglycanopathy (limb-girdle) type C1 (MDDGC1), is characterized by mental retardation and abnormal alpha-dystroglycan [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/65\">",
"       65",
"      </a>",
"      ], and is caused by a mutation in the POMT1 gene encoding the protein-O-mannosyltransferase 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. The same gene is associated with congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies (type A or MDDGA), which includes the phenotypes known as Walker-Warburg syndrome and muscle-eye-brain disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link&amp;anchor=H1689451#H1689451\">",
"       \"Oculopharyngeal, distal, and congenital muscular dystrophies\", section on 'Dystroglycanopathies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LGMD2L is the nomenclature for a LGMD characterized by adult onset, slowly progressive proximal leg weakness, often with asymmetric muscle atrophy and highly elevated serum creatine kinase levels (&gt;2000 IU) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/68-70\">",
"       68-70",
"      </a>",
"      ]. Recessive mutations in anoctamin 5 (ANO5), a putative calcium-activated chloride channel, have been identified in families with LGMD2L as well as in families with distal non-dysferlin Miyoshi myopathy (MMD3) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/71\">",
"       71",
"      </a>",
"      ]. Accumulating evidence suggests that ANO5 mutations are a relatively common cause of adult onset LGMD; the phenotype is variable and may manifest as minimally symptomatic hyperCKemia, myalgias, longstanding calf hypertrophy without significant weakness, or severe LGMD, but is consistently milder in females [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LGMD2M, now designated muscular dystrophy-dystroglycanopathy (limb-girdle) type C4 (MDDGC4), is associated with fukutin mutations (FKTN gene) and has been described in three ambulant affected children from two families that share an Israeli origin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/72\">",
"       72",
"      </a>",
"      ]. Clinical features include onset in infancy, LGMD phenotype, motor deterioration after febrile viral illnesses, marked serum creatine kinase elevations, normal intelligence and brain structure, and treatment responsiveness to glucocorticoid therapy. The authors proposed LGMD2L as the nomenclature for this disease, but it was initially classified as LGMD2M in the OMIM database and in subsequent publications [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/73\">",
"       73",
"      </a>",
"      ], and was later re-designated in the OMIM as MDDGC4. Two brothers of Japanese and Caucasian ancestry with juvenile onset of symptoms, high serum creatine kinase, normal cognitive development, and LGMD phenotype had compound heterozygosity for two FKTN missense mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/74\">",
"       74",
"      </a>",
"      ]. Mutations involving the FKTN gene are more commonly associated with Fukuyama congenital muscular dystrophy in Japanese populations; therefore the two conditions are allelic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link&amp;anchor=H19#H19\">",
"       \"Oculopharyngeal, distal, and congenital muscular dystrophies\", section on 'Fukuyama type'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LGMD2N, now designated muscular dystrophy-dystroglycanopathy (limb-girdle) type C2 (MDDGC2), has been linked to mutations in the POMT2 gene. Of the two reported individuals with POMT2 gene mutations, one was cognitively normal [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/75\">",
"       75",
"      </a>",
"      ] while the second was mentally retarded and ambulant at age 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscular dystrophy-dystroglycanopathy (limb-girdle) type C3 (MDDGC3) is the OMIM designation for an LGMD phenotype related to mutations in the POMGnT1 gene. The single affected female with a POMGnT1 mutation lost ambulation at age 19 years and had hypertrophy of the calves and quadriceps, and severe myopia, but her cognition was normal [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiac involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement is common in LGMD1B (laminopathy), LGMD1E, LGMD2E, and LGMD2I (MDDGC5) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/49,77,78\">",
"     49,77,78",
"    </a>",
"    ]. It is unusual in LGMD1A (myotilinopathy), LGMD1D, LGMD2A, and LGMD2D.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatine kinase concentration is usually modestly elevated in LGMD. However, it can be very high in sarcoglycanopathy, dysferlinopathy, and caveolinopathy.",
"   </p>",
"   <p>",
"    Electromyography shows myopathic changes with small polyphasic potentials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathology and immunoassays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A muscle biopsy reveals dystrophic changes with degeneration and regeneration of muscle fibers, fiber-splitting, internal nuclei, fibrosis, moth-eaten, and whorled fibers. Eosinophilia has been reported in muscle biopsies of patients with LGMD2A and LGMD2C [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with sarcoglycan protein deficiency, dystrophin amount is normal or slightly reduced by immunofluorescence (IF) and Western blot analysis of muscle protein. The reduction in dystrophin is presumably secondary to the destabilization of the dystrophin associated glycoprotein complex induced by the absence of one of the sarcoglycan proteins or caveolin (",
"    <a class=\"graphic graphic_figure graphicRef66588 \" href=\"UTD.htm?3/48/3846\">",
"     figure 1",
"    </a>",
"    ). Muscle biopsy with IF reveals a reduction or absence of sarcoglycans",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;LGMDs can be inherited as either autosomal recessive or autosomal dominant conditions. However, in many cases the inheritance pattern cannot be determined. Although uncommon or rare, sporadic dominant LGMD cases, and even autosomal recessive ones with modest creatine kinase elevation, may be clinically indistinguishable from spinal muscular atrophy (SMA) type 3, also known as the Kugelberg-Welander form. Because SMA type 3 may also have a modest creatine kinase elevation (&lt;1000",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    electromyography is particularly useful in this setting for differentiating a neurogenic from a myopathic process and determining whether to proceed with DNA testing for possible SMA or DNA testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a muscle biopsy for a potential myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link&amp;anchor=H7#H7\">",
"     \"Spinal muscular atrophy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a male child with muscular weakness and a serum creatine kinase level of &gt;1000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    or 10 times the upper limit of normal, in whom nonmyopathic motor unit disorders (eg, SMA) are less likely, gene mutation analysis for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) should be obtained. Such testing should also be obtained in girls with similar serum creatine kinase elevation who are suspected of being symptomatic",
"    <span class=\"nowrap\">",
"     DMD/BMD",
"    </span>",
"    carriers.",
"   </p>",
"   <p>",
"    For patients suspected of having a specific type of LGMD, we suggest genetic testing &ndash; prior to obtaining a muscle biopsy &ndash; for the specific gene mutation most likely to explain the clinical presentation. Such testing may be directed to lamin",
"    <span class=\"nowrap\">",
"     A/C",
"    </span>",
"    (LGMD1B), calpain 3 (LGMD2A), caveolin 3, sarcoglycans (LGMD2C, 2D, 2E, 2F), fukutin related protein",
"    <span class=\"nowrap\">",
"     (LGMD2I/MDDGC5),",
"    </span>",
"    other LGMD genes (if genetic testing is available), and protein or DNA testing for dysferlin. It is worth emphasizing that single-gene testing, rather than the entire LGMD profile, should be pursued first whenever the clinical findings point to a particular subtype of LGMD. Genetic testing for LGMD2I (MDDGC5) is indicated in all patients with a",
"    <span class=\"nowrap\">",
"     DMD/BMD",
"    </span>",
"    phenotype and no detectable dystrophin gene mutations, and LMNA testing is indicated in patients with an Emery-Dreifuss muscular dystrophy phenotype.",
"   </p>",
"   <p>",
"    A muscle biopsy is appropriate if genetic and protein testing for LGMD is uninformative or unavailable. In cases of LGMD, a specific biopsy diagnosis (eg, alpha-sarcoglycanopathy) may be achieved via immunohistochemical testing with antibodies directed against dystrophin, alpha and beta dystroglycans, merosin, dysferlin, sarcoglycans (alpha-, beta-, gamma-, and delta-), and other LGMD-related proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/80\">",
"     80",
"    </a>",
"    ]. While antibodies against most proteins are expected to become commercially available in the future, muscle biopsy immunohistochemistry testing will likely be superseded by the availability of DNA testing for most LGMD subtypes.",
"   </p>",
"   <p>",
"    When a biopsy that suggests a myopathic process is accompanied by normal DNA testing and normal immunohistochemistry for all the above-mentioned proteins, testing for myotilin (LGMD1A), telethonin (LGMD2G), TRIM32 (LGMD2H), titin (LGMD2J), or other LGMD genes (",
"    <a class=\"graphic graphic_table graphicRef78969 \" href=\"UTD.htm?21/34/22061\">",
"     table 1",
"    </a>",
"    ) may be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/60,81-84\">",
"     60,81-84",
"    </a>",
"    ]. These are currently performed in selected laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of LGMD is supportive. It is aimed primarily at the prevention of contractures, which can result in substantial disability. A passive stretching physical therapy program should be instituted early. Later in the course of the disease, cardiorespiratory status should be monitored. Heart transplantation has been successful in some patients with LGMD1B and other LGMDs who developed severe congestive failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary evidence from a study of nine ambulatory adult patients with LGMD2I suggests that low-intensity aerobic exercise may be safe and beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/87\">",
"     87",
"    </a>",
"    ]. Confirmation of this finding in larger trials is needed before exercise can be routinely recommended for patients with LGMD. Responsiveness to glucocorticoid therapy has been reported in patients with LGMD2M [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gene transfer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/88,89\">",
"     88,89",
"    </a>",
"    ] and exon skipping strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15881/abstract/90\">",
"     90",
"    </a>",
"    ] are currently being studied for the treatment of various LGMD subtypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=see_link\">",
"       \"Patient information: Muscular dystrophy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=see_link\">",
"       \"Patient information: Overview of muscular dystrophies (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5694282\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limb-girdle muscular dystrophy (LGMD) includes a number of disorders with heterogeneous etiologies. It is used as a generic term to describe those patients with muscular dystrophy of girdle distribution, having a predominantly proximal distribution of weakness that, early in the course of the disease, spares distal muscles as well as facial and extraocular muscles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While most cases of LGMD are inherited in an autosomal recessive fashion or are sporadic, there are subtypes with an autosomal dominant pattern of inheritance. In some families, the inheritance pattern cannot be determined. The discovery of genetically distinct subtypes has redefined the classification of LGMD and has led to nomenclature designating the autosomal dominant forms as LGMD1A, 1B, 1C, etc, and the autosomal recessive forms as LGMD2A, 2B, 2C, etc (",
"      <a class=\"graphic graphic_table graphicRef78969 \" href=\"UTD.htm?21/34/22061\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The age of onset of LGMD varies from early childhood to adulthood. In most autosomal recessive cases, weakness occurs early and leads to significant disability during childhood. In other cases, particularly those inherited in an autosomal dominant fashion, the weakness may not be apparent until early or even late in adult life. The course is usually slowly progressive, with the exception of a few cases with rapid progression. Weakness may affect the shoulder girdle (scapulohumeral type), the pelvic girdle (pelvifemoral type), or both. Facial weakness is usually mild and, in some cases, totally absent. Extraocular muscles are completely spared in the LGMDs. Distal muscle strength is usually preserved, even at the late stage of the disease; however, distal muscle weakness and atrophy may occur in certain forms of LGMD. Intellect is usually normal. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The subtypes of LGMD have specific clinical characteristics (",
"      <a class=\"graphic graphic_table graphicRef78969 \" href=\"UTD.htm?21/34/22061\">",
"       table 1",
"      </a>",
"      ). They are discussed above according to pattern of inheritance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Autosomal dominant subtypes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Autosomal recessive subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a male child with muscular weakness and a serum creatine kinase level of &gt;1000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      or 10 times the upper limit of normal, in whom nonmyopathic motor unit disorders are less likely, gene mutation analysis for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) should be obtained. Such testing should also be obtained in females with similar serum creatine kinase elevation who are suspected of being symptomatic",
"      <span class=\"nowrap\">",
"       DMD/BMD",
"      </span>",
"      carriers. Rarely, sporadic dominant or autosomal recessive LGMD cases may be clinically indistinguishable from spinal muscular atrophy (SMA) type 3 if serum creatine kinase values are low (&lt;1000",
"      <span class=\"nowrap\">",
"       IU/L).",
"      </span>",
"      Electromyography is particularly useful in this setting for differentiating a neurogenic from a myopathic process and determining whether to proceed with DNA testing for possible SMA or DNA testing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a muscle biopsy for a potential myopathy (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients suspected of having LGMD, we suggest genetic testing prior to obtaining a muscle biopsy. Single-gene testing, rather than the entire LGMD profile, should be pursued first whenever the clinical findings point to a particular subtype of LGMD. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A muscle biopsy is appropriate if genetic and protein testing for LGMD is uninformative or unavailable. In cases of LGMD, a specific biopsy diagnosis may be achieved via immunohistochemical testing with antibodies directed against dystrophin, alpha and beta dystroglycans, merosin, dysferlin, sarcoglycans (alpha-, beta-, gamma-, and delta-), and other LGMD-related proteins. When a biopsy that suggests a myopathic process is accompanied by normal DNA testing and normal immunohistochemistry for all the above-mentioned proteins, testing for myotilin (LGMD1A), telethonin (LGMD2G), TRIM32 (LGMD2H), titin (LGMD2J), and other LGMD genes may be needed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of LGMD is supportive. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/1\">",
"      Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on Limb-Girdle Dystrophies. Neuromuscul Disord 1995; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/2\">",
"      Zatz M, de Paula F, Starling A, Vainzof M. The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 2003; 13:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/3\">",
"      Kirschner J, B&ouml;nnemann CG. The congenital and limb-girdle muscular dystrophies: sharpening the focus, blurring the boundaries. Arch Neurol 2004; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     Pegoraro E, Hoffman EP. Limb-girdle muscular dystrophy overview. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1408/ (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/5\">",
"      Mitsuhashi S, Kang PB. Update on the genetics of limb girdle muscular dystrophy. Semin Pediatr Neurol 2012; 19:211.",
"     </a>",
"    </li>",
"    <li>",
"     Angelini C, Fanin M. Calpainopathy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1313/ (Accessed on January 10, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/7\">",
"      Gallardo E, Saenz A, Illa I. Limb-girdle muscular dystrophy 2A. Handb Clin Neurol 2011; 101:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/8\">",
"      Huang Y, de Morr&eacute;e A, van Remoortere A, et al. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 2008; 17:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/9\">",
"      Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007; 64:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/10\">",
"      Paradas C, Llauger J, Diaz-Manera J, et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010; 75:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/11\">",
"      Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003; 423:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/12\">",
"      Hayashi YK. Membrane-repair machinery and muscular dystrophy. Lancet 2003; 362:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/13\">",
"      Gallardo E, Rojas-Garc&iacute;a R, de Luna N, et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001; 57:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/14\">",
"      Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol 2002; 28:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/15\">",
"      Confalonieri P, Oliva L, Andreetta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003; 142:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/16\">",
"      Nagaraju K, Rawat R, Veszelovszky E, et al. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 2008; 172:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/17\">",
"      Chiu YH, Hornsey MA, Klinge L, et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009; 18:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/18\">",
"      Han R, Frett EM, Levy JR, et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 2010; 120:4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/19\">",
"      Godfrey C, Clement E, Mein R, et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007; 130:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/20\">",
"      Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics 2008; 5:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/21\">",
"      Hara Y, Balci-Hayta B, Yoshida-Moriguchi T, et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 2011; 364:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/22\">",
"      Benedetti S, Menditto I, Degano M, et al. Phenotypic clustering of lamin A/C mutations in neuromuscular patients. Neurology 2007; 69:1285.",
"     </a>",
"    </li>",
"    <li>",
"     Bonnemann CG. The limb girdle muscular dystrophies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Jones HR, De Vivo DC, Darras BT (Eds), Butterworth-Heinemann, Philadelphia 2003. p.717.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/24\">",
"      Guglieri M, Straub V, Bushby K, Lochm&uuml;ller H. Limb-girdle muscular dystrophies. Curr Opin Neurol 2008; 21:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/25\">",
"      Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000; 9:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/26\">",
"      Menezes MP, Waddell LB, Evesson FJ, et al. Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy. Neurology 2012; 78:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/27\">",
"      Carbone I, Bruno C, Sotgia F, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 2000; 54:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/28\">",
"      Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998; 18:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/29\">",
"      Garc&iacute;a-Carde&ntilde;a G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997; 272:25437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/30\">",
"      Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004; 5:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/31\">",
"      Gazzerro E, Sotgia F, Bruno C, et al. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010; 18:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/32\">",
"      Cagliani R, Bresolin N, Prelle A, et al. A CAV3 microdeletion differentially affects skeletal muscle and myocardium. Neurology 2003; 61:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/33\">",
"      Woodman SE, Sotgia F, Galbiati F, et al. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 2004; 62:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/34\">",
"      Hayashi T, Arimura T, Ueda K, et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2004; 313:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/35\">",
"      McNally EM, de S&aacute; Moreira E, Duggan DJ, et al. Caveolin-3 in muscular dystrophy. Hum Mol Genet 1998; 7:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/36\">",
"      Torbergsen T. A family with dominant hereditary myotonia, muscular hypertrophy, and increased muscular irritability, distinct from myotonia congenita thomsen. Acta Neurol Scand 1975; 51:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/37\">",
"      Ricker K, Moxley RT, Rohkamm R. Rippling muscle disease. Arch Neurol 1989; 46:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/38\">",
"      Stephan DA, Buist NR, Chittenden AB, et al. A rippling muscle disease gene is localized to 1q41: evidence for multiple genes. Neurology 1994; 44:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/39\">",
"      So YT, Zu L, Barraza C, et al. Rippling muscle disease: evidence for phenotypic and genetic heterogeneity. Muscle Nerve 2001; 24:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/40\">",
"      Ansevin CF. Phenotypic variability in rippling muscle disease. Neurology 2000; 54:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/41\">",
"      Greenberg SA. Acquired rippling muscle disease with myasthenia gravis. Muscle Nerve 2004; 29:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/42\">",
"      Vorgerd M, Bolz H, Patzold T, et al. Phenotypic variability in rippling muscle disease. Neurology 1999; 52:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/43\">",
"      Speer MC, Gilchrist JM, Chutkow JG, et al. Evidence for locus heterogeneity in autosomal dominant limb-girdle muscular dystrophy. Am J Hum Genet 1995; 57:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/44\">",
"      Sandell S, Huovinen S, Sarparanta J, et al. The enigma of 7q36 linked autosomal dominant limb girdle muscular dystrophy. J Neurol Neurosurg Psychiatry 2010; 81:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/45\">",
"      Speer MC, Vance JM, Grubber JM, et al. Identification of a new autosomal dominant limb-girdle muscular dystrophy locus on chromosome 7. Am J Hum Genet 1999; 64:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/46\">",
"      Hackman P, Sandell S, Sarparanta J, et al. Four new Finnish families with LGMD1D; refinement of the clinical phenotype and the linked 7q36 locus. Neuromuscul Disord 2011; 21:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/47\">",
"      Harms MB, Sommerville RB, Allred P, et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol 2012; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/48\">",
"      Sarparanta J, Jonson PH, Golzio C, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 2012; 44:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/49\">",
"      Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 1997; 61:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/50\">",
"      Greenberg SA, Salajegheh M, Judge DP, et al. Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann Neurol 2012; 71:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/51\">",
"      Gamez J, Navarro C, Andreu AL, et al. Autosomal dominant limb-girdle muscular dystrophy: a large kindred with evidence for anticipation. Neurology 2001; 56:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/52\">",
"      Starling A, Kok F, Passos-Bueno MR, et al. A new form of autosomal dominant limb-girdle muscular dystrophy (LGMD1G) with progressive fingers and toes flexion limitation maps to chromosome 4p21. Eur J Hum Genet 2004; 12:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/53\">",
"      Bisceglia L, Zoccolella S, Torraco A, et al. A new locus on 3p23-p25 for an autosomal-dominant limb-girdle muscular dystrophy, LGMD1H. Eur J Hum Genet 2010; 18:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/54\">",
"      Zatz M, Starling A. Calpains and disease. N Engl J Med 2005; 352:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/55\">",
"      Bushby KM, Beckmann JS. The 105th ENMC sponsored workshop: pathogenesis in the non-sarcoglycan limb-girdle muscular dystrophies, Naarden, April 12-14, 2002. Neuromuscul Disord 2003; 13:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/56\">",
"      S&aacute;enz A, Leturcq F, Cobo AM, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005; 128:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/57\">",
"      Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998; 20:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/58\">",
"      Passos-Bueno MR, Vainzof M, Moreira ES, Zatz M. Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. Am J Med Genet 1999; 82:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/59\">",
"      Zhu T, Zhou L, Mori S, et al. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 2005; 112:2650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/60\">",
"      Moreira ES, Wiltshire TJ, Faulkner G, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000; 24:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/61\">",
"      Moreira ES, Vainzof M, Marie SK, et al. The seventh form of autosomal recessive limb-girdle muscular dystrophy is mapped to 17q11-12. Am J Hum Genet 1997; 61:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/62\">",
"      Boito CA, Melacini P, Vianello A, et al. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol 2005; 62:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/63\">",
"      Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 2003; 53:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/64\">",
"      Schwartz M, Hertz JM, Sveen ML, Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology 2005; 64:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/65\">",
"      Din&ccedil;er P, Balci B, Yuva Y, et al. A novel form of recessive limb girdle muscular dystrophy with mental retardation and abnormal expression of alpha-dystroglycan. Neuromuscul Disord 2003; 13:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/66\">",
"      Balci B, Uyanik G, Dincer P, et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 2005; 15:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/67\">",
"      D'Amico A, Tessa A, Bruno C, et al. Expanding the clinical spectrum of POMT1 phenotype. Neurology 2006; 66:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/68\">",
"      Jarry J, Rioux MF, Bolduc V, et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. Brain 2007; 130:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/69\">",
"      Hicks D, Sarkozy A, Muelas N, et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011; 134:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/70\">",
"      Penttil&auml; S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012; 78:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/71\">",
"      Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010; 86:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/72\">",
"      Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 2006; 60:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/73\">",
"      Vuillaumier-Barrot S, Quijano-Roy S, Bouchet-Seraphin C, et al. Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. Neuromuscul Disord 2009; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/74\">",
"      Puckett RL, Moore SA, Winder TL, et al. Further evidence of Fukutin mutations as a cause of childhood onset limb-girdle muscular dystrophy without mental retardation. Neuromuscul Disord 2009; 19:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/75\">",
"      Biancheri R, Falace A, Tessa A, et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun 2007; 363:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/76\">",
"      Clement EM, Godfrey C, Tan J, et al. Mild POMGnT1 mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 2008; 65:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/77\">",
"      Mercuri E, Brown SC, Nihoyannopoulos P, et al. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. Muscle Nerve 2005; 31:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/78\">",
"      Sveen ML, Thune JJ, K&oslash;ber L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol 2008; 65:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/79\">",
"      Baumeister SK, Todorovic S, Mili-Rasi V, et al. Eosinophilic myositis as presenting symptom in gamma-sarcoglycanopathy. Neuromuscul Disord 2009; 19:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/80\">",
"      Charlton R, Henderson M, Richards J, et al. Immunohistochemical analysis of calpain 3: advantages and limitations in diagnosing LGMD2A. Neuromuscul Disord 2009; 19:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/81\">",
"      Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/82\">",
"      Bittner RE, Anderson LV, Burkhardt E, et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/83\">",
"      Matsuda C, Aoki M, Hayashi YK, et al. Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology 1999; 53:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/84\">",
"      Borg K, Stucka R, Locke M, et al. Intragenic deletion of TRIM32 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum Mutat 2009; 30:E831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/85\">",
"      Ambrosi P, Mouly-Bandini A, Attarian S, Habib G. Heart transplantation in 7 patients from a single family with limb-girdle muscular dystrophy caused by lamin A/C mutation. Int J Cardiol 2009; 137:e75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/86\">",
"      Margeta M, Connolly AM, Winder TL, et al. Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I. Muscle Nerve 2009; 40:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/87\">",
"      Sveen ML, Jeppesen TD, Hauerslev S, et al. Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology 2007; 68:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/88\">",
"      Rodino-Klapac LR, Lee JS, Mulligan RC, et al. Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 2008; 71:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/89\">",
"      Mendell JR, Rodino-Klapac LR, Rosales XQ, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 2010; 68:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15881/abstract/90\">",
"      Wein N, Avril A, Bartoli M, et al. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 2010; 31:136.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6190 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15881=[""].join("\n");
var outline_f15_32_15881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5694282\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54487187\">",
"      Calpainopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5283166\">",
"      Caveolinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5283180\">",
"      Dysferlinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4055140\">",
"      Dystroglycanopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4055162\">",
"      Laminopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5283195\">",
"      Sarcoglycanopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Autosomal dominant subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autosomal recessive subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiac involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathology and immunoassays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5694282\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6190\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6190|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/48/3846\" title=\"figure 1\">",
"      Dystrophin associated protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6190|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/34/22061\" title=\"table 1\">",
"      Limb-girdle muscular dystrophies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21415?source=related_link\">",
"      Emery-Dreifuss muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=related_link\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/13/34001?source=related_link\">",
"      Patient information: Muscular dystrophy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/33/32276?source=related_link\">",
"      Patient information: Overview of muscular dystrophies (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15882="Principles of burn reconstruction: Extremities and regional nodal basins";
var content_f15_32_15882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"23\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of burn reconstruction: Extremities and regional nodal basins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Jorge Leon-Villapalos, MD, FRCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Peter Dziewulski, MD, FRCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/32/15882/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/32/15882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17954484\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of reconstructive surgery for the burn patient are first to restore function, then to restore esthetic appearances. Following resuscitation and stabilization, management of the burn wounds becomes the next priority. The later effects of burns, which are related to loss of normal tissue and scarring, include limitation of movement, pain, disfigurement, and social embarrassment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles of burn reconstruction of the upper and lower extremities, including the axilla and inguinal lymph node basins, are reviewed here. Emergency management of the burn patient, local treatment, and the general principles of reconstruction are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17955286\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following resuscitation and stabilization, acute management of burns to the extremities is focused on acute compartment syndrome assessment and the need to perform an escharotomy or fasciotomy (",
"    <a class=\"graphic graphic_picture graphicRef86905 \" href=\"UTD.htm?19/38/20064\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link&amp;anchor=H25#H25\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Escharotomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary operative management of hand burns\", section on 'Neurovascular compromise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extremity and nodal basin burns are cleansed and debrided of devitalized tissue, then covered with topical agents and dressings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .) Excision and skin grafting procedures are performed early, generally within five days of the burn injury if possible, to reduce the presence of necrotic and infected tissue and to attenuate the hypermetabolic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H16#H16\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Early wound closure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044920#H8044920\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Split thickness skin grafts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954492\">",
"    <span class=\"h1\">",
"     UPPER EXTREMITY RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of reconstruction of the upper extremity is to restore function. Burns to the upper extremity cause deformities and limit function, thus affecting all activities of daily living. Numerous methods have been described to release dynamic (early phase) and static (late phase) complex scar contracture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/2\">",
"     2",
"    </a>",
"    ]. Scars cause tendon adhesions, contractures, deep adipose tissue stiffness, and limitation of major joint range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Free flaps offer the advantages of early mobilization of the upper extremity, excellent functional results, and less concern about limited donor skin availability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/3\">",
"     3",
"    </a>",
"    ]. If not available, the most common procedure to release scar contractures and reconstruct burned upper extremities is scar excision and coverage with split-thickness (STSG) or full-thickness (FTSG) skin grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/4\">",
"     4",
"    </a>",
"    ]. There are many disadvantages with this basic procedure, the most important of which include a recurrence of the contracture, prolonged immobilization, and possible limitations on donor tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H1453430#H1453430\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Free microvascular tissue transfer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954508\">",
"    <span class=\"h2\">",
"     Axilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction of the axillary contractures is performed to restore full shoulder abduction once scar maturation is complete and immobilization and physical therapy options have been exhausted. Low grade contractures can usually be managed with range of motion exercises, splint fixation, and pressure treatment with silicone gel sheets. For severe contractures that limit range of motion, these conservative measures are not effective.",
"   </p>",
"   <p>",
"    Five general types and subtypes of axillary contractures have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I: small, thin flat contractures, adipose layer is conserved",
"     </li>",
"     <li>",
"      Type IIa: band contracture of the anterior axillary line",
"     </li>",
"     <li>",
"      Type IIb: band contracture of the posterior axillary line",
"     </li>",
"     <li>",
"      Type IIIa: contractures on both the anterior and posterior line with no contractures between the lines",
"     </li>",
"     <li>",
"      Type IIIb: contractures on both the anterior and posterior line with contractures between the lines",
"     </li>",
"     <li>",
"      Type IVa: contractures extending to both the chest and upper arm with no contractures on the back",
"     </li>",
"     <li>",
"      Type IVb: contractures extending to both the back and upper arm with no contractures on the chest",
"     </li>",
"     <li>",
"      Type IVc: contractures extending to the both chest and back with no contractures on the upper arm",
"     </li>",
"     <li>",
"      Type V: extensive contractures greater than Type IV",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reconstruction procedure selected should be based on the type of contracture to be released, and the size, depth, location, and shape of the area to be covered [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/6\">",
"     6",
"    </a>",
"    ]. Reconstruction should be performed with pliable, unburned tissue, if possible, to reduce the risk of recurrence of contractures. An algorithm is provided to identify the optimal surgical reconstructive procedure based on the severity and limitations of the burn wound (",
"    <a class=\"graphic graphic_table graphicRef73863 \" href=\"UTD.htm?21/63/22523\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Reconstruction options include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Split-thickness or full-thickness skin grafting",
"     </li>",
"     <li>",
"      Z-plasty and related alphanumeric advancement flaps",
"     </li>",
"     <li>",
"      Local tissue flap transfers",
"     </li>",
"     <li>",
"      Regional tissue flap transfers, including perforator flaps and island flaps",
"     </li>",
"     <li>",
"      Free microvascular flap transfers",
"     </li>",
"     <li>",
"      Any combination of flaps and grafts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Split-thickness skin grafts are reserved for the repair of minor contractions or in instances when no other reconstructive option exists. The lack of pliability of skin grafts results in secondary contractures and limitations of mobility in the axilla. Regional advancement flaps, regional flap transfers, and free flaps are preferred for reconstructing severe axillary contractures and areas that require large amount of tissue coverage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044867#H8044867\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Burn reconstruction procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our experience, results are improved if a dermal regeneration template is used in combination with a STSG, topical negative pressure is applied, and the arm is immediately splinted in abduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044936#H8044936\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Dermal regeneration templates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .) The next best option includes the use of full-thickness grafts. However, a large defect is created when axillary contractures are released, and availability of unburned full-thickness skin may be insufficient to cover the large defects in the axilla.",
"   </p>",
"   <p>",
"    Limited axillary contractures can be satisfactorily managed with the use of the Z-plasty advancement flap or any variations such as the Y-V-plasty [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/7\">",
"     7",
"    </a>",
"    ]. The indications for using a Z-plasty for release of contractures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing scar length",
"     </li>",
"     <li>",
"      Transforming a straight line scar into a less obvious irregular line",
"     </li>",
"     <li>",
"      Realigning a scar to minimize contour deformity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of elongation of the scar that can be achieved depends on the angle of the transposing flaps. For every 15 degrees of increase in the angle of the transposing flaps, a theoretical 25 percent in elongation can be achieved. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 30 degree angle achieves 25 percent elongation",
"     </li>",
"     <li>",
"      A 45 degree angle achieves 50 percent elongation",
"     </li>",
"     <li>",
"      A 60 degree angle achieves 75 percent elongation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The limitations of the use of the Z-plasty in burn scar revision are related to this theoretic increase in elongation. The percent of elongation is dependent upon the elasticity of the tissues and the wound closure tension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/8\">",
"     8",
"    </a>",
"    ]. Unburned surrounding skin and pliable tissues provide for the greatest likelihood of a successful flap transposition.",
"   </p>",
"   <p>",
"    The indications and limitations of the V-Y-plasty are similar to those of the Z-plasty for burn scar reconstruction, however, the success of the V-Y-plasty is more dependent upon the need for unburned surrounding skin. A double reverse V-Y-plasty has been successfully used to restore axillary function when skin tension across the contracture is too great for a local flap, and when superficial scarring is localized in the contracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/9\">",
"     9",
"    </a>",
"    ]. While necrosis is a risk of flap procedures, there was no distal flap necrosis in 19 burn patients treated with this procedure.",
"   </p>",
"   <p>",
"    Additional options for release of axillary scar bands include the alphanumeric transposition flaps (eg, five-flap plasty, seven-flap plasty) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], or a combination of circular excision combined with Z-plasty reorientation of the scar for resolution of large axillary contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/13\">",
"     13",
"    </a>",
"    ]. A prospective trial found that the seven-flap interdigitating plasty&rsquo;s immediate postoperative percentage mean length gained in the axilla was 103 percent (n = 14) and compared favorably to an average of 121 percent for all other anatomic regions evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Local flaps from adjacent tissues are used to treat mild scar contractures and resurface release defects in the axilla and antecubital fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/14\">",
"     14",
"    </a>",
"    ]. Providing that healthy skin is available, subcutaneous pedicled flaps can be used to restore function and improve esthetics. The tissues adjacent to the axilla provide a rich vascular network to allow regional fasciocutaneous flap options based on pedicles such as the circumflex scapular artery for a bilobed flap [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/15\">",
"     15",
"    </a>",
"    ], intercostal perforator options [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/16\">",
"     16",
"    </a>",
"    ], or options based on ad-hoc or unnamed perforators [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of seven children with burn contractures of the axilla, functional release was achieved in all patients using a local flap (n = 4), Integra&reg; dermal regeneration template (n = 2), or an anterolateral free flap from the thigh (n = 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/18\">",
"     18",
"    </a>",
"    ]. Excellent results as measured by restoration of 75 to 100 percent of range of motion were reported for",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    local flaps,",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    Integra templates, and the free flap reconstruction. Integra was used when local tissue was not available for reconstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link&amp;anchor=H21594043#H21594043\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Biosynthetic dressings'",
"    </a>",
"    .) An innovative technique, the free medial thigh perforator flap, was used to reconstruct the burned and scarred axilla in three adults with no complications or recurrence of the contracture at 12 months following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954393\">",
"    <span class=\"h2\">",
"     Antecubital fossa and elbow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antecubital fossa burn scars are a complicated challenge and release of the contractures results in a secondary defect that requires tissue coverage. The principles of reconstruction of burn scar deformities in the antecubital fossa and elbow are to restore normal anatomy, eliminate a flexion deformity, and restore function. Reconstruction is performed after the scars are mature and conservative measures such as physical therapy, occupational therapy, and splinting have been exhausted. If the deformity is severe, early surgical intervention can preserve function. A 50 percent reduction of the range of motion of the elbow can reduce the function of the upper extremity by approximately 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H1883166#H1883166\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Timing of surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical options include excision of the scar and split-thickness or full-thickness skin graft coverage, realignment of the scar flaps based on the Z-plasty principle, and resurfacing the area with local or free flaps after partial or total excision of the scar.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin grafting is the most efficient means of coverage, but is associated with prolonged splinting and immobilization, incomplete graft take, and a high risk of contracture recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reconstruction of burn scars contractures with a free flap or local flap in five pediatric elbows resulted in an excellent functional result in three children, while the two elbows reconstructed with Integra resulted in no change in function [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective trial evaluating a technique of a bipedicle flap created from scar tissue with skin grafting of the proximal and distal parts of this bipedicle flap, no early recurrence of contracture was identified and an acceptable appearance was seen in all 12 patients with a burn scar in the antecubital fossa [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional local flaps have been described to release an antecubital contracture and include a propeller flap [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/22\">",
"       22",
"      </a>",
"      ], rhomboid rotation flap [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/23\">",
"       23",
"      </a>",
"      ], proximal and distal z-plasties [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/24\">",
"       24",
"      </a>",
"      ], and V-Y plasties [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/9\">",
"       9",
"      </a>",
"      ]. Limitations to the local flap procedures include less than optimal cosmetic appearances when using previously burned skin.",
"     </li>",
"     <li>",
"      Resurfacing of the defect can be combined with the use of dermal regeneration templates (eg, Alloderm, Integra) that add pliability to the grafted area [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. The benefits of using a dermal regeneration template include improved skin quality and rapid re-epithelialization. The disadvantages include the necessity of a two-staged procedure to complete the resurfacing, and the need for meticulous wound care.",
"     </li>",
"     <li>",
"      Regional pedicle options include the use of medial and lateral arm flaps.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A retrospective review of 12 reverse medial flaps based on the recurrent ulnar artery found a better color match, more elasticity, improved durability, easier postoperative care, and no further contractures compared with a skin graft [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/27\">",
"       27",
"      </a>",
"      ]. The disadvantages of the reverse medial flap include a large donor defect, the need for unburned and healthy medial skin, a reduction in arm circumference, inconsistent blood supply, and the possibility of ulnar nerve compression and cutaneous nerve injury.",
"     </li>",
"     <li>",
"      The reverse lateral arm flap is a regional septocutaneous flap based on the posterior radial collateral artery (PRCA). A retrospective review of 11 elbow contractures treated with a reverse lateral flap found functional improvements in all cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/28\">",
"       28",
"      </a>",
"      ]. The advantages of this flap include a one-stage procedure, no need to sacrifice a major artery or muscle, consistency of the vascular pedicle, relative ease of dissection, primary closure of donor site, and shorter immobilization of the elbow compared with other options for reconstruction of elbow post burn defects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954400\">",
"    <span class=\"h2\">",
"     Wrist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reconstruction techniques to release contractures or improve deformities of the wrist are similar to those for the antecubital fossa. The reconstruction technique selected is adapted to the tissue deficit, the functional impairment, and the deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/29\">",
"     29",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Prevention of contractures and deformities of the wrist should be the priority. To reduce the risk of edema, contracture, and resulting deformities, the hand and wrist are positioned in a thermoplastic splint in an intrinsic-plus position with 20 to 30 degrees of wrist flexion, 80 degrees of metacarpophalangeal (MCP) joint flexion, fully extended interphalangeal (IP) joints, and thumb abduction. Immobilization and rehabilitation are as important to reducing the risk of contractures and functional limitations as timing of surgery and type of wound coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/30\">",
"     30",
"    </a>",
"    ]. While there are no high quality data from prospective trials regarding splinting of the hand and wrist unit, general practice supports the efficacy of splints and physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study of 985 patients with burns to the hand and wrist found that 23 percent had developed a contracture, and the most common were contractures limiting wrist extension and wrist flexion (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/31\">",
"     31",
"    </a>",
"    ]. Challenges to adequate splinting and physical therapy included multiple surgeries, dressing changes, concomitant medical problems, and skin grafts.",
"   </p>",
"   <p>",
"    Wrist contractures and deformities respond well to incision and grafting providing that no deep structures, such as tendons or neurovascular bundles, are exposed. A dermal regeneration template may be used if additional pliability is needed and can be provided by a STSG or FTSG alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/32\">",
"     32",
"    </a>",
"    ]. Linear contractures can be repaired using Z-plasty techniques. The complexity of reconstruction is increased when deep structures are exposed, requiring regional or free flap reconstruction (",
"    <a class=\"graphic graphic_table graphicRef73863 \" href=\"UTD.htm?21/63/22523\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Flaps are reserved for coverage of exposed deep structures or when a greater degree of pliability is needed and cannot be provided with a skin graft or plasty. The availability of regional unburned skin and intact vascular pedicles are the limiting factors for use of regional, distant, or free flaps. In a retrospective review of seven children with wrist contracture release and reconstruction, three of five reconstructed with Integra had an excellent functional result while the other two had no change in function, and both treated with a free flap had an excellent functional result [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954407\">",
"    <span class=\"h2\">",
"     Hand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns to the hands have a tremendous impact on activities of daily living. Effective treatment of hand burns requires a multifaceted and interdisciplinary approach that includes burn surgeons, plastic surgeons, rehabilitation physicians, and physical therapists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050170\">",
"    <span class=\"h3\">",
"     Primary operative treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial operative management of burns to the hand, including evaluation and management, primary and secondary assessment, primary operative procedures, and postoperative care are discussed in detail in another topic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link\">",
"     \"Primary operative management of hand burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our experience, we judiciously debride the necrotic tissue with either a Goulian knife or the Hydrosurgery System, Versajet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], while avoiding unnecessary damage to deep structures, specifically tendons, joints, and neurovascular bundles. When debriding interphalangeal joints, exposure of the extensor tendon or joints should be avoided. When the joints are exposed, they are pinned with Kirschner wires (K-wires) in position of function, and treated with topical antibiotics and dressings to avoid further desiccation until definitive coverage is performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link&amp;anchor=H10#H10\">",
"     \"Primary operative management of hand burns\", section on 'Excision and skin grafting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050177\">",
"    <span class=\"h3\">",
"     Secondary reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For secondary or delayed reconstruction, we have identified five key injuries that require priority treatment. They include adduction deformities, flexion deformities, extension deformities, exposed joints, and missing digits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050184\">",
"    <span class=\"h4\">",
"     Adduction deformities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate adduction deformities of the thumb in the form of linear contractures can be addressed with Z-plasty type realignments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"     \"Z-plasty\"",
"    </a>",
"    .) For more severe contractures in which a larger amount of scarring is present, full resurfacing with a split-thickness graft with or without a dermal template addition or a full-thickness graft is our preferred option. Flap coverage, either local or regional, may be necessary for more complex or fibrotic cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050193\">",
"    <span class=\"h4\">",
"     Flexion deformities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical management of finger flexion deformities attempts to correct function and range of motion, and includes physical therapy. The principles of management can range from simple realignment of the scar by Z-plasties or alphanumeric transposition flaps to excision and full-thickness skin grafting. Deep burns may result in a skin contracture adhering to the bone or joint, causing a secondary functional deficit of the joint apparatus consistent with a tenodesis or arthrodesis. A combined teno-arthrolysis, release of the tendon and joint apparatus in conjunction with the collateral ligaments and volar plates, may be required to restore joint function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050201\">",
"    <span class=\"h4\">",
"     Extension deformities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extension deformities may be managed in a similar fashion to flexion deformities, with either scar realignment, full scar release and grafting, or the use of pliable thin regional tissue to cover deep structures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/36\">",
"     36",
"    </a>",
"    ]. Discreet areas of scarring can be realigned with Z-plasties. Posterior interosseus flaps, radial forearm, or groin flaps are options for reconstruction of large defects with exposed extensor tendons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050208\">",
"    <span class=\"h4\">",
"     Exposed joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposed joints represent a serious reconstructive challenge, and in the acute setting, careful debridement and avoidance of infection, immobilization with K-wires, and consideration of early arthrodesis are options [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/36\">",
"     36",
"    </a>",
"    ]. If healthy granulation develops, skin grafting, together with a dermal regeneration template (eg, Matriderm&reg; or Integra) is an option. Thin flaps may need to be used as coverage options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050215\">",
"    <span class=\"h4\">",
"     Amputated digits",
"    </span>",
"    &nbsp;&mdash;&nbsp;When digits are irreparably damaged or amputated, preservation of the opposition function of the thumb-fingers is fundamental, and all reconstructive maneuvers are directed to the creation or preservation of this function, either by pollicization (thumb is created from an existing finger), distraction osteogenesis (bone lengthening), first web space deepening Z-plasties, dorsal rotation flaps, and in severe cases, microsurgical reconstruction with toe transfer. Thumb reconstruction methods depend on the location of the amputation and damage to adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pollicization with a transposable index ray provides the most rapid and effective means of restoring thumb function. In a review of 15 pollicization procedures in severely burned pediatric hands, 94 percent",
"    <span class=\"nowrap\">",
"     (14/15)",
"    </span>",
"    demonstrated improved postoperative function for pinch, grasp, and opposition [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/39\">",
"     39",
"    </a>",
"    ]. Multiple digital toe transfers have been described to replace loss of fingers following burn injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9784168\">",
"    <span class=\"h3\">",
"     Electrical burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the more devastating burns to the upper extremity is the electrical burn. The electrical source is grasped by the hands (94 percent) and the current exits through the lower extremities (78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/41\">",
"     41",
"    </a>",
"    ]. High tension injuries often cause extensive tissue damage, and despite early and aggressive treatment and decompression of the neurovascular structures, there is a high likelihood of amputation or a non-functioning arm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=see_link\">",
"     \"Environmental electrical injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954516\">",
"    <span class=\"h1\">",
"     LOWER EXTREMITY RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key complications of lower extremity burns include contractures in the inguinal and popliteal areas; exposure of neurovascular structures, bone, and joints; and rehabilitation. Major joints that are scarred result in deformity and disability. The primary goal of secondary reconstruction is to restore function. Exposed deep structures that are not amenable to simple reconstruction with split thickness (STSG) or full thickness (FTSG) skin grafts may require complex procedures with regional flaps or free flaps and microvascular anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954524\">",
"    <span class=\"h2\">",
"     Inguinal region",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited abduction of the hip is a common complication of burns to the inguinal region [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/12\">",
"     12",
"    </a>",
"    ]. Secondary reconstruction following release of inguinal contractures is usually straightforward, and provided that no deep neurovascular structures are exposed, the use of skin grafts with or without the addition of a dermal regeneration template is usually sufficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044867#H8044867\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Burn reconstruction procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful permanent release of contractures is limited by tension and movement in the inguinal region. The application of topical negative pressure to the grafted wound [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protects the skin graft from shearing",
"     </li>",
"     <li>",
"      Absorbs wound drainage (eg, hematoma, seroma)",
"     </li>",
"     <li>",
"      Avoids desiccation of the graft",
"     </li>",
"     <li>",
"      Reduces risk of infection",
"     </li>",
"     <li>",
"      Serves as a barrier to contamination from the genitalia or perineum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link&amp;anchor=H13#H13\">",
"     \"Negative pressure wound therapy\", section on 'Clinical applications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dermal regeneration templates (eg, Integra), used in acute burn wound care, also are used to manage hypertrophic and keloid burn scars [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044936#H8044936\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Dermal regeneration templates'",
"    </a>",
"    .) The scar is excised, Integra is placed over the wound, and several weeks later a very thin, split-thickness skin graft",
"    <span class=\"nowrap\">",
"     (6/1000",
"    </span>",
"    inch) is placed over the stabilized matrix. In a retrospective, multicenter evaluation of Integra in hypertrophic scar reconstruction release procedures involving 127 contracture sites, physicians rated the outcome of function as good or excellent in 76 percent of cases, and 82 percent of the patients expressed overall satisfaction of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/45\">",
"     45",
"    </a>",
"    ]. Patient satisfaction was 86 percent for range of motion, 82 percent for cosmetic appearance, and 84 percent for alleviation of pain. Contractures recurred in 25 percent of patients. The patient population of the study included burns and other trauma in adults and children and various anatomic sites. There are no high quality data from prospective trials that assess the long-term outcomes of using dermal regeneration templates in burn scar reconstruction of the inguinal region.",
"   </p>",
"   <p>",
"    In the patient with extensive burns, there may be insufficient skin available to create full-thickness grafts to cover the inguinal soft tissue defect. The next option is to use local transposition flaps based on the Z-plasty principle. In our experience, straight forward transposition of triangular flaps based on the Z-plasty principle is usually sufficient to warrant adequate release of contracture bands. The seven-flap plasty is an interdigitation flap that serves to release the contracture without the need for prolonged immobilization, splinting, or physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/12\">",
"     12",
"    </a>",
"    ]. A retrospective review of nine patients with burn scar contractures in the axilla or inguinal region treated with the seven-flap plasty reported that shoulder and hip range of motion improved significantly and no recurrences were identified at 24 months of observation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link&amp;anchor=H11#H11\">",
"     \"Z-plasty\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular pedicled flaps are used to cover deep structures in the inguinal region, and require undamaged or unburned tissue for a successful, pliable coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/46\">",
"     46",
"    </a>",
"    ]. Five patients treated with a pedicled anterolateral thigh flap for an inguinal contracture resulting from a burn had no recurrence of the contracture at 10 months after surgery. The flap has a reliable blood supply and can be used to cover large defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954422\">",
"    <span class=\"h2\">",
"     Popliteal fossa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn scar contractures in the popliteal fossa and knee limit the extension and flexion of the leg, and therefore limit mobility and increase disability. Treatment options for burn scars in the popliteal fossa are similar to the options described for secondary reconstruction of the upper extremity and inguinal scars. (See",
"    <a class=\"local\" href=\"#H17954492\">",
"     'Upper extremity reconstruction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17954524\">",
"     'Inguinal region'",
"    </a>",
"    above.) There are no high quality trials that have reported on the optimal reconstruction of burn scars in the popliteal fossa.",
"   </p>",
"   <p>",
"    Simple contracture bands can be treated using Z-plasties, Y-V plasties, or other alphanumeric interdigitating flaps. A prospective trial found that two patients achieved 135 percent immediate postoperative percentage gain in length using the seven-flap interdigitating plasty in the popliteal fossa, which compared favorably to an average of 121 percent for all other anatomic regions evaluated (n = 47) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/11\">",
"     11",
"    </a>",
"    ]. If healthy tissue is available in the immediate vicinity of the contracture area, a transposition flap containing fascia and based on a patent and undamaged perforator vessel provides pliable and durable tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044944#H8044944\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Local flaps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If realignment of the scar is not an option, excision of the contracture area and resurfacing with skin grafts or dermal regeneration templates (eg, Integra or Matriderm) adds elasticity to the reconstruction, and decreases the possibility of recurrence. Fixing the grafts with topical negative pressure and splinting the joint in extension maintains the normal anatomic integrity of the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of tissue expanders in burned lower extremities provides donor skin that is an optimal match for color, texture, sensation, and hair bearing qualities, but has risks and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Technical challenges include difficulty in creating a pocket for the expander, potential suboptimal subcutaneous tissue to cover the expander, and an incision in the area to be expanded. Extrusion of the implant occurs for these reasons as well as the mechanical compressive and disruptive forces from the muscles.",
"   </p>",
"   <p>",
"    A retrospective review of 20 expanders placed in burned limb sites (upper and lower) found no significant difference in rate of complications (30 versus 10 percent) or failure (15 versus 2.5 percent) compared with 40 expanders placed in burned non-limb sites [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/48\">",
"     48",
"    </a>",
"    ]. There were seven expanders inserted into the lower extremity, four were infected including one partially extruded, and two were subsequently removed. There is insufficient evidence to support the use of tissue expanders in burned lower extremities. If the surgeon elects to insert expanders in burned lower extremities, particularly in situations when there may be no other options, close observation of the patient is necessary to prevent complications proceeding to failures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H1453206#H1453206\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Tissue expansion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954429\">",
"    <span class=\"h2\">",
"     Exposed bone and joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposed bone and joints, such as the tibia and knee, that occur from the burn are classified as fourth degree burns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    .) Exposure can also be the result of overzealous fascial debridement. These complicated burns require multistage reconstructive procedures, but limb salvage is possible in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/49\">",
"     49",
"    </a>",
"    ]. In a 10-year retrospective review of 21 patients with fourth degree burns involving 40 lower extremities, a mean of eight operations was required for limb salvage, 18 percent of limbs were amputated, and 77 percent of patients were ambulatory at one year following hospital discharge. There are no high quality data from prospective trials regarding the optimal reconstruction of exposed bone in the tibia or knee following a burn injury.",
"   </p>",
"   <p>",
"    Osteomyelitis and septic arthritis are serious complications of an exposed bone or joint. There is little data regarding the incidence of bone and joint infections following severe burns. A retrospective study of 80 burn patients with a range of follow-up from six months to over five years found the clinical rate of osteomyelitis was 1.25 percent and radiographic evidence was present in 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/50\">",
"     50",
"    </a>",
"    ]. A retrospective study of 41 severely burned children undergoing a total of 357 skeletal fixation procedures found the rate of osteomyelitis to be 4.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/51\">",
"     51",
"    </a>",
"    ]. Loose pins, pin site cellulitis, burn wound infection, and sepsis were not associated with osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=see_link\">",
"     \"Pathogenesis of osteomyelitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412740\">",
"    <span class=\"h3\">",
"     Knee joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep burns to the knee and joint capsule, which includes the tendons, ligaments, and the femoral and tibial condyles, can be reconstructed with an autologous dermis graft [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/52\">",
"     52",
"    </a>",
"    ]. A small retrospective series of cases of burns to the knee has shown that this procedure can provide good and rapid articular stability, and early mobilization, with maintenance of flexibility at one year of observation.",
"   </p>",
"   <p>",
"    Vacuum assisted closure of a knee burn may encourage the growth of granulation tissue. However, this technique cannot be used when tendons and ligaments are exposed. Soft tissue coverage of the knee in these situations is achieved by using gastrocnemius muscle flaps or fasciocutaneous flaps [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/53\">",
"     53",
"    </a>",
"    ]. Functional outcome is reported to be good. These approaches are adapted from principles for coverage of the knee in other clinical situations (eg, trauma, infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2412747\">",
"    <span class=\"h3\">",
"     Tibia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposed bone and limited local tissue with a poor vascular supply and little laxity of the tissues are major challenges in reconstructing burns wounds involving the tibia. Options that can be used to facilitate secondary reconstruction of the exposed tibia include burring the bone and topical negative pressure. These procedures serve as the basis for additional reconstructive procedures, such as a pedicle or free flap or skin graft.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Burring of the bone to expose vascularized tissue, including the tibia, can stimulate the growth of granulation tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/49,57\">",
"       49,57",
"      </a>",
"      ]. In a review of five burn patients treated with the burring technique of the tibia, all had developed significant granulation tissue for skin grafting.",
"     </li>",
"     <li>",
"      Applying topical negative pressure to exposed bone can prepare the site for later grafting or flap procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/53,58\">",
"       53,58",
"      </a>",
"      ]. Topical negative pressure has been shown to reduce tissue edema and promote granulation tissue growth in 75 patients with lower extremity wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 17 exposed bone wounds from burns or other trauma, coverage of the defect with artificial dermis and split-thickness skin grafts revealed complete healing in 88 percent of wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Options that can be used for secondary reconstruction of exposed tibia include pedicled flaps and free microvascular flaps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H553839#H553839\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Regional and distant flaps'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pedicled transfer flaps &ndash; Providing that the lateral and medial perforator arteries along the deep fascia surrounding the tibia are intact and can be mapped with a hand held Doppler, fasciocutaneous tissue flaps can be based on the perforator arteries to cover tibial defects. These flaps can be used as a &ldquo;propeller&rdquo; flap that turns itself up to 180 degrees to provide soft tissue cover.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The proximal tibia can be reconstructed using gastrocnemius flaps [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The middle and distal third of the tibia can be covered by soleus flaps or fasciocutaneous perforator flaps [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. If the adjacent muscle is viable, a longitudinally split tibialis anterior turnover flap can be used for reconstructive coverage [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/63\">",
"       63",
"      </a>",
"      ]. This flap is simple in design, reliable, with minimal donor site dysfunction.",
"     </li>",
"     <li>",
"      The distally based superficial sural flap [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/64\">",
"       64",
"      </a>",
"      ] and the medial sural flap [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/65\">",
"       65",
"      </a>",
"      ] can be used to cover the exposed distal tibia and ankle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free microvascular transfer flaps &ndash; Free flaps are the most complex types of reconstruction and are the preferred wound coverage to salvage extremities and correct contracted burn scars when local and regional options are not available [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/66\">",
"       66",
"      </a>",
"      ]. Muscle and fascia flaps along with the vascular pedicle (eg, latissimus dorsi, radial forearm, anterolateral thigh) are effective options for reconstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a retrospective review of 11 patients with deep burns to the lower extremities with 9 exposed bones and 2 contracted scars, all lower extremity free flaps survived compared to 94 percent flap survival in the entire cohort of 53 free flaps used at various anatomic sites [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The medial sural flap can also be transferred as a free flap to cover the exposed distal tibia, ankle, and foot [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 215 cases of distal third leg defects, there was no significant difference in complication rates for patients treated with a pedicled flap compared to those treated with a microvascular free flap (18 versus 27 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/68\">",
"       68",
"      </a>",
"      ]. Pedicled flaps used in this study included lateral supramalleolar, medial plantar, and soleus flaps. The latissimus myocutaneous flap was used as the free flap in this study for the distal leg and a medial plantar flap or the lateral malleolus flaps were used to reconstruct the heel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17954436\">",
"    <span class=\"h2\">",
"     Ankle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thinness of the skin and the limited available local tissue near the malleolar areas of the ankle are a challenge for burn reconstruction. Hypertrophic scar formation that results in contractures of the ankle or foot impairs ambulation. Reconstruction procedures are performed to improve function and ambulation. There are no high quality data from prospective trials that have identified optimal reconstruction of the ankle or foot following a burn injury.",
"   </p>",
"   <p>",
"    A simple scar contracture without exposure of the underlying structures is managed by realignment, incision, excision, skin grafting, or local flap coverage plus splinting. Perforator flaps and free flaps are options for complex burn scars, as skin grafts cannot be used to cover exposed tendons, bones, or joints. Joint realignment procedures may be needed in cases of fourth degree burns. (See",
"    <a class=\"local\" href=\"#H17954429\">",
"     'Exposed bone and joint'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2412747\">",
"     'Tibia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413352\">",
"    <span class=\"h3\">",
"     Dorsiflexion contractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dorsiflexion contractures limit ambulation and are not amenable to skin graft repairs. A Z-plasty technique can be used to release a scar traversing the ankle joint, however, triangular flaps are at risk for necrosis due to possible vascular impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. A three quarter paratenon-cutaneous Z-plasty is used in cases of extensive scarring and lack of unburned adjacent skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413359\">",
"    <span class=\"h3\">",
"     Anterior contracture deformities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior contracture deformities generally occur following improper splinting and scar formation. This deformity may be corrected by proper splinting and physical therapy, however, surgical intervention for scar contracture release and reconstruction of periarticular structures may become necessary in refractory cases. Capsulotomy and tendon transfers may also be performed to correct this deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pedicled tissue transfer and microvascular free flaps have been used in complex cases of burn scars and trauma. A distally based lateral supramalleolar adipofascial flap has been used in seven trauma patients for reconstruction of the dorsum of the foot and ankle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/71\">",
"     71",
"    </a>",
"    ]. The flap is versatile, thin, and can be used for both the foot and ankle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413554\">",
"    <span class=\"h3\">",
"     Achilles tendon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Achilles tendon is in a superficial location and vulnerable to injury by a deep burn. The paratenon is immediately beneath the subcutaneous tissue and frequently damaged in a severe burn, hence skin grafts are not an option for coverage of an exposed tendon. Scar contractures can lead to a pes equinus deformity (toes extremely flexed) and ambulatory disabilities. An exposed Achilles tendon may be reconstructed with free flaps (eg, anteromedial thigh fasciocutaneous flap with a vascularized iliotibial band) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/72\">",
"     72",
"    </a>",
"    ], negative pressure wound therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/73\">",
"     73",
"    </a>",
"    ], or an island adipofascial flap covered by a split-thickness skin graft [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up at three years revealed almost complete normal range of motion for the patient treated with the anteromedial thigh fasciocutaneous flap [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/72\">",
"     72",
"    </a>",
"    ]. In a review of 10 patients with an exposed Achilles tendon after trauma or burn, the island adipofascial flap was viable in all patients, there was no functional deficit of the Achilles tendon, and a good cosmetic appearance was reported for all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25050360\">",
"    <span class=\"h2\">",
"     Foot and toes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dorsal and plantar contractures require splinting to maintain position and may require bone corrective surgery if joints have been permanently damaged. Incision and excision techniques with grafting are usually enough to provide adequate coverage for reconstruction. Because of the unique anatomy and function of the plantar surface of the foot, any full-thickness reconstruction will not be able to preserve the inherent resilience of the foot to trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/75\">",
"     75",
"    </a>",
"    ]. The key element to reconstruction is the preservation of foot function (eg, ambulation and weightbearing) by providing restoration of anatomy with avoidance of secondary deformities due to tendon or joint contracture. Adequate splintage preserves reconstruction integrity until adequate healing is achieved.",
"   </p>",
"   <p>",
"    As described in the section on ankle and tibia burns, simple scars can be treated with realignment, incision, excision, and skin grafting. Flaps, including pedicled, perforator and free flaps are reserved for complex situations. (See",
"    <a class=\"local\" href=\"#H2412747\">",
"     'Tibia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17954436\">",
"     'Ankle'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When deep burns occur on the plantar surface of the feet and toes, plantar flexion and claw toes deformities are the most common complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/70\">",
"     70",
"    </a>",
"    ]. There is a paucity of high quality data from clinical trials regarding the optimal reconstruction of burns to the ankles, feet, and toes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413538\">",
"    <span class=\"h3\">",
"     Plantar foot surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin of the plantar surface of the foot is thick, glabrous, and carries the main weight stress of the body. The non-weight bearing surface of the instep can be reconstructed with a FTSG or STSG and a dermal regeneration template. The weight bearing surfaces are reconstructed using sensate and mechanically durable tissue. Flaps that lack sensation are more likely to be damaged because of lack of deep pressure sensation and unfavorable weight distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Musculofascial flaps based on the dorsalis pedis arterial system, such as the reversed dorsalis pedis flap, can be used to resurface the distal foot and great toe [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/75\">",
"     75",
"    </a>",
"    ]. When regional options are not available, reconstruction is performed with free flaps. Key points that must be addressed and clear for patients with extensive loss of the plantar surface from burns include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amputation may be required in cases of extensive loss of tissue where functional outcome is uncertain",
"     </li>",
"     <li>",
"      Amputation may be required because of patient circumstances (eg, advanced age, comorbid illnesses) or lack of rehabilitation services",
"     </li>",
"     <li>",
"      Reconstruction is successful only if function is returned",
"     </li>",
"     <li>",
"      Deep burns treated with skin grafts will lead to unstable scars and exposure of deep structures",
"     </li>",
"     <li>",
"      Free muscle flap with skin grafts or a perforator based skin flap, if sensate, are effective reconstruction options in the absence of local or regional options",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413651\">",
"    <span class=\"h3\">",
"     Dorsal foot surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin overlying the dorsal surface of the foot is thin and relatively taut. Burns to this area have been reconstructed with skin grafts if tendons are not exposed or with a distally based lateral supramalleolar adipofascial flap [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/71\">",
"     71",
"    </a>",
"    ]. Other flaps for use on this surface include reverse flow fasciocutaneous island flaps based on the peroneal, anterior tibial, and posterior tibial arteries and a distally based medial plantar flap [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/78-81\">",
"     78-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342870\">",
"    <span class=\"h3\">",
"     Plantar flexion deformities of the foot",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plantar flexion deformity can result from a deep burn to the heel and inadequate splinting of the ankle and foot [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/70\">",
"     70",
"    </a>",
"    ]. Lengthening of the Achilles tendon, coverage of the burn, arthrodesis, and proper splinting can restore ankle mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/82\">",
"     82",
"    </a>",
"    ]. Burn wounds with exposed tendons can be covered with a fasciocutaneous Z-plasty or a three quarter fasciocutaneous Z-plasty technique. (See",
"    <a class=\"local\" href=\"#H17954429\">",
"     'Exposed bone and joint'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413562\">",
"    <span class=\"h3\">",
"     Dorsally contracted or extended toes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deformities to the toes can be caused by burn scars and scar contractures. The contracted toes are released by incising the scar at the level of the metatarsal phalangeal joint and the proximal interphalangeal joint [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/70\">",
"     70",
"    </a>",
"    ]. For children with extension contractures, Kirschner wire insertion through the proximal phalanx will correct the deformity. Once the wires are removed, skin grafts can be applied as needed. A volar capsulotomy is used in adults to realign the joint. A three quarter paratenon-cutaneous Z-plasty technique can be used to cover the joints [",
"    <a class=\"abstract\" href=\"UTD.htm?15/32/15882/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2413242\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of reconstruction of the upper and lower extremity is to restore function and achieve a cosmetically acceptable result.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For reconstruction of scars and contractures of the upper extremity (eg, axilla, antecubital fossa, wrist, and hand), low grade contractures can usually be managed with conservative measures including range of motion exercises, splint fixation, massage, and pressure treatment with silicone gel sheets. Full-thickness or split-thickness skin grafts are reserved for the repair of minor contractions. (See",
"      <a class=\"local\" href=\"#H17954492\">",
"       'Upper extremity reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For severe contractures of the upper extremity, the reconstruction procedure selected should be based on the type of contracture to be released, and the size, depth, location, and shape of the area as well as the availability of unburned regional skin. Reconstruction options include split-thickness grafts together with dermal regeneration templates to increase pliability, full-thickness skin grafts, Z-plasty type of realignments, advancement flaps, free microvascular flaps, and rotation or transposition flaps. (See",
"      <a class=\"local\" href=\"#H17954492\">",
"       'Upper extremity reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key complications of lower extremity burns include contractures in the inguinal and popliteal areas, destruction of the surface of the foot, and exposure of neurovascular structures, bone, and joints. Exposed deep structures that are not amenable to simple reconstruction with skin grafts, Z-plasty realignment procedures, or local flaps may require complex procedures with regional flaps or free flaps and microvascular anastomosis. The reconstruction procedure selected should be based on the type of contracture to be released, and the size, depth, location, and shape of the area as well as the availability of unburned regional skin. (See",
"      <a class=\"local\" href=\"#H17954516\">",
"       'Lower extremity reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/1\">",
"      Shelley OP, Dziewulski P. Late management of burns. Surgery Oxford 2006; 24:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/2\">",
"      Yenidunya MO. A classified approach to burn contractures. Burns 2005; 31:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/3\">",
"      Feng CH, Yang JY, Chuang SS, et al. Free medial thigh perforator flap for reconstruction of the dynamic and static complex burn scar contracture. Burns 2010; 36:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/4\">",
"      Iwuagwu FC, Wilson D, Bailie F. The use of skin grafts in postburn contracture release: a 10-year review. Plast Reconstr Surg 1999; 103:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/5\">",
"      Kobus K, W&oacute;jcicki P. Surgical treatment of Treacher Collins syndrome. Ann Plast Surg 2006; 56:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/6\">",
"      Ogawa R, Hyakusoku H, Murakami M, Koike S. Reconstruction of axillary scar contractures--retrospective study of 124 cases over 25 years. Br J Plast Surg 2003; 56:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/7\">",
"      Lin TM, Lee SS, Lai CS, Lin SD. Treatment of axillary burn scar contracture using opposite running Y-V-plasty. Burns 2005; 31:894.",
"     </a>",
"    </li>",
"    <li>",
"     Richards, AM.. Plasty techniques. In: Key Notes in Plastic Surgery, Blackwell SCience LTD, Oxford 2002. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/9\">",
"      Askar I. Double reverse V-Y-plasty in postburn scar contractures: a new modification of V-Y-plasty. Burns 2003; 29:721.",
"     </a>",
"    </li>",
"    <li>",
"     Shehab el-din SAM, Shouman OM. Reconstruction of post-burn axillary scar contracture A surgical approach. Egypt J Plast Reconstr Surg 1998; 22:229 www.medbc.com/meditline/review/egypt/vol_22/num_2/text/vol22n2p229.htm (Accessed on February 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/11\">",
"      Daya M. Clinical experience and analysis of length gain with the use of seven-flap plasty in burn contractures. Burns 2008; 34:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/12\">",
"      Karacaolan N, Uysal A. Use of seven-flap plasty for the treatment of axillary and groin postburn contractures. Burns 1996; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/13\">",
"      Ezoe K, Yotsuyanagi T, Saito T, et al. A circumferential incision technique to release wide scar contracture. J Plast Reconstr Aesthet Surg 2008; 61:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/14\">",
"      Hyakusoku H, Iwakiri I, Murakami M, Ogawa R. Central axis flap methods. Burns 2006; 32:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/15\">",
"      Karacalar A, G&uuml;ner H. The axial bilobed flap for burn contractures of the axilla. Burns 2000; 26:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/16\">",
"      Stillaert FB, Casaer B, Roche N, et al. The inframammary extending lateral intercostal artery perforator flap for reconstruction of axillary contractures: a case report. J Plast Reconstr Aesthet Surg 2008; 61:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/17\">",
"      Waterston SW, Quaba O, Quaba AA. The ad hoc perforator flap for contracture release. J Plast Reconstr Aesthet Surg 2008; 61:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/18\">",
"      Young RC, Burd A. Paediatric upper limb contracture release following burn injury. Burns 2004; 30:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/19\">",
"      S&oslash;jbjerg JO. The stiff elbow. Acta Orthop Scand 1996; 67:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/20\">",
"      Achauer BM, Spenler CW, Gold ME. Reconstruction of axillary burn contractures with the latissimus dorsi fasciocutaneous flap. J Trauma 1988; 28:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/21\">",
"      Hassanpour SE, Motamed S, Ghazisaidi M. Treatment of wide scar contracture of antecubital fossa with bipedicle flap from scar tissue. Burns 2007; 33:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/22\">",
"      Aslan G, Tuncali D, Cigsar B, et al. The propeller flap for postburn elbow contractures. Burns 2006; 32:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/23\">",
"      G&uuml;m&uuml; N. A new approach to the antecubital scar contracture: rhomboid rotation flap. J Plast Reconstr Aesthet Surg 2010; 63:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/24\">",
"      Ulkur E, Acikel C, Evinc R, Celikoz B. Use of rhomboid flap and double Z-plasty technique in the treatment of chronic postburn contractures. Burns 2006; 32:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/25\">",
"      Yim H, Cho YS, Seo CH, et al. The use of AlloDerm on major burn patients: AlloDerm prevents post-burn joint contracture. Burns 2010; 36:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/26\">",
"      Chou TD, Chen SL, Lee TW, et al. Reconstruction of burn scar of the upper extremities with artificial skin. Plast Reconstr Surg 2001; 108:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/27\">",
"      Yang JY. Experience of reverse medial arm flaps in the reconstruction of burned elbow scar contractures. Burns 1989; 15:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/28\">",
"      T&uuml;reg&uuml;n M, Nisanci M, Duman H, et al. Versatility of the reverse lateral arm flap in the treatment of post-burn antecubital contractures. Burns 2005; 31:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/29\">",
"      Schwarz RJ. Management of postburn contractures of the upper extremity. J Burn Care Res 2007; 28:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/30\">",
"      Kamolz LP, Kitzinger HB, Karle B, Frey M. The treatment of hand burns. Burns 2009; 35:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/31\">",
"      Schneider JC, Holavanahalli R, Helm P, et al. Contractures in burn injury part II: investigating joints of the hand. J Burn Care Res 2008; 29:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/32\">",
"      Haslik W, Kamolz LP, Manna F, et al. Management of full-thickness skin defects in the hand and wrist region: first long-term experiences with the dermal matrix Matriderm. J Plast Reconstr Aesthet Surg 2010; 63:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/33\">",
"      Gravante G, Delogu D, Esposito G, Montone A. Versajet hydrosurgery versus classic escharectomy for burn d&eacute;bridment: a prospective randomized trial. J Burn Care Res 2007; 28:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/34\">",
"      Shafer DM, Sherman CE, Moran SL. Hydrosurgical tangential excision of partial-thickness hand burns. Plast Reconstr Surg 2008; 122:96e.",
"     </a>",
"    </li>",
"    <li>",
"     Saffar, P.. Treatment of stiffness of the proximal interphalangeal joint. In: Joint stiffness of the upper limb, Copeland, SA, Gschwend, N, Landi, A, Saffar, P. (Eds), Dinitz, M, Oxford 1997. p.265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/36\">",
"      Hassan MK. Experience with finger joint arthrodesis for the management of stiff post burn deformities. Egyptian Journal of Plastic and Reconstructive Surgergy 2003; 27:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/37\">",
"      Muzaffar AR, Chao JJ, Friedrich JB, Freidrich JB. Posttraumatic thumb reconstruction. Plast Reconstr Surg 2005; 116:103e.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/38\">",
"      Kurtzman LC, Stern PJ, Yakuboff KP. Reconstruction of the burned thumb. Hand Clin 1992; 8:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/39\">",
"      Ward JW, Pensler JM, Parry SW. Pollicization for thumb reconstruction in severe pediatric hand burns. Plast Reconstr Surg 1985; 76:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/40\">",
"      Fumiaki S, Wei FC, Sassu P, et al. Multiple toe transplantations to reconstruct three amputated neighbouring distal fingers by heat press injury--a case report. J Plast Reconstr Aesthet Surg 2009; 62:e309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/41\">",
"      Mazzetto-Betti KC, Am&acirc;ncio AC, Farina JA Jr, et al. High-voltage electrical burn injuries: functional upper extremity assessment. Burns 2009; 35:707.",
"     </a>",
"    </li>",
"    <li>",
"     Vogt PM, Niederbichler AD, Spies M, Muehlberger T. Chapter 40: Electrical injury: reconstructive problems. In: Total Burn Care, 3rd edition, Herndon, DN (Eds), Saunders Elsevier, Philadelphia 2007. p.526.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/43\">",
"      Kanakaris NK, Thanasas C, Keramaris N, et al. The efficacy of negative pressure wound therapy in the management of lower extremity trauma: review of clinical evidence. Injury 2007; 38 Suppl 5:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/44\">",
"      Clayman MA, Clayman SM, Mozingo DW. The use of collagen-glycosaminoglycan copolymer (Integra) for the repair of hypertrophic scars and keloids. J Burn Care Res 2006; 27:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/45\">",
"      Frame JD, Still J, Lakhel-LeCoadou A, et al. Use of dermal regeneration template in contracture release procedures: a multicenter evaluation. Plast Reconstr Surg 2004; 113:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/46\">",
"      Uygur F, Sever C, Kulahci Y, Giderolu K. Reconstruction of postburn inguinal contractures using the pedicled anterolateral thigh flap. Burns 2009; 35:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/47\">",
"      Pandya AN, Vadodaria S, Coleman DJ. Tissue expansion in the limbs: a comparative analysis of limb and non-limb sites. Br J Plast Surg 2002; 55:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/48\">",
"      Elshahat A. Management of burn deformities using tissue expanders: a retrospective comparative analysis between tissue expansion in limb and non-limb sites. Burns 2011; 37:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/49\">",
"      Parrett BM, Pomahac B, Demling RH, Orgill DP. Fourth-degree burns to the lower extremity with exposed tendon and bone: a ten-year experience. J Burn Care Res 2006; 27:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/50\">",
"      Pandit SK, Malla CN, Zarger HU, et al. A study of bone and joint changes secondary to burns. Burns 1993; 19:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/51\">",
"      Barret JP, Desai MH, Herndon DN. Osteomyelitis in burn patients requiring skeletal fixation. Burns 2000; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     Masellis, M. Deep burns of the knee:Joint capsule reconstruction with dermis graft. Annals of Burns and Fire Disasters - vol. X - n. 1 - March 1997.  www.medbc.com/annals/review/vol_10/num_1/text/vol10n1p3.htm. (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/53\">",
"      Balakrishnan C, Flanagan TL, Klein JD, et al. Soft tissue coverage of the knee joint following burns. Can J Plast Surg 2006; 14:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/54\">",
"      Feldman JJ, Cohen BE, May JW Jr. The medial gastrocnemius myocutaneous flap. Plast Reconstr Surg 1978; 61:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/55\">",
"      McCraw JB, Fishman JH, Sharzer LA. The versatile gastrocnemius myocutaneous flap. Plast Reconstr Surg 1978; 62:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/56\">",
"      Sanders R, O'Neill T. The gastrocnemius myocutaneous flap used as a over for the exposed knee prosthesis. J Bone Joint Surg Br 1981; 63-B:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/57\">",
"      Bhattacharya V, Sinha JK, Tripathi FM. Management of scalp injuries. J Trauma 1982; 22:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/58\">",
"      Nugent N, Lannon D, O'Donnell M. Vacuum-assisted closure - a management option for the burns patient with exposed bone. Burns 2005; 31:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/59\">",
"      DeFranzo AJ, Argenta LC, Marks MW, et al. The use of vacuum-assisted closure therapy for the treatment of lower-extremity wounds with exposed bone. Plast Reconstr Surg 2001; 108:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/60\">",
"      Chen X, Chen H, Zhang G. Management of wounds with exposed bone structures using an artificial dermis and skin grafting technique. J Plast Reconstr Aesthet Surg 2010; 63:e512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/61\">",
"      Hallock GG. Multiple, synchronous ipsilateral soleus muscle flaps, including the Achilles' \"wraparound\" flap. Ann Plast Surg 1998; 41:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/62\">",
"      Kauffman CA, Lahoda LU, Cederna PS, Kuzon WM. Use of soleus muscle flaps for coverage of distal third tibial defects. J Reconstr Microsurg 2004; 20:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/63\">",
"      Chang J, Most D, Hovey LM, Yim KK. Tibialis anterior turnover flap coverage of exposed tibia in a severely burned patient. Burns 1997; 23:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/64\">",
"      Rajacic N, Darweesh M, Jayakrishnan K, et al. The distally based superficial sural flap for reconstruction of the lower leg and foot. Br J Plast Surg 1996; 49:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/65\">",
"      Cavadas PC, Sanz-Gim&eacute;nez-Rico JR, Gutierrez-de la C&aacute;mara A, et al. The medial sural artery perforator free flap. Plast Reconstr Surg 2001; 108:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/66\">",
"      De Lorenzi F, van der Hulst R, Boeckx W. Free flaps in burn reconstruction. Burns 2001; 27:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/67\">",
"      Mozafari N, Moosavizadeh SM, Rasti M. The distally based neurocutaneous sural flap: a good choice for reconstruction of soft tissue defects of lower leg, foot and ankle due to fourth degree burn injury. Burns 2008; 34:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/68\">",
"      Pinsolle V, Reau AF, Pelissier P, et al. Soft-tissue reconstruction of the distal lower leg and foot: are free flaps the only choice? Review of 215 cases. J Plast Reconstr Aesthet Surg 2006; 59:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/69\">",
"      Rooks MD. Coverage problems of the foot and ankle. Orthop Clin North Am 1989; 20:723.",
"     </a>",
"    </li>",
"    <li>",
"     Huang, T. Chapter 59: Reconstruction of burn deformities of the foot and ankle. In: Total Burn Care, 3rd, Herndon, DN (Eds), Saunders Elsevier, Philadelphia 2007. p.759.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/71\">",
"      Lee YH, Rah SK, Choi SJ, et al. Distally based lateral supramalleolar adipofascial flap for reconstruction of the dorsum of the foot and ankle. Plast Reconstr Surg 2004; 114:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/72\">",
"      Naganawa T, Ohno Y, Ohnishi K, Shimizu K. Reconstruction of the Achilles tendon and overlying soft tissue using an anteromedial thigh flap for a post-burn pes equinus deformity: a case report. J Orthop Surg (Hong Kong) 2009; 17:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/73\">",
"      Heugel JR, Parks KS, Christie SS, et al. Treatment of the exposed Achilles tendon using negative pressure wound therapy: a case report. J Burn Care Rehabil 2002; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/74\">",
"      el-Khatib H. Island adipofascial flap for resurfacing of the Achilles tendon. Plast Reconstr Surg 1996; 98:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/75\">",
"      Shah BR. Burns of the feet. Clin Podiatr Med Surg 2002; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/76\">",
"      Oh SJ, Moon M, Cha J, et al. Weight-bearing plantar reconstruction using versatile medial plantar sensate flap. J Plast Reconstr Aesthet Surg 2011; 64:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/77\">",
"      Van Landuyt K, Hamdi M, Blondeel P, Monstrey S. The compound thoracodorsal perforator flap in the treatment of combined soft-tissue defects of sole and dorsum of the foot. Br J Plast Surg 2005; 58:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/78\">",
"      Yoshimura M, Imura S, Shimamura K, et al. Peroneal flap for reconstruction in the extremity: preliminary report. Plast Reconstr Surg 1984; 74:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/79\">",
"      Wee JT. Reconstruction of the lower leg and foot with the reverse-pedicled anterior tibial flap: preliminary report of a new fasciocutaneous flap. Br J Plast Surg 1986; 39:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/80\">",
"      Hong G, Steffens K, Wang FB. Reconstruction of the lower leg and foot with the reverse pedicled posterior tibial fasciocutaneous flap. Br J Plast Surg 1989; 42:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/81\">",
"      Uygur F, Duman H, Ulk&uuml;r E, et al. Reconstruction of distal forefoot burn defect with retrograde medial plantar flap. Burns 2008; 34:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/32/15882/abstract/82\">",
"      Liu T, Wang D, Qian Y, et al. New experiences in treating postburn talipes equinovarus associated with bone and joint pathologic changes. Burns 2009; 35:852.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15538 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15882=[""].join("\n");
var outline_f15_32_15882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2413242\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17954484\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17955286\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17954492\">",
"      UPPER EXTREMITY RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954508\">",
"      Axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954393\">",
"      Antecubital fossa and elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954400\">",
"      Wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954407\">",
"      Hand",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25050170\">",
"      - Primary operative treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25050177\">",
"      - Secondary reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25050184\">",
"      Adduction deformities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25050193\">",
"      Flexion deformities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25050201\">",
"      Extension deformities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25050208\">",
"      Exposed joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25050215\">",
"      Amputated digits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9784168\">",
"      - Electrical burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17954516\">",
"      LOWER EXTREMITY RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954524\">",
"      Inguinal region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954422\">",
"      Popliteal fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954429\">",
"      Exposed bone and joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412740\">",
"      - Knee joint",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2412747\">",
"      - Tibia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17954436\">",
"      Ankle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2413352\">",
"      - Dorsiflexion contractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2413359\">",
"      - Anterior contracture deformities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2413554\">",
"      - Achilles tendon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25050360\">",
"      Foot and toes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2413538\">",
"      - Plantar foot surface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2413651\">",
"      - Dorsal foot surface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H342870\">",
"      - Plantar flexion deformities of the foot",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2413562\">",
"      - Dorsally contracted or extended toes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2413242\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15538|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/38/20064\" title=\"picture 1\">",
"      Lower extremity escharotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/63/22523\" title=\"table 1\">",
"      Reconstruction techniques for contractures from burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=related_link\">",
"      Pathogenesis of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=related_link\">",
"      Primary operative management of hand burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_32_15883="Injury prevention resources UK";
var content_f15_32_15883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Injury prevention resources (UK)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Child Accident Prevention Trust",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.capt.org.uk\" target=\"_blank\">",
"         www.capt.org.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Royal Society for the Prevention of Accidents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.rospa.co.uk\" target=\"_blank\">",
"         www.rospa.co.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Injury Minimization Programme for Schools (IMPS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.impsweb.co.uk\" target=\"_blank\">",
"         www.impsweb.co.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gloucestershire Home Safety Check Scheme and Herefordshire Home Check",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.homesafety.co.uk\" target=\"_blank\">",
"         www.homesafety.co.uk",
"        </a>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Maconochie I. Accident prevention. Arch Dis Child 2003; 88:275.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15883=[""].join("\n");
var outline_f15_32_15883=null;
var title_f15_32_15884="Hypothermia treatment";
var content_f15_32_15884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preferred rewarming methods by stage of hypothermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Rewarming methods*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Notes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       All",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Remove wet clothing",
"      </td>",
"      <td>",
"       Check ECG, continuously monitor cardiac rhythm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Provide dry insulation",
"      </td>",
"      <td>",
"       Monitor core temperature",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Warm airway humidity",
"      </td>",
"      <td>",
"       Monitor circulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Warm IV (40-44&deg;C)&bull;",
"      </td>",
"      <td>",
"       Warmed volume support",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Mild (&gt;34&deg;C, 93&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Active external",
"      </td>",
"      <td>",
"       Watch for afterdrop",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Moderate (30-34&deg;C, 86-93&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td rowspan=\"2\">",
"       Active external (forced air preferred)",
"      </td>",
"      <td>",
"       Watch for afterdrop",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Direct heating methods (eg, hot packs, heating pads) may cause burns",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Severe (&lt;30&deg;C, 86&deg;F) - or if methods above prove ineffective",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Circulation intact",
"      </td>",
"      <td>",
"       Left pleural lavage or forced air rewarming &Delta;",
"      </td>",
"      <td>",
"       As above, plus ensure warming is effective",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Circulation absent",
"      </td>",
"      <td>",
"       Extracorporeal rewarming (ECR)",
"      </td>",
"      <td>",
"       Left pleural lavage (if ECR is unavailable)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG: electrocardiogram.",
"     <br>",
"      * Many rewarming methods may be appropriate. The choice of methods should be based on provider experience, equipment availability, and individual patient needs.",
"      <br>",
"       &bull; Warmed oral fluids may be given instead of warmed intravenous fluids to patients with mild hypothermia and normal mental status.",
"       <br>",
"        &Delta; When using forced air rewarming in a patient with severe hypothermia, the clinician should also provide aggressive fluid resuscitation with warmed intravenous normal saline and remain vigilant for core afterdrop and rewarming shock.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15884=[""].join("\n");
var outline_f15_32_15884=null;
var title_f15_32_15885="Mgmt fecal incontinence ACG I";
var content_f15_32_15885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79705%7EGAST%2F62138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79705%7EGAST%2F62138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Gastroenterology recommendations for management of fecal incontinence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with fecal incontinence may be categorized into passive or urge incontinence or fecal seepage and their severity can be graded on a prospective stool diary and clinical features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should include a detailed physical and neurological examination of the back and lower limbs to evaluate for a systemic or neurological disorder.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digital rectal examination can identify patients with fecal impaction and overflow but is not accurate enough for diagnosing sphincter dysfunction or initiating therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Investigations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopic evaluation of the rectosigmoid region is appropriate for detecting mucosal disease or neoplasia that may contribute to fecal incontinence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorectal manometry with rectal sensory testing is the preferred method for defining the functional weakness of the external or internal anal sphincter and for detecting abnormal rectal sensation. Measurement of rectal compliance (reservoir function) may be helpful in some patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Imaging of the anal canal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anal endosonography is the simplest, most widely available and least expensive test for defining structural defects in the anal sphincter and should be considered in patients with suspected fecal incontinence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Defecography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is useful in patients with suspected rectal prolapse or those with poor rectal evacuation but is otherwise of limited value.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Balloon expulsion test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can identify impaired evacuation in patients with fecal seepage or in those with fecal impaction and overflow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pudendal nerve terminal latency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be useful in the assessment of patients prior to anal sphincter repair and is particularly helpful in predicting the outcome of surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Saline infusion test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can serve as a simple method for evaluating fecal incontinence, in particular for assessing clinical improvement after surgery or biofeedback therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rao, SS. Diagnosis and management of fecal incontinence. Am J Gastroenterol 2004; 99:1585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Gastroenterology recommendations for management of fecal incontinence (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supportive measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Such as avoiding offending foods, ritualizing bowel habit, improving skin hygiene and instituting lifestyle changes may be useful adjuncts.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pharmacologic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loperamide or diphenoxylate/atropine can produce modest improvement in symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Biofeedback therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is a safe and effective treatment. It improves symptoms of fecal incontinence, restores quality of life, and improves objective parameters of anorectal function. It is useful in patients with weak sphincters and/or impaired rectal sensation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Plugs, bulkers, electrical stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anal plug devices, sphincter bulking therapies or electrical stimulation should be considered as experimental and merit controlled clinical trials.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should be considered in selected patients who have failed conservative measures or biofeedback therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Rao, SS. Diagnosis and management of fecal incontinence. Am J Gastroenterol 2004; 99:1585.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15885=[""].join("\n");
var outline_f15_32_15885=null;
var title_f15_32_15886="FEV1 growth curves I";
var content_f15_32_15886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 growth curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 351px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The smoothed percentiles of FEV",
"    <sub>",
"     1",
"    </sub>",
"    by height for white girls; six cities, United States.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wang X, Dockery DW, Wypij D, et al. Pediatric Pulmonology 1993; 15:75.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15886=[""].join("\n");
var outline_f15_32_15886=null;
var title_f15_32_15887="CW Doppler AS severe";
var content_f15_32_15887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous wave Doppler shows a peak velocity across the aortic valve of 4.6 m/sec or a gradient of 85 mmHg, which is compatible with severe aortic stenosis. No aortic regurgitation is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_32_15887=[""].join("\n");
var outline_f15_32_15887=null;
